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Heart failure is a grave cardiac condition that affects approximately 15 million people in 
Europe alone and has a four-year mortality of 40% after the first hospital admission1, 2. The 
clinical syndrome of heart failure occurs when the capacity of the heart to distribute oxygen- 
and nutrient-rich blood to bodily cells is no longer capable of meeting peripheral demands. 
It is the common final pathway of different cardiovascular disorders, including myocardial 
infarction, valvular heart disease, hypertension, rhythm disturbances, and genetic, viral, 
toxic and autoimmune cardiomyopathies2. The significance of altered hemodynamics and 
neurohumoral signaling in patients with heart failure has long been recognized. In addition, 
the emergence of molecular biology in cardiovascular research in the nineties has provided 
important insights into the intracellular events that accompany these alterations. Cellular 
functions are governed by the dynamic expression of genes in our DNA. Such genes 
encode for proteins with a wide variety of cellular functions, such as cell structure 
reinforcement, energy production, intercellular communication and the regulation of gene 
expression. In heart failure, cardiac cells – including cardiomyocytes, fibroblasts, endothelial 
cells, vascular smooth muscle cells, and resident macrophages or dendritic cells – respond 
to altered environmental demands by activation of gene expression networks that can be 
adaptive or maladaptive3. An important research goal in molecular cardiology is to identify 
such adaptive or maladaptive gene programs involved in heart diseases, and design targeted 
therapies that stimulate or block them, respectively.
MicroRNAs represent a relatively new class of gene expression regulators. Though already 
described in the early nineties4, their wide importance for maintaining homeostasis in 
virtually all human cell types has only been recognized in the past decade. They form a 
class of highly conserved small RNA molecules (20-23 nucleotides long) that do not encode 
for proteins, but that can influence the expression of protein-coding genes5. MicroRNAs 
bind to target messenger RNAs (mRNA) through complementarity between microRNA 
sequences and sequences in the mRNA 3’ untranslated regions. This binding causes 
inhibition of target mRNA protein synthesis, either through mRNA destabilization or 
translational inhibition5. While microRNAs have a modest influence on the expression of 
individual target genes, they have profound effects on cellular biology through concerted 
inhibition of up to hundreds of genes6. MicroRNAs therefore act as post-transcriptional 
fine-tuners of gene expression. More than 1000 microRNAs have currently been identified 
in humans and their targetome is predicted to cover over 50% of all human protein-coding 
genes7, 8. MicroRNAs are indispensable for cardiac development and homeostasis9, 10. 
Additionally, many cardiac diseases, including hypertrophic remodeling and heart failure, 
are associated with altered microRNA expression patterns11, 12 which in turn may affect 
disease development and progression13. For instance, miR-199b expression is induced by 
the transcription factor NFAT during pressure overload-induced heart failure, and contributes 
to disease progression by further promoting NFAT activity in a positive feedback loop14. 
Similarly, many individual miRNAs have been linked to specific cardiac diseases including 
hypertrophic remodeling (miR-19914, miR-208a15), fibrosis (miR-2116, miR-2917), ischemia 
(miR-2418, miR-49919, miR-92a20), and arrhythmias (miR-121). 
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This thesis focuses on the role of microRNAs in the regulation of cardiac inflammation, 
which represents an important common characteristic of different cardiac diseases22. 
Inflammatory responses involve coordinated activities by cells from the innate (such as 
macrophages and granulocytes) and adaptive immune system (predominantly T and B 
lymphocytes) in response to infection or tissue damage. The importance and relative 
contribution of such responses to either adaptive or maladaptive mechanisms varies widely 
per disease and depends on adequate dosing of the response. For instance, while 
inflammation after myocardial infarction is important for the clearance of dead cells and 
scar formation, excessive inflammation can cause wall rupture22. During pressured overload 
secreted factors from infiltrating inflammatory cells promote fibrosis through stimulating 
cardiac fibroblasts, or directly enhance the development of cardiomyocyte hypertrophy and 
arterial hypertension23-25. Elevated cytokine levels in heart failure cause myocyte death and 
suppressed contractility, thereby contributing to heart failure progression in a positive 
feedback loop26. In viral myocarditis, immune responses eliminate virus from the infected 
heart but simultaneously inflict irreversible damage to the myocardium27. Both the initiation 
and resolution of inflammatory responses are tightly regulated by various signaling 
mechanisms including the orchestration of inflammatory gene expression by microRNAs28. 
However, the involvement of microRNAs in cardiac inflammation and their contribution to 
cardiac pathologies has hitherto remained unstudied. Such studies are attractive since 
microRNAs are therapeutically targetable regulators of physiology and pathology while 
inflammation is an important focus of therapeutically driven cardiovascular research29. 
In addition to their intracellular function as regulators of gene expression, microRNAs can 
also be detected in circulating plasma30. Though the mechanisms by which microRNAs 
exit cells and enter the blood stream are incompletely understood, plasma microRNAs are 
protected from degradation by exonucleases through interaction with (lipo)proteins or 
packaging in exosomes or microvesiscles, theoretically allowing their use as biomarkers31. 
Pioneer studies have shown the feasibility of cancer diagnosis through detection of tumor-
specific microRNAs32, fostering interest in the use of plasma microRNAs as biomarkers 
for cardiovascular disease. At the time that research for this thesis commenced, no 
exploratory studies of plasma microRNAs as biomarkers in cardiac diseases were 
available”.
Aims and outline of this thesis
The first goal of this thesis was to investigate the biological contribution of microRNAs to 
cardiac inflammation. To address this issue, two approaches were used. First, we profiled 
microRNA expression during virus-induced myocarditis, which by definition involves 
inflammation of the heart. This allowed us to identify microRNAs involved in cardiac 
inflammation in an unbiased manner. Next, we analyzed the functional importance of a 
known inflammatory microRNA, microRNA-155, during pressure overload-induced 
hypertrophy and heart failure. The second goal of this thesis was to explore the utility of 
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circulating microRNAs for the diagnosis of cardiovascular disorders. Hereto, plasma levels 
of microRNAs were examined in patients with different cardiovascular diseases, including 
acute myocardial infarction, heart failure and myocarditis and comparing them to appropriate 
controls.  
Chapters 2 and 3 of this thesis provide a more comprehensive background for the 
aforementioned studies. Chapter 2 outlines basic concepts of microRNA biology, including 
biogenesis, mode of action and plasma stability, while Chapter 3 discusses the pleiotropic 
role of inflammation in viral myocarditis. Chapters 4 through 7 represent the experimental 
studies performed. MicroRNA profiling and the functional roles of microRNA-155 and the 
microRNA-221-222 family in viral myocarditis are discussed in Chapters 4 and 5. Chapter 
6 describes the importance of microRNA-155 for cardiac hypertrophy and failure. The 
feasibility of using plasma microRNA as biomarkers for cardiovascular disease diagnosis 
in patients is described in Chapter 7. 
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Introduction
MicroRNAs (miRNAs) are short RNAs of 20-23 nucleotides in length that are involved in the 
post-transcriptional regulation of gene expression in animals and plants1. The first miRNAs 
were discovered in a screen for genes that control developmental timing in worms: antisense 
complementarity between the small RNAs lin-4 and let-7 and messenger RNA (mRNA) of 
protein-coding heterochronic genes repressed their protein expression2, 3. Lin-4 and let-7 
appeared exemplary for a large class of small endogenous RNAs able to bind to partially 
complementary mRNAs and repress their protein levels. MiRNAs are expressed by in plants, 
algae, viruses, bacteria, fungi and mammals and are remarkably conserved throughout 
phylogeny, suggesting importance for competitive fitness4. The number of miRNAs identified 
in humans is currently approaching one thousand, many of which are expressed in a tissue- 
and time-dependent manner. Single miRNAs can target up to hundreds of mRNAs. 
Consequently, human miRNAs are ramified to collectively regulate the expression of more 
than half of all protein-coding genes5, 6. MiRNAs affect virtually every cellular process in 
eukaryote physiology including development, growth, energy metabolism, and cell death. 
In addition, a wide range of diseases is associated with differential miRNA expression, 
including cancer and cardiovascular diseases7, 8. This chapter aims to summarize elementary 
aspects of miRNA biogenesis and their function in cardiovascular physiology and diseases. 
Finally, the recent finding that miRNAs are detectable in circulating plasma and may be used 
as biomarkers for cardiovascular disease will be discussed.
MicroRNA biogenesis
Mature miRNAs are processed from precursor molecules (primary or pri-miRNAs), which 
are transcribed from independent miRNA genes or processed from the introns of protein-
coding genes9. Transcription of pri-miRNA is mediated by the transcription factor-dependent 
polymerase II, allowing dynamic regulation of pri-miRNA levels (Figure 1). Typically, pri-
miRNAs are long transcripts that contain one or more local hairpins harboring a mature 
miRNA. Canonical processing of pri-miRNAs involves two steps of enzymatic processing 
by the RNAse III family members Drosha and Dicer, respectively5. In the first step, Drosha 
cleaves the pri-miRNA in the nucleus to yield a ~70 nt hairpin precursor (pre-miRNA). 
Alternatively, non-canonical processing involves the Drosha-independent generation of pre-
miRNA directly through splicing of short introns (called mirtrons). Both mechanisms converge 
when the pre-miRNA precursor is shuttled from the nucleus to the cytoplasm by exportin-5. 
This process is energy-dependent and follows exportin-5 recognition of the 3’ overhang of 
the pre-miRNA caused by Drosha cleavage10. Once in the cytoplasm, the stem-loop structure 
of the pre-miRNA hairpin is cleaved by Dicer, thereby removing the loop to yield a small 20 
to 23-bp double stranded  miRNA/miRNA* duplex. Of this duplex, the strand with the least 
stable 5’ binding (the mature miRNA) will be incorporated into the microRNA-induced 
silencing complex (miRISC), where it acts as guide strand to complementary messages. 
The other strand, referred to as the passenger or miRNA* strand, is often degraded11. 
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Of note, miRNA* strands are not always waste products of miRNA biogenesis and can also 
be loaded into miRISC complexes. Ratios of miRNA/miRNA* loading into miRISC are in fact 
variable between cell types and states5. This insight has led to a recent strand reclassification 
in miRBase, the most widely used online miRNA database, which since 2012 differentiates 
between a miRNA-3p/miRNA-5p strand rather than miRNA/miRNA*. 
MicroRNA function
MiRNAs are involved in a mechanism called transcriptional silencing. By binding to 
complementary regions in the 3’UTR of target mRNAs, miRNAs guide the actions of effector 
proteins in the miRISC complex, including Argonaute (Ago) and glycine-tryptophan protein of 
Figure 1. MicroRNA biogenesis. MicroRNAs (miRNAs) are transcribed from independent genes or 
from non-coding parts of other genes by polymerase II (Pol II). Their rate of transcription is dynamically 
regulated by transcription factors (TF), similar to protein-coding genes, and yields poly-adenylated primary 
precursor transcripts (pri-miRNA) that require two steps of enzymatic processing for the generation of 
mature miRNAs. In the nucleus, pri-miRNAs are cleaved by the RNAse III enzyme Drosha into hairpin 
precursors (pre-miRNAs), before being actively exported from the nucleus by Exportin 5. The process of pri-
miRNA cleavage by Drosha is regulated by a number of accessory proteins, such as DGCR8. In the cytosol, 
Dicer cleaves the stem-loop structure from the miRNA/miRNA* duplex, thereby yielding a 20 to 23-bp 
double stranded miRNA/miRNA* duplex. Incorporation of the miRNA or miRNA* strand into RNA-induced 
silencing complexes (RISC) depends on thermodynamic strand stability and varies between miRNAs. 
Once incorporated, miRNAs guide the silencing effect of the RISC complex by binding to complementary 
sequences in the 3’ untranslated regions (3’UTR) downstream of the open reading frame (ORF) of target 
messenger RNAs (mRNA). Target mRNA degradation of translational repression is effectuated by effector 
proteins in RISC, such as Argonaute (Ago) and GW182.
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182 kDa (GW182)5. These effector proteins generally inhibit the protein output from that 
message through a variety of mechanisms, including degradation, destabilization or translational 
repression of the message12. Interestingly, the modes of miRNA function in plants and animals 
are different. In plants, miRNAs bind to targets with extensive complementary for the mature 
miRNA sequence which induces direct cleavage of the targeted message. Though this 
mechanism is also present in animals, it is uncommon and such extensive complementarity 
is rare1. In contrast, metazoan miRNA binding to target sequences strongly relies on 3’UTR 
complementarity to the first 8 nucleotides of the miRNA’s 5’ end, called the seed region. It is 
currently not possible to deduce definite targets for miRNAs based on sequence information 
available in public databases, and experimental validation of targets using luciferase reporters 
tailed by the 3’UTR of interest remains the golden standard. However, improvements in target 
prediction algorithms have significantly reduced the false positive rates of such predictions 
over the past decade1. One important reason for this improvement has been the incorporation 
of evolutionary conservation into the prediction methods13. Targets sites that are conserved 
more than would be expected by chance are considered to be under selective pressure and 
likely biologically relevant. Evolutionary conservation of target sites therefore adds confidence 
to the prediction as compared to site with similar complementarity for which mutations have 
gone unpunished13. However, predicted non-conserved binding sites for miRNAs outnumber 
conserved binding sites about ten-to-one1, and many non-conserved predicted targets are 
increased in abundance following miRNA deletion in high-throughput analyses14, 15. Since 
3’UTR regions of genes harbor a high frequency of single nucleotide polymorphisms in 
comparison to protein coding regions, evolving generation and disruption of miRNA binding 
sites may reflect an evolutionary strategy that promotes quick and nuanced adaptations in 
gene expression. In conclusion, while some of such non-conserved targeting may represent 
biologically inconsequential interactions, species-specific miRNA regulation may contribute 
to biological homeostasis or pathology in humans.
Figure 2. MiRNAs influence biology through gene networks. MiRNAs can directly target hundreds of 
targets (miR-x in the figure). In turn, these targets can affect the transcription, stability or localization of a 
large number or indirect target messenger RNA or proteins. Phenotypic effects of altered miRNA signaling 
are therefore the resultants of small changes in entire signaling networks. In turn, such phenotypical traits 
are ofter regulated by multiple miRNAs at the same time (miR-y and miR-z). 
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Multiple mechanisms for miRNA target silencing exist, raising the question which of them 
is dominant in mammalian biology. While initial studies suggested that miRNAs reduced 
target protein output through translational repression without affecting mRNA levels12, 16, 
later mRNA-array studies demonstrated that many miRNA target mRNA levels are 
decreased in response to miRNA overexpression, which was associated with shortening 
of the poly(A) tail17-19. This mechanism is known as mRNA destabilization and is mediated 
by the effector protein GW182 in the miRISC complex, which can promote transcript 
deadenylation followed by mRNA decapping and destabilization20. Since the effect of 
miRNAs on transcript levels is generally small, a prevailing belief has been that translational 
repression is the dominant mode of miRNA action in mammals. This belief has been 
challenged by recent evidence that miRNA-associated reductions in ribosome-associated 
target mRNA (nascent proteins) are paralleled by whole-cell mRNA reductions and that 
84% of target repression effects are mediated by mRNA destabilization rather than 
translational repression12. Observations of stronger miRNA effects on the protein than 
mRNA level therefore likely reflect the methodological sampling difference between 
transcriptomics and proteomics: small differences in snapshot measurements of mRNAs 
with short half-lives may be amplified in stably accumulated protein levels. Though our 
knowledge about miRNA targeting has significantly increased in the past years, much 
remains to be learned about the different silencing mechanisms and the factors determining 
which mechanism will be activated following miRNA binding.
MiRNA impact on gene networks
A consistent observation of miRNA target regulation is that miRNAs suppress their individual 
targets only to a mild degree. High throughput proteomics analyses have revealed that 
protein levels of most miRNA targets with perfect seed matching change only 10-20% 
after miRNA overexpression or knockout14, 15. Conversely, the same studies showed that 
hundreds of direct miRNA targets are affected by such miRNA manipulations, and that 
direct and indirect effects cooperatively regulate the expression of up to thousands of 
genes (Figure 2). MiRNAs therefore direct their effects through a collection of nuanced 
perturbations, which may be a favorable aspect for their use as therapeutic targets21. The 
flipside of this regulatory mechanism is that it complicates the identification or miRNA 
targets that explain observed phenotypes, as focusing on single targets may not be 
sufficient to explain the cooperative effects of targets in reality. 
It is tempting to speculate that miRNA targets should functionally relate to cooperatively 
orchestrate biological functions. Target sets of some microRNAs are indeed enriched for 
specific functions. For example, the miR-17~92 cluster has well-known oncogenic 
properties22 and is enriched in target genes with a role in growth control23. Such enrichment 
is nonetheless not always observed and many miRNAs seem to influence a range of 
different processes. Moreover, their functions can vary across different cell types based 
on the differential availability of miRNA targets in such cell types1. Vice versa, many 
biological functions are regulated by different miRNAs simultaneously. In line with such 
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observations, many individual miRNA knockouts in worms lack overt phenotypes due to 
buffering by both miRNA family members and non-family members24, 25 The same 
phenomenon occurs in mice in cardiovascular research, where single miRNA knockouts 
often fail to produce deviant phenotypes until challenged by disease models, such as 
myocardial infarction or aortic banding7. 
Regulation of miRNA activity
As regulators of gene expression, miRNAs themselves are also subject to sophisticated 
control. Promoters of miRNA genes are very similar to those of coding genes and contain 
elements that suggest cis-regulation of transcription, including TATA box sequences, CpG 
islands, initiation elements and histone modifications5. Following transcription, processing 
of pri-miRNAs by Drosha and Dicer is influenced by the abundance and activity of accessory 
proteins such as DGCR8, which stabilizes the Drosha microprocessor complex to increase 
pri-miRNA processing26. Some accessory proteins selectively influence processing of 
specific miRNAs or families, such as Lin-28 that binds to the terminal loop of pre-let-7 and 
interferes with Drosha cleavage27. After processing and incorporation into the miRISC 
complex, miRNA-interactions are affected by levels of the miRISC core proteins Argonaute 
and GW182, and by dozens of additional proteins that either counteract or facilitate miRNA 
target repression5. Such repression is also influenced by the intracellular localization of 
miRNAs: many cells contain cytoplasmic foci known as processing bodies (p-bodies) that 
are enriched in miRNA, mRNA, Dicer and Argonaute. Disruption of miRNA biogenesis leads 
to disappearance of p-bodies suggesting that they play a functional role in miRNA biology28. 
The turnover of miRNAs may also affect miRNA levels and function, but has not extensively 
been studied thus far. 
MiRNAs are also subject to accelerated decay under certain cellular conditions. For instance, 
miR-29b decays quicker in actively proliferating cells as compared to cells arrested in 
mitosis29. Though the underlying mechanisms are incompletely understood, it is likely that 
miRNA turnover is an important determinant of miRNA function. Finally, highly proliferating 
or activated cells tend to produce mRNAs with shorter 3’UTRs that are less sensitive to 
miRNA-mediated repression30. In conclusion, endogenous regulation of miRNA function 
appears as complex as miRNA targetome silencing itself and adds to the complexity of 
miRNA biology.
Roles of miRNAs in the heart
The heart expresses approximately 200 different miRNAs including abundant levels of the 
cardiomyocytes-specific miR-208a, muscle-specific miRNAs including miR-1, miR-133, miR-
499, miR-206, and miR-208b, as well as non-myocyte specific miRNAs such as miR-29a, 
miR-26a, and members of the let-7 family31, 32. Interruption of miRNA biogenesis in 
cardiomyocytes through targeted myocyte-specific deletion of Dicer in mice results in 
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embryonic mortality or rapidly progressing postnatal heart failure and death33, 34. In addition, 
targeted dicer deletion in cardiomyocytes of adult mice leads to severe dilated cardiomyopathy, 
indicating that miRNA regulation of cardiomyocytes homeostasis remains essential beyond 
the developmental phase35. In subsequent studies, multiple individual miRNAs have been 
identified to play important roles in cardiac development and diseases7,36,37. During normal 
heart development, embryonic stem cell commitment to the mesodermal lineage is 
cooperatively stimulated by miR-1 and miR-133, two highly expressed myocyte-specific 
miRNAs that are transcribed from a common pri-miRNA precursor. Subsequently, miR-1 
promotes further differentiation into cardiomyocytes while miR-133 inhibits this transition38. 
These actions of miR-1 and miR-133 are buffered to some degree by each other and other 
miRNAs, since half of the miR-1 or miR-133 knockout mice are viable34, 39. Several miRNAs 
that are highly expressed in cardiomyocytes impact the onset and progression of cardiac 
diseases such as hypertrophic remodeling or dilated cardiomyopathy40-42. In addition, miRNAs 
in other cardiac cells, such as fibroblasts and endothelial cells, also affect cardiac 
pathophysiology (Figure 3). To give a few examples, miR-21 is up-regulated in fibroblasts 
during pressure overload and contributes to cardiac hypertrophy and fibrosis43. After 
myocardial infarction, fibroblasts in the ischemic border zone down-regulate miR-29b to 
derepress pro-fibrotic genes leading to collagen deposition. In endothelial cells, miR-92a 
suppresses pro-angiogenic factors and miR-92a inhibition in vivo in mice results in improved 
cardiac angiogenesis and function after myocardial infarction44. An important cardiac cell 
Figure 3. MiRNA roles in different cardiac cell types during cardiac disorders. The onset and 
progression of heart failure is impacted by miRNA signaling in different cardiac cell types. For instance, 
miR-199b and miR-208 are highly expressed in cardiomyocytes and affect NFAT signaling and myosin 
switching, respectively; two signaling cascades with important roles in heart failure. Similarly, miR-499 
affect cardiomyocyte apoptosis. In addition to cardiomyocytes, miRNAs in cardiac fibroblasts (miR-21, miR-
29b) and endothelial cells (miR-92b) also influence cardiac failure. In contrast, while immune activation is 
important in many forms of heart failure, contributions of individual miRNAs expressed by inflammatory 
cells on cardiac disease have not been reported so far.
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type that has received little attention thus far is the leukocyte: the heart harbors a population 
of resident macrophages or dendritic cells under basal conditions and many cardiac diseases 
are characterized by pronounced activation of inflammatory signaling associated with the 
influx of recruited inflammatory cells into the heart45. Since inflammation is subject to 
stringent miRNA control46, the impact of inflammatory miRNA signaling in cardiac disease 
represents a gap in our current knowledge that mandates investigation.
Circulating microRNAs
Beyond their intracellular function, miRNAs have recently been found in several bodily fluids, 
including blood and cell-free fractions such as plasma, serum and urine47. MiRNA levels in 
such fluids are remarkably stable and resistant to a broad range of damaging conditions, 
including boiling, repeated freeze-thaw cycles, prolonged storage at room temperature, and 
acidic or basic pH environments48-50. In contrast, when short RNAs are exogenously added 
to plasma they are rapidly degraded by RNAse, suggesting that endogenous plasma miRNAs 
are shielded from exonucleases activity48. Indeed, miRNAs are stably transported through 
the circulation by incorporation into vesicles such as endosome-derived exosomes and cell 
membrane-derived microvesicles or apoptotic bodies or through association with lipoproteins 
like high-density lipoprotein (HDL)51-54. In addition, a large fraction of plasma miRNAs is 
protected by directly associating with chaperone proteins such as Argonaute or by 
Nucleophosmin-1 (NMP1)55, 56. This protein-bound fraction is estimated to represent 
approximately 90% of circulating miRNAs in human plasma55, 57. Individual miRNAs can be 
preferentially exported into either vesicle- or protein-associated miRNA55, and their altered 
release under stressed or transformed conditions appears a selective process58. However, 
much remains to be learned about the factors that determine cellular miRNA export and their 
physiological significance. The stable detectability of miRNAs in patient samples nonetheless 
offers direct diagnostic opportunities. MiRNAs are detected in plasma with high sensitivity 
and specificity, and plasma measurement of tumor-specific miRNAs allows accurate 
separation of healthy subjects from patients with a variety of malignancies48-50 and identification 
of diabetic or pre-diabetic patients49, 59. Therefore, the use of single or combined plasma 
miRNA biomarkers may also aid in the diagnosis or prognosis of a range of cardiovascular 
diseases, such as acute coronary syndrome, heart failure and viral myocarditis. 
 
Conclusions
The broad importance of miRNAs for cardiovascular development, physiology, and disease 
are by now well established. A major challenge lies in the capitalization of such basic insights 
by translating them into diagnostic and therapeutic tools with clinical perspectives. 
Therapeutically, the multitude of subtle gene changes caused by individual miRNAs is 
attractive since this may allow for more ‘physiologic’ manipulation than single protein 
therapeutics. On the other hand, the prediction of potential side effects is complicated by 
2012100 proefschrift Maarten Corsten.indd   22 07-08-2012   08:37:39
MicroRNA Biology
23
2
miRNA versatility and will mandate careful analysis in clinical studies. Despite such concerns, 
selective miRNA inhibitors have been successfully used in non-human primates and are 
currently in phase II clinical trials60, 61, providing basic researchers with an important stimulus 
to pursue screening for therapeutic miRNA candidates. In addition, the potential of miRNA 
use as biomarkers for cardiovascular disease invites experimental and clinical investigation 
and may be directly translatable to clinical decision-making.
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ABSTRACT
Viral myocarditis is an important cause of heart failure for which no specific treatments are 
available. Direct viral injury to cardiac cells provokes an inflammatory response that 
significantly contributes to cardiac damage and ensuing morbidity. Despite the central 
pathogenic role of autoimmune injury, broad inhibition of the inflammatory response does not 
result in patient benefit. Many preclinical studies collectively emphasize that modulating 
distinct inflammatory signaling pathways may yield effective viral clearance while preserving 
cardiac structure. This review aims to provide an overview of the sometimes-contrasting 
observations from experimental viral myocarditis models and to translate the lessons learned 
into opportunities for future investigations and therapies. 
Inflammation in Viral Myocarditis; 
Friend or Foe?3
Modified from Trends in Molecular Medicine 2012;18:426-437 [IF 10.3]
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Background
Myocarditis is broadly defined as an inflammatory condition of the heart. It represents one 
of the most challenging clinical problems in cardiology, associated with a broad spectrum 
of pathological triggers and a wide range of clinical presentations that vary from mild 
dyspnea to acute heart failure and sudden death1, 2. Although the true incidence of 
myocarditis is unknown due to its difficult diagnosis and infrequent collection of 
endomyocardial biopsies, myocarditis is found in 9.6% of patients with unexplained heart 
failure3. It frequently affects young, previously healthy individuals4 and has been estimated 
to account for up to 12% of sudden deaths in patients under 40 years of age5. Although 
its prognosis varies by cause, five-year survival in aggregate cohorts of biopsy-proven 
myocarditis is approximately 50%6. Although mycarditis can also be caused by infection 
with bacteria, fungi, parasites, and non-infectious agents such as autoimmune disorders 
and drug-induced hypersensitivity, viruses are the most common cause of myocarditis in 
western society2, 7. Viruses associated with myocarditis in humans include enteroviruses, 
adenoviruses, influenza viruses, cytomegaloviruses, parvoviruses, herpes viruses, and 
human immunodeficiency virus7. Traditionally, the enteroviral coxsackievirus B3 (CVB3) and 
adenoviruses have been the most prevalent pathogens found in myocarditis biopsies, but 
more frequent identification of parvovirus B19 and human herpes virus 6 has been observed 
recently, the cause of which is incompletely understood7-9. Although most of these 
‘cardiotropic’ viruses are common viruses that cause only mild upper respiratory or 
gastrointestinal complaints in most individuals, their infection of the heart can, in some 
patients, cause direct cardiac damage followed by an inflammatory response that inflicts 
additional injury to the heart4. Clinical outcome is determined by the interplay between 
virulence, host response, and therapeutic intervention, and may range from subclinical 
disease to congestive heart failure with hemodynamic instability and death in the acute 
phase1. Subsequently, dilated cardiomyopathy (DCM) may result from chronic inflammatory 
activation due to incomplete clearance of cardiac viral genomes10-12, or due to an autoimmune 
response triggered by exposure to cardiac auto-antigens13-16. In the case of complete viral 
elimination with resolution of cardiac inflammation, patient outcome depends on the 
amount of irreversible damage inflicted to the myocardium17. Intriguingly, the observation 
that cardiotropic viruses are frequently found in heart tissue from patients with DCM8, 18 
suggests that viruses may also be hitherto unrecognized triggers for DCM by causing 
subclinical myocarditis. 
Although viruses can directly damage cardiac cells, the reactive inflammatory response 
significantly contributes to cardiac injury and ensuing morbidity1. A central theme in viral 
myocarditis research is therefore whether cardiac damage is primarily caused by direct 
virus-induced injury or by immune mechanisms. In this review we discuss the evidence 
for the beneficial versus adverse roles of inflammation in viral myocarditis and recapitulate 
the lessons learned from preclinical and clinical studies about inflammation as therapeutic 
target for this disease. 
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Infection versus autoimmune disease
There is strong clinical and experimental evidence demonstrating that viruses can directly 
cause cardiomyopathy19, 20 and that unsuccessful viral elimination may lead to progressive 
disease4, 10-12. Such observations support the idea that immune responses are required for 
defense of the virus-infected heart. By contrast, the extent of inflammation in patients with 
acute myocarditis is in itself an independent negative predictor of outcome9, and many 
preclinical studies have shown a protective effect of anti-inflammatory interventions during 
viral myocarditis in mice21-23. For example, a pioneer study by Woodruff in 1974 showed 
that depletion of T lymphocytes in mice by either thymectomy or anti-thymocyte serum 
reduced cardiac injury without affecting viral elimination21. Therefore, clearly not all 
inflammatory responses are beneficial and, consequently, the potential of interventions in 
the inflammatory response during myocarditis has been intensely studied24. While broad 
immunosuppression fails to improve cardiac function in myocarditis patients25, accumulating 
evidence from clinical and preclinical studies supports the feasibility of targeted strategies 
to improve disease outcome22, 26-28. The use of CVB3 infection in mice as a model of 
enteroviral infection in humans29, 30 (Figure 1) and our capability of genetically manipulating 
the mouse genome have broadened widely our understanding of the mechanisms 
underlying the acute and chronic pleiotropic effects of inflammation in viral inflammatory 
heart disease. Building on knowledge acquired from such animal models, the next sections 
will discuss the pathogenesis of cardiac injury during enteroviral infection, direct virus 
effects on myocyte homeostasis, and summarize our current understanding of the 
respective roles of the innate and adaptive immune system in both viral elimination and 
cardiac injury. 
Figure 1. Immunopathological features of viral myocarditis in humans and mice. Panels A-D show 
stainings of a right ventricular septal biopsy from a 49-year old female patient with acute viral myocarditis, 
presenting with acute dyspnea and soon developing cardiogenic shock due to impaired cardiac contractile 
function (left ventricular ejection fraction 15%). Histological examination showed foci of myocyte necrosis 
(A) and infiltration of the myocardium by CD45-positive leukocytes (B) containing both CD68-positive 
macrophages (C) and CD3-positive T lymphocytes (D). Panels E-H show comparable cardiac injury and 
leukocyte infiltration in Coxsackievirus-induced myocarditis in the heart of a male adult C3H mouse. 
Magnification: 200x. Human images were kindly provided by Dr. Bart de Vries from the Maastricht University 
Medical Center Pathology Department. 
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Pathogenesis of CVB3 induced myocarditis 
Coxsackieviruses are non-enveloped, single stranded RNA enteroviruses, belonging to the 
family of Picornaviridae. They are fecal-orally transmitted. While 50-80% of non-poliovirus 
enteroviral diseases are completely asymptomatic31, the group B coxsackieviruses (CVB) 
are associated with the development of myocarditis in humans, in particular serotype B34. 
Following uptake through the host gastrointestinal tract, CVB3 infects and replicates in 
lymphocytes and macrophages of Peyer’s patches and the spleen32, 33. Subsequently, 
infectious virions are released into the bloodstream and disseminate into organs such as 
the heart and pancreas. Target cell internalization occurs through interaction with two well-
studied surface receptors: the decay accelerating factor (DAF) is responsible for anchoring 
the virion to the cell surface, after which the coxsackievirus and adenovirus receptor (CAR) 
– which is shared by humans and mice – mediates cellular entry4. CAR-mediated 
internalization is a prerequisite for the development of CVB3-induced myocarditis as CAR 
deficient mice are resistant to both cardiac infection and inflammation34. Following virus 
uncoating, the 7.4 kilobase viral genome is translated into a single polyprotein, which is 
cleaved into functional proteins by virus-encoded proteases. The detailed molecular biology 
of CVB3 infection is beyond the scope of this review but has been excellently reviewed 
elsewhere4.
The development of viral myocarditis is generally divided into three distinct phases (Figure 
2). The first 3-4 days are the ‘acute’ phase, which is characterized by virus replication and 
interaction with myocyte signaling prior to cardiac infiltration by innate immune cells. Both 
direct proteolytic damage by the virus19 and recognition of viral pathogen motifs through 
cardiac toll-like receptors (TLRs)35 contribute to the increasing expression of pro-inflammatory 
cytokines including interleukin-1β (IL-1 β), IL-6, IL-18, tumor necrosis factor-α (TNFα), and 
type I and type II interferons (IFNs). These cytokines are produced by cardiac resident cells, 
including myocytes, fibroblasts, endothelial cells, and dendritic cells (DC)27, 36. Type I 
interferons (IFN-α and IFN-β) are especially important in the early antiviral response and 
have a range of effects on infected cells. They downregulate protein synthesis, stimulate 
p53-mediated apoptosis37, and upregulate the immunoproteasome and major 
histocompatibility complex (MHC) classes I and II. In concert, these cytokine signals activate 
local macrophages and upregulate endothelial adhesion molecules as well as chemokines 
and chemokine receptors to collectively trigger the recruitment of innate immune cells38.
The subacute phase, from day 4-5 to approximately day 14, commences with infiltration 
of the heart by cells of the innate immune system, including natural killer (NK) cells that 
are important for viral elimination by directly recognizing and killing infected cells39. In 
addition, monocytes engage in phagocytosis of dead cells and strongly augment the 
expression of pro-inflammatory cytokines. Within days, immune cells from the adaptive 
immune system also accumulate in the infected heart, including both T and B lymphocytes. 
CD8+ cytotoxic T cells directly bind and eliminate infected cells by recognizing MHC class 
I antigens on infected cardiomyocytes, assisted by the effects of TNF-α and IFN-γ which 
promote MHC class I presentation and facilitate cell-cell contact between T cells and 
myocytes40. CD4+ T helper cells do not directly kill infected cells but are important 
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mediators between professional antigen presenting cells and cytotoxic T cells as well as 
B cells, which produce neutralizing antibodies to limit viral replication41. During the subacute 
phase, the immune response not only eliminates infected and dead cells but also 
significantly contributes to irreversible cardiac damage. 
The third stage of viral myocarditis starts after complete elimination of the virus and is 
characterized by cardiac repair and remodeling. Anti-inflammatory cytokines such as 
transforming growth factor-β (TGF-β) and IL-10 secreted by regulatory T cells and alternatively 
activated (M2) macrophages promote resolution of the immune response and replacement 
of dead tissue by a fibrotic scar38. Depending on the extent of myocardial damage, cardiac 
dilation and compensatory hypertrophy during this phase may contribute to contractile 
dysfunction in the long term4. Alternatively, failure to completely clear virus from the heart 
may result in chronic inflammation and accelerated progression to DCM10, 12. In mice, acute 
viral myocarditis can result either in complete resolution of disease or chronic viral 
persistence and inflammation depending on the mouse strain used. Since awareness of 
such strain differences is helpful in tailoring experimental studies and interpreting results, 
they will be discussed in the next section. 
Figure 2. Pathogenesis of viral myocarditis. The pathogenesis of viral myocarditis if often divided 
into three phases. During the acute phase of viral myocarditis, viral infection (represented by the green 
pentagon) and replication in the heart cause cell death and cytokine responses from resident cells. During 
this phase, inflammatory signaling is largely protective to the heart. Cytokine signaling then causes an influx 
of immune cells (first innate, then adaptive) marking the subacute phase. These inflammatory cells engage 
in viral elimination but importantly contribute to cardiac injury. In the chronic phase, effective viral elimination 
leads to inhibition of the immune response by anti-inflammatory macrophages and regulatory T cells. These 
cells additionally stimulate repair processes such as fibrotic remodeling. Cardiac outcome is determined by 
the extent of irreversible damage inflicted during the acute and subacute phases. Conversely, replicating 
or nonreplicating virus can persist in the myocardium causing chronic inflammation and progressive left 
ventricular dysfunction.   
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Mouse models of enteroviral myocarditis
The susceptibility to enterovirus-induced viral myocarditis varies between mouse strains 
(as it does between patients), both with respect to the extent of cardiac inflammation and 
damage invoked during the subacute phase and with respect to viral elimination and 
development of chronic disease42. Such strain differences are important because they can 
affect findings from experimental studies, and these differences are summarized in Table 
1. Factors that have been associated with susceptibility include MHC haplotype43, 44, the 
balance of Th1 versus Th2 immune responses45, 46, the efficiency of DC antigen 
presentation47, 48, and genetic variations in the DAF and IFN-γ genomic regions49. Although 
all of these factors appear to influence disease severity, none of them is an exclusive 
determinant. For instance, the MHC haplotype H-2b has been associated with mild 
susceptibility to CVB3-induced myocarditis in C57Bl/6 and 129/SvJ mice, but haplotype-
matched A.BY/SnJ mice develop both an acute and chronic disease associated with failure 
to eliminate the virus4, 42, 47. Strains can also differ in the cardiospecificity of disease. C3H/
HeJ mice develop severe myocardial lesions while survival is high due to minimal systemic 
disease, whereas C57Bl/6 mice generally show a higher mortality despite limited cardiac 
damage, possibly associated with systemic pathology (unpublished observations). The 
enhanced susceptibility to viral myocarditis in males compared to females is well 
documented and will be discussed in more detail later in this review23, 45, 50. 
Differences in CVB3 strains used may also impact experimental data51. For instance, 
although the widely used Nancy strain of CVB352 results in cardiac disease that is highly 
similar to the originally patient-propagated Woodruff (H3) strain53, there may be subtle 
differences between the two, as it has been suggested that pathogenicity in from H3 strain 
may be more dependent on IFN-γ-mediated CD8+ T cell responses while reduction of IFN-γ 
signaling in Nancy-strain CVB3 disease is not beneficial, possibly due to more direct viral 
Table 1. Mouse strain susceptibility to the development of viral myocarditis
Mouse strain H-2 haplotype Susceptibility Viral elimination Reference
C57Bl/6 b low yes Chow et al.42
129/SvJ bc low yes Zaragoza et al.68
A.BY/SnJ b high no Klingel et al.12
A/J a severe yes Chow et al.42
C3H/HeJ k severe yes Chow et al.42
BALB/c d high yes Chow et al.42
CD1 ND high yes Godeny et al.39
DBA/1J q high no Klingel et al.12
DBA/2 d high yes Lee et al.69
SWR/J q high no Klingel et al.12
A.CA/SnJ f high no Klingel et al.12
a ND, not determined
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pathogenicity54. Finally, the encephalomyocarditis virus (EMCV) has also been used to study 
Picornaviral myocarditis in a smaller but significant number of studies as a histopathologically 
comparable model to CVB3 infection55.
Different mouse models of myocarditis resemble different aspects of human disease. 
Mice that develop acute myocarditis followed by complete viral clearance and resolution 
of inflammation are well suited to study inflammatory components during the acute 
phase in human patients. However, many patients present after the acute phase and 
their management may require the use of different mouse models. For instance, low-
grade inflammation associated with viral persistence is observed in a significant 
proportion of patients and this phenomenon may be better investigated in mice that fail 
to eliminate virus (Table 1). In addition, chronic autoimmune responses directed at self-
antigens that are temporarily exposed during the acute viral phase are well mimicked 
by the experimental autoimmune myocarditis (EAM) model. Integration of lessons 
learned from these different models will be important to identify suited therapeutic 
targets in different patients (acute versus chronic, virus positive versus negative) at 
different time points.
Determinants of cardiac injury in viral myocarditis
While cardiac viral replication and persistence are associated with the development and 
progression of myocarditis1, 10, 12, the relative contributions of virus and immune response 
to myocardial tissue destruction have long been debated. This debate is rooted in contrasting 
findings from early experimental studies of viral myocarditis in immune compromised mice. 
Woodruff and Woodruff reported in 1974 that T cell-deficient mice were protected from 
cardiac injury during CVB3 infection, suggesting that the T cell response contributes to 
adverse cardiac damage without being required for viral elimination21. By contrast, Chow 
et al. later found that severe combined immunodeficiency (SCID) mice, which lack both B 
and T cells, display aggravated disease with increased mortality, cardiac damage, and viral 
titers20, providing evidence for CVB3 virulence as an important causal factor in myocarditis. 
Although damage from uninhibited viral activity may not accurately reflect the viral 
contribution to myocarditis in an immune competent host31, these studies have ignited 
extensive research into the contributions of components from both the innate and adaptive 
immune system. In this section we describe the available evidence for direct cytopathic 
effects from CVB3, as well as for the roles of inflammatory activation during the course of 
viral myocarditis. A comprehensive overview of experimental manipulations to the immune 
system and associated phenotypes is provided in Table 2.
Direct virus-mediated cardiac injury
In line with the aggravated damage observed in SCID animals, the potential of CVB3 to 
directly damage myocardial cells has clearly been demonstrated in vivo and in vitro4, 56. 
Microscopically, infection of the virus leads to cardiomyocyte vacuolation, apoptosis, and 
necrosis before the infiltration of inflammatory cells57. Also, transgenic overexpression of 
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replication-deficient CVB3 in the mouse heart leads to low-grade degeneration of myocytes 
and cardiac dilation58. Following entry into the cellular cytosol, CVB3 translation leads to 
the release of viral proteases. These proteases manipulate cellular homeostasis, for instance 
by inhibiting host protein synthesis, and damage structural proteins. A well-known example 
is cleavage of the cytoskeletal protein dystrophin and the dystrophin-associated glycoproteins 
α-sarcoglycan and β-dystroglycan by the enteroviral protease 2A19, 59. Dystrophin plays an 
important role in myocardial integrity by connecting the muscle fibers to the extracellular 
matrix. In line with these findings, transgenic mice with cardiac overexpression of protease 
2A develop spontaneous DCM60. Finally, myocyte apoptosis, induced by either host 
interferon responses or virus signaling to release progeny at the end of the infectious cycle, 
can contribute to myocyte loss in the acute phase of myocarditis4.
The innate immune response
The innate immune system provides a fast, non-specific response to tissue damage and 
infections. It recognizes pathogen-associated molecular patterns by either circulating 
proteins of the complement system, which neutralize extracellular pathogens, or by cellular 
TLRs, leading to activation of downstream signaling. Non-immune cells and innate immune 
cells (including monocytes-macrophages, DCs, and NK cells) interact with each other 
through a wide variety of cytokines including type I and II IFNs, which have potent antiviral 
effects. Most of these aspects have been experimentally manipulated with widely varying 
protective or detrimental effects in the context of viral myocarditis. 
Complement proteins, as immediate effectors of innate antimicrobial defense, appear to 
have protective effects on the heart. Mice deficient for complement protein 1 and 2 
receptors display increased cardiac damage and macrophage infiltration during CVB3 
infection61, whereas C3 is required for the rapid formation of splenic antiviral germinal 
centers62. NK cells are also important for cardiac protection by selectively killing CVB3 
infected cells, thus limiting CVB3 infection63, and depletion of NK cells prior to CVB3 
infection leads to increased viral titers in the heart and aggravated myocyte degeneration39. 
Similarly, natural killer T (NKT) cells – an innate subset of T cells that are important for early 
antiviral responses – are also beneficial in the early phase; administration of an activating 
ligand for invariant NKT cells suppresses viral levels and inflammation in the heart through 
an early increase in IFN-γ activity64. By contrast, broad depletion of innate immune cells 
by administering antibodies against Mac-1 (expressed on monocytes, macrophages, and 
NK cells) reduces both viral levels and myocardial inflammation after encephalomyocarditis 
virus (EMCV) infection65, indicating that innate immune cells other than NK cells may not 
be equally beneficial to the host. Macrophages, which represent the most abundant cells 
in inflammatory lesions during the acute phase12, may account for part of this effect. It 
was recently shown that classically activated (M1) macrophages – which produce abundant 
pro-inflammatory cytokines including TNF-α and IL-1266 – are important contributors to 
cardiac inflammation and injury during myocarditis in BALB/c mice23. Hearts of male 
animals (who are more susceptible than females) display higher proportions of M1 
macrophages than female hearts. Adoptive transfer of M1 polarized macrophages into 
female mice significantly increased the female inflammatory response to infection. 
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Table 2. Phenotypic effects of experimental immune manipulations during viral myocarditisa,b,c
Manipulation Strain Virus
Cardiac 
damage
Cardiac 
titers Mortality Reference
Innate immune system
Complement receptor 1/2 global KO A/J CVB3-Nancy + = + Fairweather et al.61
MAC-1+ cell depletion DBA/2 EMCV - - NR Hirasawa et al.65
NK cell depletion CD1 CVB3-Nancy + + NR Godeny et al.39 
NKT cell activating compound BALB/c CVB3-Nancy - - - Wu et al.64
Adoptive transfer of 'M1' macrophages BALB/c CVB3-Nancy + NR NR Li et al.23
Adoptive transfer of 'M2' macrophages BALB/c CVB3-Nancy - NR NR Li et al.23
NOS inhibition B10.A CVB3-H3 NR + + Lowenstein et al.67
Genetic NOS2 gene disruption 129/Sv CVB3-Nancy + + + Zaragoza et al.68
Serine elastase inhibition DBA/2 EMCV - = = Lee et al.69
TLR4 global KO BALB/c CVB3-Nancy - - NR Fairweather et al.71
TLR9 global KO C57Bl/6 CVB3-Nancy - = NR Riad et al.72
MyD88 global KO C57Bl/6J CVB3-CG - - - Fuse et al.27
TLR3 global KO C57Bl/6 CVB3-Nancy + + NR Weinzierl et al.47
TRIF global KO C57Bl/6 CVB3-Nancy + + + Riad et al.28
Myocyte-specific SOCS1 TG BALB/c CVB3-H3 + + + Yasukawa et al.77
Myocyte-specific SOCS3 TG BALB/c CVB3-H3 + + + Yajima et al.78
IFN-β administration CD1 CVB3 (NF) - * = NF Lutton et al.73
IFN-β inhibition CD1 CVB3 (NF) - ** NR NF Lutton et al.73
IFN-β global KO 129Sv/C57Bl/6 CVB3-CG + = + Deonarain et al.74
Pancreatic TGF-β TG NOD/shi CVB3-Nancy - = Horwitz et al.88
IFN type I receptor KO 129/SvJ CVB3-H3 NR = + Wessely et al.75
IFN type II receptor KO 129/SvJ CVB3-H3 NR = = Wessely et al.75
IFN gamma global KO BALB/c CVB3-Nancy = + NR Fairweather et al.71
Pancreatic IFN-y TG NOD/shi CVB3-Nancy - - - Horwitz et al.76
TNF-α administration C57Bl/10 CVB3-Nancy + NR NR Lane et al.79
Stabilized TNF-α global knock-in 129Sv/C57Bl/6 EMCV + - + Huang et al.80 
TNF-α global KOs C57Bl/6J EMCV - + + Wada et al.81
Il-6 administration C3H/HeJ EMCV - - NR Kanda et al.83
Il-6 global TG C57Bl/6 EMCV + + NR Tanaka et al.82
Il-1 administration C57Bl/10 CVB3-Nancy + NR NR Lane et al.79
Il-18 administration C3H/HeJ EMCV - ** - - Kanda et al.84 
Il-12Rβ1 global KO BALB/c CVB3-Nancy - - NR Fairweather et al.71
TIM-3 inhibition BALB/c CVB3-Nancy + NR NR Frisancho et al.89
Il-10 global KO C57Bl/6 CVB3-Nancy + = NR Szalay et al.87
Pancreatic Il-4 TG NOD/shi CVB3-Nancy = = = Horwitz et al.88
MIP-1α global KO C57Bl/6 CVB3 (NR) - NR NR Cook et al.85
IP-10 global KO C57Bl/6 CVB3-Nancy + = NR Weinzierl et al.47
DN IP-10 mutant gene therapy BALB/c CVB3-Nancy - = - Yue et al.86
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follow up of table 2
Manipulation Strain Virus
Cardiac 
damage
Cardiac 
titers Mortality Reference
uPA global KO C57Bl/6 CVB3-Nancy # - = NR Heymans et al.90
AdV-TIMP1 C57Bl/6 CVB3-Nancy # - NR NR Heymans et al.90
AdV-PAI-1 C57Bl/6 CVB3-Nancy # - NR NR Heymans et al.90
MMP-2 global KO C57Bl/6 CVB3 (NR) + + + Westermann et al.92
MMP-9 global KO 129/SvEv CVB3-CG + + = Cheung et al.91
MMP-8 global KO C57Bl/6 CVB3-CG = = = Cheung et al.91
Adaptive immune system
Thymectomy/antithymocyte serum BALB/c CVB3-H3 - = NF Woodruff et al.21 
Athymic nude mice BALB/c CVB3-Nancy - = = Hashimoto et al.99 
Athymic nude mice BALB/c CVB3 (NF) = = NF Robinson et al.100
Athymic nude mice NFR CVB3 (NF) = - NF Schnurr et al.101
SCID C3H/HeSnJ CVB3-CG + + + Chow et al.20
CD4 KO A/J CVB3-CG = = = Opavsky et al.102
CD8 KO A/J CVB3-CG = = = Opavsky et al.102
CD4/8 double KO A/J CVB3-CG - = - Opavsky et al.102
TCR β-chain KO A/J CVB3-CG - = - Opavsky et al.102
Perforin KO C57Bl/6 CVB3-H3 - = - Gebhard et al.104
Perforin global KO C57Bl/6 CVB3-Nancy = = = Klingel et al.103 
Fas global KO BALB/c CVB3-H3 - NR NR Huber et al.106
FasL global KO BALB/c CVB3-H3 - NR NR Huber et al.106
γδ T cell depletion C57Bl/6*** CVB3-H3 - - NR Huber et al.107
Adoptive transfer of T cells F-to-M BALB/c CVB3-H3 - = NR Huber et al.45
MHC class II global KO C57Bl/6 CVB3 (NR) - + NR Leipner et al.110
β-2 microglobulin global KO C57Bl/6 CVB3-Nancy + + = Klingel et al.103 
CD1d global KO BALB/c CVB3-H3 - = = Huber et al.126
B cell KO C57Bl/6 CVB3-Nancy + + NR Mena et al.111
Adoptive transfer of regulatory T cells C57Bl/6 CVB3 (CG) - - - Shi et al.22
Estradiol administration to males C57Bl/6*** CVB3-H3 - - NR Huber et al.107
Testosterone administration to females C57Bl/6*** CVB3-H3 + + NR Huber et al.107
Male gonadectomy BALB/c CVB3-Nancy - = NR Frisancho et al.50
“+”, “=”, and “-“ signify increases, no changes, and decreases, respectively
Abbreviations: NR not reported; NF not found; KO knockout; TG transgenic mouse; DN dominant negative; AdV adenoviral 
overexpression; F-to-M female to male; CVB3-CG Charles Gauntt strain (propagated from and closely related to the H3 strain)
* Only when treated early in disease
** Only when treated late in disease
*** Transgenic C57Bl/6 strain (B1.Tg.Eα) expressing MHC class II IE
# Lipopolysacharide (LPS) was also administered as adjuvant stimulus
General comment: many components of the immune system are not exclusive to either innate or adaptive responses. We have 
made a rough separation for heuristic purposes only
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By contrast, transfer of M2 macrophages, which secrete anti-inflammatory cytokines such 
as IL-1066, into male animals inhibited cardiac disease, with non-significant effects on viral 
levels23. Importantly, the detrimental effects of innate cells on the myocardium are not 
mediated by the toxicity of nitric oxide (NO), which is secreted in large quantities by 
macrophages and neutrophils, because pharmacological or genetic targeting to reduce the 
concentration of NO both result in increased viral titers and aggravated disease67, 68. By 
contrast, serine elastase activity from leukocyte infiltration has been shown to mediate 
adverse effects and be a potential therapeutic target69.
There is strong evidence that the activation of distinct TLR signaling cascades following 
pathogen recognition leads to beneficial or adverse immune responses35 (Figure 3). 
Figure 3. Effects of toll-like receptor (TLR) signaling pathways in viral myocarditis. Schematic 
representation of signaling from selected TLRs after PAMP (pathogen associated molecular pattern) 
recognition. TLR4 and TLR9 signaling contribute to disease severity in mouse viral myocarditis through their 
common adapter protein MyD88. TLR4 is located on the cell membrane and recognizes lipopolysacharide 
(LPS) as well as several viruses. TLR9 recognizes unmethylated CpG motifs on bacterial or viral DNA in 
endosomes. Signaling through the MyD88-dependent pathway initiates a signal transduction cascade 
involving TNF receptor-associated factor 6 (TRAF-6) and Interleukin-1 associated kinase (IRAK) that 
ultimately leads to nuclear factor kappa B (NF-κB) activation, which may contribute to the inflammatory 
response. Alternatively, signaling through TLR3 is protective in viral myocarditis. TLR3 is the only TLR that 
does not signal through MyD88 but through TIR domain-containing adapter-inducing interferon-β (TRIF), 
which promotes type I and II interferon responses via interferon regulatory factor 3 (IRF-3) and is necessary 
for adequate antiviral defense in myocarditis.
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Of the 10 TLRs shared by humans and mice, the majority signal through a common 
downstream adaptor molecule called myeloid differentiation primary response gene 88 
(MyD88), which typically leads to activation of nuclear factor kappa B (NF-κB)35. An important 
exception is TLR3, which recognizes double-stranded RNA and signals through TIR-domain-
containing adapter-inducing interferon-β (TRIF), which activates interferon regulatory factor 
3 (IRF3) to upregulate both type I and type II IFN expression35, 70. 
Although not all TLRs have been investigated in knockout models, both TLR4- and TLR9-
deficient mice are protected against CVB-induced cardiac injury with uncompromised viral 
clearance71, 72. In agreement with these studies, deficiency of the common adaptor protein 
MyD88 leads to nearly absent inflammation in combination with suppressed viral levels in 
cardiac tissue27. These data indicate that the effects of the MyD88-mediated TLR signaling 
pathways contribute to cardiac pathology while bearing little importance for viral elimination. 
By contrast, viral replication and cardiac damage are aggravated in TLR3 knockout animals47, 
70, and transgenic overexpression of TLR3 decreases mortality even in type I IFN deficient 
animals through stimulation of type II IFN signaling70. In agreement, mice lacking the TLR3-
adaptor TRIF have impaired type I IFN responses and develop severe myocarditis with high 
viral loads, resulting in 100% mortality28.
Cytokines in the innate immune response
In line with the central role of IFNs in antiviral responses, administration of IFN-β reduces 
myocardial lesions when given in the acute stage of CVB3-induced myocarditis73. Conversely, 
inhibiting IFN-β ameliorates disease only when given in a later stage, suggesting that the 
favorable effects of type I IFN may be time-dependent73. Survival is markedly reduced in 
mice lacking either the IFN-β gene74 or the type I IFN receptor75 (thus deficient in both IFN-α 
and IFN-β signaling). Interestingly, although IFN-β knockouts also display increased 
myocardial damage, cardiac viral levels are unchanged in both knockouts despite dramatic 
viral replication in the liver, possibly causing the observed mortality. Mortality and viral titers 
were not affected in IFN-γ deficient animals75, although pancreatic overexpression of IFN-γ 
protects against cardiac damage, viral replication, and mortality following CVB3 infection76. 
IFN effects are partly mediated through the janus kinase (JAK)-signal transducer and 
activator of transcription (STAT) signaling pathway, and myocyte-restricted transgenic 
overexpression of either of two key inhibitors of this pathway, suppressor of cytokine 
signaling-1 (SOCS-1) and SOCS-3, markedly augments cardiac damage and viral replication, 
showing that JAK-STAT signaling is important for myocyte resistance to CVB377, 78. Aiming 
to translate the beneficial effects of IFN signaling to the patient setting, a phase II pilot 
study reported that 6 months of IFN-β administration to 22 patients with persistent left 
ventricular (LV) dysfunction and viruses in LV biopsies resulted in complete viral clearance 
and improved LV function26. Although promising, these results await confirmation in 
randomized controlled studies17. 
In addition to IFNs, a broad range of pro- and anti-inflammatory cytokines have been 
functionally studied as treatment targets in the context of viral myocarditis; their effects are 
often dose- and time-dependent. For example, exogenous TNF-α administration during CVB3 
infection aggravates myocardial damage79, and transgenic mice bearing a genetically 
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stabilized form of TNF-α (which leads to enhanced TNF expression and activity) display 
increased cardiac damage after EMCV infection, albeit with enhanced viral clearance80. 
However, systemic TNF-α deficiency also leads to more cardiac injury and mortality after 
EMCV infection, which can be rescued by exogenous administration of TNF-α during the 
acute phase of disease81. Collectively, these studies demonstrate that TNF-α is an antidote 
for cardiac viral infection but with the need for accurate dosing, given that either insufficient 
or exaggerated expression of TNF-α is equally harmful. Dose- and time-dependency were 
also observed for IL-6, as transgenic overexpression of IL-6 aggravates the course of EMCV 
myocarditis82 whereas recombinant IL-6 administration in the acute, but not subacute phase, 
is protective83. Similarly, beneficial effects of IL-18 treatment (involving enhanced NK cell 
activity) were only observed from treatment at the time of infection, whereas initiation of 
treatment at day 2 post-infection failed to provide cardioprotection84. Detrimental roles have 
been ascribed to two other pro-inflammatory cytokines, IL-1 and IL-12. IL-1 administration 
increases cardiac damage during CVB3 infection79 and mice deficient for the IL-12 receptor 
have dramatically reduced damage and cardiac viral loads71. Chemokines have diverging 
effects during myocarditis: myocardial damage is reduced in knockout mice for macrophage 
inflammatory protein-1α (MIP-1α, also known as CCL3)85 as well as in animals treated with 
inhibitors for IFNγ-induced protein-10 (IP-10, also known as CXCL10)86. However, damage 
is increased in animals systemically deficient for IP-10, and more research is required to 
draw conclusions about the roles of chemokines during viral myocarditis47.
In general, anti-inflammatory cytokines have been associated with the attenuation of viral 
myocarditis. For instance, IL-10 knockout animals fail to resolve the inflammatory response 
after the acute phase leading to chronic disease and cardiac injury87. Myocarditis is also 
inhibited by pancreatic overexpression of TGF-β, although surprisingly not by the anti-
inflammatory IL-488. Also, expression of immunomodulatory T cell Ig mucin-3 (TIM-3) during 
the innate immune response is important for controlling adverse inflammation, partly 
through cross-talk with the adaptive immune system89, 90.
A final molecular class that merits mentioning are the matrix metalloproteinases (MMPs); 
although not exclusively part of the immune system, they exert critical functions in the 
inflammatory response, including matrix degradation and facilitation of leukocyte migration, 
as well as cytokine processing and regulation38. Many MMPs are upregulated during viral 
myocarditis and seem to be net detrimental, given that inflammation and fibrosis are 
reduced by broad inhibition of MMP activity in mice deficient for the MMP-activating 
urokinase-type plasminogen activator (uPA) or viral overexpression of endogenous inhibitors 
tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor-1 (PAI-
1)90. Surprisingly, mice deficient in single MMPs have yielded contrasting findings. Whereas 
inflammation and viral load is not affected in MMP-8 knockouts, mice lacking MMP-9 have 
increased myocardial damage and dysfunction associated with higher viral loads and 
infiltration91. Similar findings were recently reported for MMP-3, which seems related to 
increased expression of the macrophage chemoattractant protein-3 (MCP-3)92. Further 
research is required for a better understanding of the role of MMPs during viral 
myocarditis.
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The adaptive immune response
The adaptive immune system responds to specifically recognized antigenic epitopes 
through clonal expansion of antigen-specific T and B lymphocytes, causing cellular and 
humoral antibody-mediated immune responses, respectively. Pathogen neutralization by 
the adaptive immune system is more sophisticated than during the innate response, and 
its contribution to cardiac injury is more complex. Although CD8+ T lymphocytes directly 
contribute to myocyte death by killing infected cells, there is strong evidence that the 
generation of autoimmune reactivity during virus-induced inflammation may significantly 
contribute to disease severity46, 93. For instance, following early antiviral antibody production, 
the accumulation of antibodies directed at cardiomyocyte constituents, such as myosin, 
is a common finding in both CVB3-infected mice and myocarditis patients94, 95. Factors that 
influence the likelihood and severity of self-reactivity include the duration of viral antigenic 
exposure17. In addition, Th1 signaling favoring IFN-γ-mediated cellular immune responses 
seems to promote autoimmune cardiac damage as compared with Th2 signaling which 
favors antibody-mediated immune responses45. Differential propensities to Th1 versus 
Th2 responses have been shown to account for variable susceptibility across different 
mouse strains, as well as differential responses based on gender44, 45. 
Auto-reactive responses during viral myocarditis develop in different ways93. Increased 
exposure to auto-antigens from dying cells can cause activation of low-affinity self-reactive 
clones that have evaded negative selection during lymphocyte maturation. Alternatively, 
similarity between viral epitopes and host proteins leads to cross-reactivity, a process called 
molecular mimicry. Whereas antibodies against CVB3 can cross-react with cardiac myosin 
and aggravate viral myocarditis in mice96, the parallel presence of autoantibodies directed 
against a range of host proteins is more in agreement with pathogenetic mechanisms of 
auto-exposure93. Concordantly, injection of apoptotic cardiomyocytes in combination with 
lipopolysaccharide (LPS) stimulation is sufficient to provoke myocarditis97. In fact, the most 
frequently used models of experimental autoimmune myocarditis (EAM) involve injecting 
either dendritic cells loaded with a self antigen (typically myosin) or free myosin into mice 
in combination with appropriate adjuvants that stimulate TLRs and T cell receptors93, 97, 98. 
As previously mentioned, it has long been known that mice deficient in T cells develop milder 
myocarditis irrespective of viral levels21. Several studies in athymic nude mice subsequently 
showed either cardiac protection or no change in disease, suggesting that T cells are at least 
not essential to CVB3 defense, if not detrimental99-101. These observations were followed by 
a more detailed study of T cell subsets by Opavsky and colleagues, using mice deficient in 
CD4, CD8, or both co-receptors102. Whereas the phenotypes of single CD4 and CD8 knockout 
mice were grossly unaffected, survival and cardiac histology were markedly improved in 
CD4/CD8 double knockouts. Viral loads were unaffected in all of the strains. In addition, 
deficiency of the T cell receptor beta chain was equally protective as CD4/CD8 deficiency102. 
An important insight from this study was that both CD4 and CD8 cells contribute to adverse 
inflammation and that each can compensate for deletion of the other.
Given the prominent role of T cells in the pathogenesis of viral myocarditis, two subsequent 
studies have evaluated the role of perforin, the main cytotoxic effector molecule of CD8+ 
cytotoxic cells. Their findings are slightly discrepant. Whereas Klingel et al. found no 
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differences in myocarditis, viral load, and mortality between perforin knockout and wild-type 
mice103, Gebhard and colleagues reported improved survival and cardiac histology in perforin 
deficient animals104. Although the reasons for these discrepancies are unclear, both studies 
are consistent with the borderline protection observed in CD8 knockout animals102. 
Also, both indicate that perforin is not vital for an adequate immune response in enteroviral 
myocarditis.
A series of papers from Huber et al. has indicated that γδ T cells (a subset of T cells 
expressing the γδ T cell receptor) may be central mediators of myocarditis susceptibility, as 
they are enriched in lymphocytes isolated from myocarditis mouse hearts105. Activity of γδ 
T cells promotes cardiac damage through Fas-mediated killing of myocytes and Th2 cells, 
hence polarizing the cell population towards Th1 responses105, 106, whereas depletion of γδ 
T cells results in a shift towards Th2 signaling that results in disease resistance44, 107. 
An effective immune response requires the adequate temporal and spatial regulation of 
inflammatory activity. Within the adaptive immune system, CD4+CD25+FOXp3+ regulatory 
T cells fulfill this function by secreting anti-inflammatory cytokines such as IL-10 and 
dampening Th1 responses108. Regulatory T cells are efficiently induced in the heart by CVB3 
infection109, and adoptive transfer of regulatory T cells to BALB/C mice prior to CVB3 
infection reduces mortality, histological injury, and cardiac viral titers compared with naïve 
T cells and PBS controls22, identifying regulatory T cells as important modulators of 
inflammation with a beneficial role in viral myocarditis.
In addition to isolated T cell subset studies, the involvement of adaptive immunity has been 
addressed in a broader fashion. Interestingly, MHC class II knockout mice display diminished 
subacute inflammation similar to T cell deficient mice, but this is associated with a lack of 
neutralizing antibodies, viral persistence, and chronic disease with marked cardiac fibrosis110. 
In agreement with this finding, it has been proposed that effective MHC class II-antigen 
presentation by DC may be an important determinant of resistance against viral myocarditis47. 
Strong evidence for the beneficial importance of lymphocyte responses was also provided 
by the inability of severely immune deficient SCID mice to control viral replication, leading 
to both increased myocarditis and mortality20. It is conceivable that differential B lymphocyte 
defects may explain some of the discrepancies between these models. Consistent with 
this notion, B cell knockout animals fail to eliminate virus throughout their lifetime and 
develop severe inflammatory pathology over time111.
Interplay between viral replication and inflammation
Table 2 summarizes the details and outcomes of inflammatory manipulations during viral 
myocarditis. From this table emerges a striking and perhaps surprising correlation 
between reported cardiac inflammatory changes and cardiac viral loads. Although it 
might be hypothesized that attenuating inflammatory activity could allow for increased 
viral replication, it is the opposite that occurs. From 46 studies that primarily intervened 
in the immune response and reported on both cardiac inflammation (increased or 
attenuated) and viral titers, 25 (54%) observed homodirectional viral load changes, 18 
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(39%) did not find differences in viral titers, and only 3 (7%) reported viral load changes 
to be inversely correlated to the level of myocarditis. These paradoxical findings are 
consistent with the view that many immune activities are not required for viral elimination. 
They also indicate that inflammatory signaling and viral replication may be closely 
intertwined112. Indeed, inflammatory signaling environments support virus-driven cellular 
signaling for successful replication113-116. For example, p38 mitogen-activated protein 
kinases (p38 MAPK) are a class of stress-responsive kinases that mediate cellular 
signaling responses to a variety of stress-stimuli such as cytokines117, 118. CVB3 infection 
also causes p38 MAPK activation, which is required for viral replication116, and inhibition 
of p38 MAPK signaling impairs viral replication both in vitro and in vivo113. An addition, 
ERK signaling promotes enteroviral replication in both T cells and cardiomyocytes4. Such 
observations may reflect a viral strategy of adapting to host signaling and help explain 
the positive correlation between inflammatory activity and viral loads. In addition, 
because viral replication in hematopoietic cells seems important, at least in the early 
infectious phase, immune signaling may directly affect early CVB3 replication in 
leukocytes to impact remote viral titers33, 111, 119.
Gender differences in viral myocarditis
The impact of gender on susceptibility to viral myocarditis is widely recognized, both in 
humans and mice. Myocarditis more frequently affects men versus women1, 2. Also, CVB3 
infection in mice leads to more severe inflammation and lesions in males compared with 
female mice45. Several explanations have been proposed to explain such differences. Huber 
et al. reported in 1994 that infiltrates in male BALB/c mice contained many lymphocytes 
of the Th1 subtype, whereas Th2 cells were more predominant in female lesions45. 
Moreover, treatment of male mice with estrogen increased the frequencies of IL-4 
producing Th2 cells and conferred myocarditis resistance, whereas testosterone 
administration to female mice enhanced their susceptibility and cardiac accumulation of 
IFN-γ expressing Th1 cells45. A follow-up study suggested that the differential Th1/Th2 
response may in part be explained by the polarizing effects of γδ T cells, which were more 
abundant in male and testosterone-treated female mice107. Indeed, IFN-γ deficient females 
develop more myocarditis and higher viral titers than males54, confirming the importance 
IFN-γ signaling mediated effects for gender susceptibility. In addition to IFN-γ, elevated 
TLR4 levels in male versus female mouse lesions have also been linked to the diverging 
immune response, as well as the higher abundance of anti-inflammatory mediators (such 
as TIM-3, IL-4, and regulatory T cells) in females120. 
Macrophage activity also affects sex-related susceptibility. Macrophages in the inflammatory 
infiltrates of male BALB/c mice are predominantly of the classically activated M1 subtype, 
associated with high expression of pro-inflammatory cytokines including IL-12 and TNF23. 
By contrast, female mice have large numbers of anti-inflammatory M2 macrophages. 
Adoptive transfer of M2 macrophages ameliorates myocarditis in male mice whereas M1 
macrophages aggravate inflammation in females, convincingly demonstrating the 
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importance of such subsets for disease development23. Also, gonadectomy in male mice 
protects them against CVB3 induced myocarditis by increasing the numbers of M2 
macrophages, Th2 cells, and T regulatory cells50. It is therefore likely that gender differences 
in susceptibility are governed by an intricate crosstalk between innate and adaptive 
mechanisms rather than a single culprit mechanism. 
Concluding remarks
Management of viral myocarditis represents a difficult challenge for both clinicians and 
biomedical researchers. Factors including symptomatic and etiological heterogeneity, low 
incidence in the general population, and the limited collection of endomyocardial biopsies 
have complicated systematic investigation and the development of specific therapies. 
Because virulence and immune responses both contribute to the pathogenesis of viral 
myocarditis, both could be targets of therapeutic intervention. However, the clinical 
benefits of antiviral therapy to prevent an inflammatory response may be limited because 
most patients present in the subacute or chronic phases of disease. Broad suppression 
Figure 4. Protective and adverse cellular factors in viral myocarditis. Different leukocyte subsets 
have divergent effects on myocarditis severity in mice. Predominantly protective cell types include natural 
killer (NK) cells, alternatively activated (M2) macrophages, T helper 2 (Th2) cells, regulatory T cells, and B 
cells. NK cells are important for viral elimination and B cells through neutralizing antibody production. M2 
macrophages, Th2 cells and regulatory T cells have ‘anti-inflammatory’ properties, which disfavor cellular 
immune responses leading to tissue injury. Leukocyte subsets with predominantly adverse effects include 
classically activated (M1) macrophages, Th1 cells, cytotoxic T cells and γδ T cells. These cells contribute 
to pro-inflammatory signaling, cellular immune responses and cardiac injury, which may outweigh their 
contribution to viral elimination.
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of inflammation has not shown benefits for patients with an aggregate, non-specified 
diagnosis of myocarditis17, 25, 121, however, there is evolving evidence that tailored treatment 
for patients subgroups may be feasible26, 122-125. These insights are paralleled by a rapidly 
growing understanding of the inflammatory contribution to cardiac injury in viral myocarditis, 
which suggests that effective therapies should aim for selective intervention in the 
immune response rather than broad immunosuppression. In this review, we have 
summarized the available evidence for beneficial and detrimental pathways of both the 
innate and adaptive immune system during viral myocarditis. Such evidence suggests 
that potential targets for immune modulation include selectively stimulating or suppressing 
TLR signaling pathways (Figure 3), exogenous polarization of macrophage activation 
subtypes, and suppression of Th1 versus Th2 responses, for instance by stimulating 
regulatory T cell differentiation (Figure 4). 
The most clinically advanced strategy encompasses immune modulation through IFN-β 
administration, which was suggested to benefit patients from the results of a 2003 
phase II trial but is awaiting validation under randomized and placebo-controlled 
conditions17, 26. Finally, it will be important to extend the findings generated in experimental 
models of enteroviral myocarditis to models of other viruses such as PVB19 and HHV6, 
which are increasingly found in hearts of myocarditis patients and may differ in their 
response to treatment. While viral myocarditis remains a daunting task for cooperation 
between cardiologists and immunologists, steadily accumulating insights have identified 
novel therapeutic opportunities, such as modulating TLR activity and stimulating anti-
inflammatory cell types, that mandate further exploration and clinical translation in the 
near future.
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MicroRNA profiling identifies microRNA-155 
as an adverse mediator of cardiac injury and 
dysfunction during acute viral myocarditis 
Modified from Circulation Research 2012;111:415-425 [IF 9.5]
ABSTRACT
Rationale  Viral myocarditis results from an adverse immune response to cardiotropic 
viruses, which causes irreversible myocyte destruction and heart failure in previously healthy 
people. The involvement of microRNAs and their usefulness as therapeutic targets in this 
process are unknown.
Objective  To identify microRNAs involved in viral myocarditis pathogenesis and 
susceptibility.
Methods and Results  Cardiac microRNAs were profiled in both human 
myocarditis and in Coxsackievirus B3-injected mice, comparing myocarditis-susceptible to 
non-susceptible mouse strains longitudinally. MicroRNA responses diverged depending on 
the susceptibility to myocarditis after viral infection in mice. MicroRNA-155, -146b and -21 
were consistently and strongly up-regulated during acute myocarditis in both humans and 
susceptible mice. We found that microRNA-155 expression during myocarditis was localized 
primarily in infiltrating macrophages and T lymphocytes. Inhibition of microRNA-155 by a 
systemically delivered LNA-antimiR attenuated cardiac infiltration by monocyte-macrophages, 
decreased T lymphocyte activation and reduced myocardial damage in acute myocarditis in 
mice. These changes were accompanied by the de-repression of the direct microRNA-155 
target PU.1 in cardiac inflammatory cells. Beyond the acute phase, microRNA-155 inhibition 
reduced mortality and improved cardiac function during 7 weeks of follow-up.
Conclusions  Our data show that cardiac microRNA dysregulation is a characteristic 
of both human and mouse viral myocarditis. The inflammatory microRNA-155 is up-regulated 
during acute myocarditis, contributes to the adverse inflammatory response to viral infection 
of the heart, and is a potential therapeutic target for viral myocarditis.
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Introduction
Acute viral myocarditis (VM) is an important cause of sudden cardiac death and heart 
failure in otherwise healthy young persons1. Its pathogenesis is based on an adverse 
immune response evoked by infection of the cardiac muscle by cardiotropic viruses, 
which leads to viral elimination as well as cardiac myocyte destruction, reparative fibrosis 
and heart failure. The lack of effective therapies to treat myocarditis mandates a better 
understanding of the basic molecular mechanisms that govern the adequate and auto-
destructive inflammatory signaling pathways within the immune system2. Here, we 
investigated the hitherto unknown role of microRNAs as possible molecular drivers in 
the pathogenesis of VM.
MicroRNAs (miRNAs) represent a class of small non-coding RNAs that control the 
expression of entire networks of complementary transcripts3. In the heart, miRNAs have 
been shown to be necessary for normal embryonic development4 and homeostasis5. While 
individual miRNAs have been linked to specific cardiac diseases including hypertrophic 
remodeling (miR-1996, miR-208a7), fibrosis (miR-218, miR-299) and ischemia (miR-2410, 
miR-49911, miR-92a12), the role of miRNAs in inflammatory cardiac processes and more 
specifically during VM has not yet been established. Here, we report diverging expression 
profiles of miRNAs in VM-susceptible compared to VM-resistant mouse strains. Among 
others, miR-155, a known pro-inflammatory regulator of myeloid and lymphoid immune 
cell function13-15, is consistently up-regulated in human and mouse cardiac samples of VM 
during the acute inflammatory phase, and is primarily expressed by recruited inflammatory 
cells. Pharmacological inhibition of miR-155 by a systemically delivered locked nucleic acid 
(LNA)-antimiR – a class of miRNA inhibitors that has been successfully used in primate 
studies16, 17 and is currently in human clinical trials – attenuates cardiac inflammation and 
necrosis in acute mouse VM, and reduces mortality and contractile dysfunction in long-term 
follow-up. These data identify miR-155 as a contributor to the adverse inflammatory 
response and a potential therapeutic target in VM.
Methods 
An expanded Methods section is available in the Supplemental material
Animal studies
All mouse experiments were performed according to the local relevant guidelines. For viral 
myocarditis (VM) miRNA profiling experiments, 4-week-old male susceptible C3H mice or 
resistant N-strain C57Bl/6 mice18 (Harlan, Boxmeer, The Netherlands) were used (n=3 per 
group). For microRNA knockdown in vivo, mice received 3 iv. injections per week (25 mg/
kg/injection) of a 15-mer LNA-antimiR oligonucleotide targeting mmu-miR-155 or an LNA 
control. Chronic treatment for the 7-week-follow-up included 2 weeks of high dose 
treatment (25 mg/kg/injection iv) followed by 5 weeks of low dose treatment (5 mg/kg/
injection ip). Group sizes were at least n=6 for sham and n=11 for VM groups in the 1-week 
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analysis, n=6 per sham and n=8 for VM for flow cytometry, and n=6 for sham and n=20 
for VM in the 7-week analysis.
Patient material
All human material was obtained during routine clinical sampling and available for research 
purposes in accordance with the Declaration of Helsinki and the ethical committee at 
Maastricht University Medical Center. MicroRNAs were profiled in right ventricular septal 
biopsies from patients with acute myocarditis (n=4) with a definite clinical history of 
myocarditis1 and confirmed virus presence in the cardiac biopsies (Supplementary Table 
1). Controls (n=6) consisted of age-matched patients with unexplained ventricular tachy-
arrhythmias but with a normal ejection fraction and the absence of systemic or cardiac 
inflammation or virus presence at the time of biopsy (Supplementary Table 1). 
In situ hybridization 
In situ hybridization was performed as described previously19, 20. Details are available the 
Methods section in the online-only Data Supplement. 
MicroRNA and Messenger RNA expression array analysis 
For microRNA array analysis, total RNA from human biopsies was hybridized to Illumina 
Human miRNAv2 Expression Panel arrays by ServiceXS (Leiden, The Netherlands) and total 
RNA from mouse left ventricles was hybridized to µParaflo® arrays (LC Sciences, Houston, 
TX). Detailed information about arrays analyses are available in the Methods section in the 
Data Supplement. Messenger RNA analysis from hearts of LNA control- and LNA-antimiR-
155-treated mice (sham and 7 days post CVB3 injection) was performed by hybridizing to 
Affymetrix GeneChip Mouse Gene 1.0 ST arrays.
Statistical analyses
Statistical analyses for miRNA arrays were performed in R. Analyses for experimental work 
were performed using GraphPad Prism 5.0d for Macintosh (GraphPad Software Inc., La 
Jolla, CA, USA). Pearson’s correlation coefficients were determined to study correlations 
of quantitative variables in data sets with a Gaussian distribution. Comparisons between 
2 groups were performed with two-tailed Student’s t testing for Gaussian data or Mann-
Whitney tests for non-Gaussian data. For comparisons of more than 2 groups, one-way 
ANOVA was used, followed by post hoc testing using Bonferroni correction for more 
groups. Probability values below 0.05 were considered statistically significant. Data are 
presented as mean ± SEM unless otherwise indicated.
Results 
Cardiac miRNA profiles during Coxsackievirus B3 induced murine viral myocarditis 
To identify miRNAs with a role in acute viral myocarditis (VM) we first analyzed miRNA 
expression profiles of Coxsackievirus B3 (CVB3)-induced VM in mice. To differentiate 
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between miRNA changes associated with viral infection and inflammation, two mouse 
strains were used: C3H mice that are highly susceptible to CVB3-induced myocarditis and 
C57Bl/6N mice that are resistant to CVB3-induced cardiac inflammation despite similar 
accumulation of viral genomes in the heart18. Cardiac miRNA expression was evaluated at 
baseline, and days 4 and 7 after CVB3 inoculation to study viral replication before and after 
the onset of macroscopic inflammation, respectively. Histological analysis confirmed 
extensive myocyte necrosis and leukocyte infiltration in C3H mice at 7 days, whereas only 
small patches of inflammation were observed in C57Bl/6N animals (Figure 1A and B). 
Expression of CVB3 virus was detected in all mice at days 4 and 7, and did not significantly 
differ between strains (Figure 1C). 
A heat map of cardiac miRNA expression during VM in both strains shows diverging 
expression between the strains for clusters of miRNAs, most prominently after the onset 
of inflammation at day 7 after infection (Figure 1D-F; Supplementary Figure 1A and 2A). 
Figure 1. MicroRNA (miRNA) expression profiles of viral myocarditis in susceptible (C3H) or non-
susceptible (C57Bl/6N) mice. (A, B) H&E staining of left ventricular sections from C3H and C57Bl/6N mice 
showing absence of necrosis in sham hearts and minimal necrosis at day 4 after CVB3 infection. Necrosis 
at day 7 was necrosis in C57Bl/6N animals (4.4% of left ventricular area) but widespread in C3H animals 
(32.3% of left ventricular area) (n=6 per group). (C) CVB3 viral genome expression did not significantly differ 
between mouse strains at day 4 or 7 and was undetectable in sham mice. (D) Heat map of differentially 
regulated miRNAs (p<0.05) in C57Bl/6N and C3H mice. (E) Venn diagrams showing the numbers and 
overlap of differentially regulated miRNAs (p<0.05) between groups. The most profound changes occur 
during myocarditis (day 7) in C3H mice. (F) Volcano plots showing fold changes (log2 values) and p values 
(log10) for individual miRNAs. *P < 0.05. Scale bar: 100µm
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The most extensive differences were observed in the highly inflamed C3H hearts at 7 days 
compared to sham, where miRNA changes were markedly larger than in the mildly inflamed 
C57Bl/6N hearts: 78 versus 221 miRNAs were differentially regulated at 7 days compared 
to sham in C3H mice and C57Bl/6N mice, respectively. The majority of these differentially 
regulated miRNAs in C57Bl/6N animals overlapped with the C3H miRNA changes, indicating 
consistency in the inflammatory response that was mild but not absent in C57Bl/6N, as 
shown in Figure 1A and B. 
At day 4 after infection, during cardiac viral replication but before infiltration of immune 
cells, 11 (resistant C57Bl/6N) and 16 miRNAs (susceptible C3H) were differentially regulated 
as compared to sham. These miRNA changes showed little overlap with day 7 changes in 
both strains, indicating that day 4 differences reflect biological signaling distinct from 
inflammation (Supplementary Figure 1B). Importantly, the miRNAs differentially expressed 
at day 4 did not overlap between species, reflecting the diverging molecular response to 
CVB3 infection that may determine the severity of cardiac inflammation.
Individual cardiac miRNAs are regulated during Coxsackievirus B3 induced murine 
viral myocarditis
We next focused on individual dysregulated miRNAs. Notably, miRNAs that are well known 
for their roles in the immune system and inflammatory responses21 were among the most 
strongly up-regulated miRNAs during the inflammatory phase of VM (C3H mice at day 7), 
including miR-155, miR-21, miR-146a, miR-146b, and miR-223 (Supplementary Tables 3 
and 4; Supplementary Figure 2 and 3). In addition, miR-106a and 130b were strongly up-
regulated, whereas miR-361, miR-30e*, miR-149, miR-574-3p, and myocyte-enriched miR-
208a and miR-499 were significantly down-regulated. The down-regulation of miR-208a 
and miR-499 may reflect their known regulation in cardiac stress7, 11, or may reflect necrosis 
present in myocarditis hearts. In support of the latter, other myocyte miRNAs (myomiRs) 
were either down-regulated (miR-1) or unchanged in hearts of C3H mice at day 7, in contrast 
to C57Bl/6 hearts in which miR-1, miR-133a and miR-133b were up-regulated at the same 
time point (Supplementary Figure 3 and 4). 
A number of miRNAs were regulated only in VM-resistant C57Bl/6N mice and may be 
involved in disease susceptibility. Dysregulated miRNAs at day 4 in C57Bl/6N included 
miR-483*, miR-411, miR-135*, miR-300 and miR-140. In addition, miR-93* and miR-17* 
were up-regulated at both day 4 and 7 after infection. Furthermore, miR-361 was consistently 
found down-regulated in both strains as early as 4 days post-infection and persisting until 
day 7 (Supplementary Tables 3 and 4). 
We selected a set of microRNAs with interesting profiles in either C3H or C57Bl/6N VM 
for qRT-PCR verification of microarray expression profiles. Overall, qRT-PCR measurements 
confirmed expression patterns observed by microarray analysis, showing significant up-
regulation of miR-155 (5.9-fold), miR-146b (13.9 fold) and miR-21 (12.8 fold), as well as 
down-regulation of miR-499 (1.9-fold) (Supplementary Figure 3). 
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Cardiac microRNA expression during human viral myocarditis   
In parallel, we analyzed miRNA expression in a set of right ventricular septal biopsies 
obtained from patients with acute VM and controls. A total of 107 miRNAs were 
differentially expressed between VM and control hearts of which 21 miRNAs were up- 
and 37 miRNAs were down-regulated by more than 1.5-fold (Figure 2A, Supplementary 
Figure 5A and Supplementary Table 5). Among the most up-regulated miRNAs were 
miR-155 (3.5-fold, p<10-4) and miR-146b (11.9-fold, p<0.01), besides miR-511 (5-fold), a 
stimulator of toll-like receptor (TLR) signaling22, miR-212 (2.6-fold), involved in 
cardiomyocyte hypertrophy23, and the relatively unknown miR-889 (3.2-fold). Down-
regulated miRNAs included the inflammatory miR-106a (2.3-fold) and miR-93 (1.6-fold), 
and miR-361-3p (2.3-fold). 
We compared mouse and human miRNA profiles during VM. Out of the 107 miRNAs 
differentially expressed in human VM, 66 miRNAs could be matched to their mouse 
homologues, of which 16 were also differentially expressed during mouse VM (Figure 
2B-C, Supplementary Figure 5B and Supplementary Table 5). These 16 miRNAs included 
miR-155, miR-146b, miR-21, and miR-501-3p (consistently up-regulated) and miR-103a, 
miR-107, miR-99b, miR-149, miR-30a*, and miR-30e* (consistently down-regulated). 
Interestingly, the miR-499(-5p) was significantly down-regulated in mouse, but not in human 
VM, while its opposite strand miR-499-3p was the most down-regulated miRNA in humans 
(3.1-fold, p<0.05) (Supplementary Figure 3C and 5C). MyomiRs that were regulated in 
humans included miR-133a and miR-133b, which were both significantly down-regulated 
(Supplementary Table 5). In general, miRNAs with a role in inflammation were dysregulated 
most robustly while myomiRs were predominantly down-regulated during VM.
Figure 2. MiRNA expression in human viral myocarditis. (A) Volcano plot of fold changes (log2 values) 
and p values (log10) for individual miRNAs in biopsies of VM patients compared to controls. (B) Venn diagram 
showing the number and overlap of differentially regulated miRNAs in human versus mouse (C3H 7 days) 
VM. Fold changes for these miRNAs in both species are plotted in panel (C) correlating significantly (r=0.40, 
p<0.0001). 
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MiR-155 is expressed by infiltrating inflammatory cells in both mouse and human VM
Since miR-155 was strongly and significantly up-regulated in hearts of both VM-susceptible 
mice and VM patients, we focused on its expression and role in the pathogenesis of VM. 
To address which cells produce miR-155 during VM, in situ hybridization (ISH) was 
performed on sections of mouse hearts and human cardiac biopsies. Perinuclear miR-155 
staining was observed specifically in inflammatory patches, while no in situ signal was 
detected in adjacent myocardium. When hybridization was performed with a scrambled 
control probe no signal was detected, indicating that miR-155 detection was sequence-
specific (Figure 3A and Supplementary Figure 6). To learn whether miR-155 preferentially 
localized in macrophages or T lymphocytes we stained sequential sections for miR-155, 
CD45, Mac3 and CD3 (Figure 3B). Staining for miR-155 co-localized with CD45-positive 
leukocytes, including many Mac3-positive macrophages and CD3-positive T lymphocytes. 
Double staining for miR-155 and CD3 showed that miR-155 signal in infiltrating T 
lymphocytes was of comparable intensity as in surrounding macrophages (Supplementary 
Figure 3C). These findings are consistent with previous studies showing specificity of 
miR-155 for hematopoietic cells and up-regulation during activation of virtually all leukocyte 
subtypes, including macrophages and T cells13, 15, 24, 25. 
Figure 3. MiR-155 is expressed by infiltrating immune cells during VM. (A) In situ hybridization of miR-
155 (blue) on a left ventricular biopsy of human VM, showing blue cellular staining in inflammatory patches 
but not in adjacent myocardium. Panel (B) shows consecutive mouse cardiac ventricular sections (C3H day 
7) stained in blue for miR-155, or for markers of leukocytes (CD45), macrophages (Mac3), or T lymphocytes 
(CD3). The pattern of miR-155 positivity closely resembles that of CD45-positive leukocytes, including many 
macrophages and also T cells. (C) Co-staining for miR-155 (blue) and CD3 (brown) reveals comparable miR-
155 staining intensity in T lymphocytes versus other immune cells. Scale bars: 100µm.
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To compare miR-155 expression in inflammatory cells to that of cardiac resident cells, we 
measured miR-155 in a cell panel including neonatal (rat) cardiomyocytes and fibroblasts, 
mouse endothelial cells (SVEC), mouse bone-marrow derived macrophages (BMM) and 
splenic T lymphocytes. Cells were incubated for 24 hours with pro-inflammatory stimuli to 
recapitulate the cardiac inflammatory environment: TNF-α for myocytes, fibroblasts and 
endothelial cells, LPS for BMM and concanavalin A for T cells. Expression of miR-155 was 
most pronounced in activated macrophages and T lymphocytes (over 100-fold higher 
compared to cardiomyocytes; Supplementary Figure 6C). Expression of miR-155 was low 
in cardiomyocytes, endothelial cells and fibroblasts at baseline, and only induced in 
fibroblasts by TNF-α stimulation. In conclusion, miR-155 is mainly localized in inflammatory 
cells during VM in both mice and humans. 
LNA-antimiR inhibits miR-155 function in vivo 
We next asked whether the known inflammatory effects of miR-155 contribute to a 
beneficial immune response or to adverse inflammation and cardiac injury during VM. 
Therefore, we inhibited miR-155 in vivo in inflammation-susceptible C3H mice during the 
first 7 days of VM. Three individual doses of LNA-antimiR targeting mouse miR-155 or LNA 
control were administered on days 1, 4 and 6 after CVB3 inoculation to continuously inhibit 
miR-155 throughout the hematopoietic proliferative response (Figure 4A). Northern blotting 
showed marked induction of miR-155 during VM and revealed that mature miR-155 was 
sequestered in a heteroduplex by the LNA-antimiR-155, as evidenced by a band shift of 
the mature miR-155 (Figure 4B). qRT-PCR for miR-155 confirmed significant knockdown 
in the inflamed heart (72%, p<0.001). Knockdown was significant but modest in sham 
hearts (30%, p<0.01) and more pronounced in sham spleens that have a high miR-155 
expression (Supplementary Figure 7A and B). We verified functional cardiac miR-155 
inhibition in an unbiased way using Affymetrix microarrays which showed that mRNAs 
with canonical 3’ UTR seed-match sites for miR-155 were de-repressed in VM animals 
treated with LNA-anti-155 compared to those from LNA control treated hearts (Figure 4D 
and Supplementary Figure 7C). Significantly up-regulated genes included validated miR-155 
targets such as Activation Induced Cytidine Deaminase (AID), and the transcription factors 
BACH1, Jumonji AT rich interactive domain 2 (JARID2) and CCAAT/enhancer binding protein 
beta (C/EBP-β). In agreement, unsupervised clustering could differentiate LNA-anti-155 
versus LNA scrambled-treated animals with VM but not sham animals (Figure 4E). To 
investigate antimiR biodistribution, we injected a FAM-labeled fluorescent LNA-antimiR-155 
in a parallel group of animals, and could detect its accumulation in cardiac myocytes and 
endothelial borders as well as in circulating monocytes, lymphocytes and neutrophils (Figure 
4F and G). Together, these data confirm that miR-155 was inhibited by LNA-anti-155 
treatment in VM animals. 
Inhibition of miR-155 reduces cardiac injury and inflammation during VM
At day 7 after infection, miR-155 inhibition significantly reduced cardiac inflammation and 
necrosis (Figure 5A and B). In agreement, miR-155 inhibition significantly attenuated heart 
weight increase during VM, a marker of cardiac inflammatory edema (Figure 5C and 
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Supplementary Table 6). Suppression of miR-155 additionally reduced body weight loss 
associated with systemic illness, as well as the numbers of circulating leukocytes induced 
by CVB3 infection (Figure 5D and E). We next analyzed the effect of miR-155 inhibition on 
cardiac recruitment of inflammatory cells using immunohistochemistry. MiR-155 inhibition 
significantly reduced the number of CD11b-stained monocyte-macrophages and Ly6-stained 
neutrophils and reduced CD3-stained T cells by trend (p=0.09) (Figure 6 A-B and Supplementary 
Figure 8A). These findings were in keeping with reduced transcripts of CD11b, Ly6G and 
CD3 (Supplementary Figure 8B), and a more than 50% reduction of the cytokines interferon 
Figure 4. LNA-antimiR effectively inhibits miR-155 during VM. (A) Study design: LNA-antimiR 
oligonucleotide targeting miR-155 was administered by three intravenous injections throughout the first 
7 days of CVB3-induced viral myocarditis. (B) Northern blot analysis shows duplex formation between the 
LNA-antimiR-155 and mature miR-155, in agreement with decreased miR-155 levels detected by qPCR-
RT (C) in sham (40%, p<0.05, n=6 per group) and VM animals (~75%, p<0.05, n=11 per group). (D) De-
repression of mRNAs with predicted 7-mer miR-155 seed sites in sham and VM animals after miR-155 
inhibition with LNA-antimiR-155. Cumulative distributions of mRNA changes between antimiR-155- and 
LNA control-treated hearts are shown, demonstrating de-repression of miR-155 targets in VM animals 
but only modestly/not in sham animals after antimiR treatment (one-sided Kolmogorov-Smirnov test; VM: 
p=4.7*10-9 and sham: p=1.1*10-4). In line, unsupervised hierarchical clustering (E) of experimental groups 
using microarray expression data could separate VM but not sham groups based on antimiR-treatment, 
reflecting the more prominent role for miR-155 in the inflamed versus normal hearts. (F) FAM-labeled 
fluorescent LNA-antimiR accumulates in cardiac nuclei (white arrows) and endothelial linings, as well as in 
all major hematopoietic lineages present in circulating blood, as shown by flow cytometry. Scale bar: 25µm. 
*P < 0.05.
2012100 proefschrift Maarten Corsten.indd   63 07-08-2012   08:38:08
MicroRNA-155 mediates cardiac injury in viral myocarditis
64
4
beta (IFN-β), IFN-γ, interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α) (Figure 6C and 
Supplementary Figure 8C). The expression of the anti-inflammatory cytokine Il-10 as well as 
the markers for alternatively activated ‘anti-inflammatory’ macrophages Arginase and YM-1 
were markedly reduced by miR-155 inhibition, while Il-17 levels were around the detection 
limit and thus too low for reliable quantification. Finally, cardiac CVB3 genomes were lower 
in LNA-antimiR-155 treated hearts as compared to controls (Supplementary Figure 8C). 
Figure 5. Inhibition of miR-155 reduces myocardial damage in viral myocarditis. (A, B) Left ventricular 
H&E stainings at day 7 of CVB3-induced VM reveal reduced cardiomyocytes necrosis after miR-155 inhibition 
(scale bar: left 2mm, inset 200 µm) (LV necrotic area quantified in B: LNA-scrambled: 35.3% versus LNA-
antimiR-155 19.7%), in line with a reduced increase in heart weight caused by inflammatory edema (C). 
Systemically antimiR-155 treatment ameliorated the body weight loss observed in control-treated VM 
animals (D) and reduced the circulating leukocytosis (LNA-control 4.3*109 cells/L versus LNA-antimiR-155 
2.0*109 cells/L, p<0.05) (E); WBC: circulating white blood cell count. (n=6 per sham group and n=11 per VM 
group). *P < 0.05, **P < 0.01, ***P < 0.001.
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To better characterize the effects of miR-155 inhibition on immune cell subtypes, we 
performed flow cytometry on the cardiac immune cell fraction at day 7 of VM. Flow 
cytometry revealed that LNA-antimiR-155 treatment markedly reduced the activation of 
CD4+ and CD8+ T lymphocytes (Figure 7 and Supplementary Table 7). The percentages 
of naïve (CD62LhighCD44low) T cells in LNA-antimiR-155-treated versus LNA control-treated 
hearts were 21.7% versus 4.2%, and 26.6% versus 10.0% for CD4+ and CD8+ T cells, 
respectively. Proportions of Foxp3+CD25+ regulatory T cells did not differ between treatment 
groups. Flow cytometry confirmed that miR-155 inhibition suppressed infiltrating monocytes, 
without affecting the proportion of pro-inflammatory Ly6Chigh monocytes. 
Figure 6. Inhibition of miR-155 reduces cardiac immune cell infiltration and de-represses the direct 
miR-155 target PU.1 in viral myocarditis. MiR-155 inhibition reduced cardiac infiltration of CD11b-
immunoreactive monocyte-macrophages (A) caused a trend towards reduction in CD3+ T cells numbers 
(B) (scale bars: 100µm). (C) Cardiac expression levels of pro-inflammatory cytokines Il-6, TNF-α, interferon-γ 
(IFN-γ) and IFN-β were suppressed by LNA-antimiR-155. (VM day 7: n=11 per group for all analyses). 
(D) Western blots for the direct miR-155 targets PU.1 and SHIP1 in the cardiac immune fraction during 
myocarditis, showing that miR-155 inhibition significantly de-repressed PU.1 and increased SHIP1 levels by 
trend (n=4 per group). *P < 0.05, **P < 0.01, ***P < 0.001.
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Together, these data suggest that the attenuation of the immune response after miR-155 
suppression is broad and involves both the innate and adaptive immune system, rather 
than supporting a preferential activation of anti-inflammatory cells or signaling. 
AntimiR-155 treatment de-represses the direct miR-155 target PU.1 in cardiac 
inflammatory cells
We next performed western blots on previously confirmed direct miR-155 targets, 
whose de-repression in leukocytes could explain protection by antimiR treatment. 
Expression of PU.1 (an inhibitor of dendritic cell antigen presentation to T cells26), and 
SHIP1 (a regulator of myeloid proliferation27, 28) was hardly detectable in sham hearts 
but increased with severity of inflammation, in agreement with their expression by 
inflammatory cells (Supplementary Figure 9). Since the extent of cardiac inflammation 
might thus confound protein levels in whole-hearts, we focused on protein levels in 
Figure 7. MiR-155 inhibition suppresses T lymphocyte activation in myocarditis hearts. (A) Flow 
cytometry of the cardiac immune fraction. MiR-155 inhibition significantly increased the percentage of naïve 
(CD62LhighCD44low) versus effector/effector-memory (CD62LlowCD44high) CD4+ and CD8+ T lymphocytes in 
myocarditis hearts (LNA-antimiR-155 vs LNA control: 21.7% vs 4.2% and 26.6% vs 10.0% for CD4+ and 
CD8+, respectively). (B) The amount of Foxp3+CD25+ regulatory T cells was not different between treatment 
groups. (C) MiR-155 inhibition significantly reduced the percentage monocytes of the cardiac infiltrates, but 
did not affect the proportion of pro-inflammatory Ly6Chigh monocytes (n=4 per sham group and n=8 per VM 
group). *P < 0.05, **P < 0.01, ***P < 0.001.
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isolated cardiac immune fractions. Protein expression of PU.1 was significantly increased 
in cardiac leukocytes after inhibition of miR-155, while SHIP1 de-repression was not 
statistically significant (Figure 6D). 
Inhibition of miR-155 inhibition does not directly affect viral replication or myocyte 
viability
To investigate whether miR-155 inhibition directly impacts CVB3 load or early cytokine 
signaling by cardiac resident cells, we sacrificed animals at day 4 after infection, before 
onset of inflammation. We found no significant differences in viral load between treatments 
in the heart, spleen or liver (Supplementary Figure 10A). Also, miR-155 inhibition did not 
affect cardiac expression of cytokines including TNF-α, Il-6, Il-12a, Il-10, IFN-β, IFN-γ, and 
the chemokine macrophage chemo-attractant protein-1 (MCP-1) at this time point 
(Supplementary Figure 10B). 
In addition, in vitro knockdown of miR-155 prior to CVB3 infection did not affect cell death, 
caspase 3 cleavage, or viral replication in neonatal rat cardiomyocytes (Supplementary 
Figure 11). These data support that the adverse effects of miR-155 during VM are leukocyte-
autonomous and independent from viral load in cardiomyocytes, myocyte viability, or cardiac 
cytokine signaling prior to infiltration by inflammatory cells. 
Figure 8. MiR-155 inhibition protects against mortality and systolic dysfunction in viral myocarditis. 
(A) Kaplan-Meier curve showing reduced mortality after miR-155 inhibition compared to controls (1/20 
versus 6/20, respectively; p<0.05). (B) Fractional shortening was decreased in VM control hearts at weeks 
2 and 7 compared to shams, but not in miR-155 inhibited VM hearts. After 7 weeks, fractional shortening 
was significantly higher in LNA-antimiR-155 versus LNA control animals (23.4% versus 18.4%, respectively; 
p<0.05). (C) The cardiac increase in fetal gene markers in surviving animals was attenuated by miR-155 
inhibition, although this difference was not statistically significant. We did not observe differences in cardiac 
collagen deposition between antimiR treatment groups (D). (n=6 per sham group and n=20 per VM group). 
*P < 0.05, **P < 0.01.
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Prolonged inhibition of miR-155 during myocarditis improves survival and cardiac 
function
To assess the long-term effects of miR-155 inhibition during VM, mice were followed for 
7 weeks after CVB3 infection. Treatment with miR-155 inhibitors significantly reduced 
mortality (1/20 versus 6/20) (Figure 8 and Supplementary Table 6). In addition to decreasing 
mortality, miR-155 inhibition improved cardiac function in animals surviving after 7 weeks 
(fractional shortening 23.4% versus 18.4%) (Figure 8 and Supplementary Table 8). RNA 
analysis revealed complete viral elimination in both groups and a trend to reduced induction 
of cardiac fetal gene markers (ANF, BNP), although this was not statistically significant. 
Cardiac fibrosis was similar in both groups after 7 weeks though early fibrosis at 1 week 
was reduced by miR-155 inhibition (Figure 8 and Supplementary Figure 12). In conclusion, 
miR-155 inhibition improved mortality and cardiac function after long-term treatment.
Discussion 
This study is the first to investigate microRNA (miRNA) expression profiles related to cardiac 
virus infection and resulting inflammation in both mice and humans. We identify 
microRNA-155 as a key contributor to exaggerated antiviral surveillance. 
Two of the most important questions in myocarditis research are (1) why infection by 
cardiotropic viruses triggers myocarditis in some patients while remaining asymptomatic 
in others, and (2) what signaling pathways contribute to cardiac injury during the inflammatory 
response, since distinct components of the inflammatory response can contribute to either 
efficient viral elimination and cardiac protection, or to irreversible cardiac damage and 
functional deterioration in VM2, 29, 30. The current study addresses these questions by 
establishing a set of susceptibility- and inflammation-related miRNAs in mice, and identifying 
miR-155 as a contributor to adverse inflammation during VM both in mice and human VM. 
Moreover, our results suggest therapeutic opportunities by targeting miR-155 in mice to 
limit cardiac injury and mortality in VM.
The pro-inflammatory effects of miR-155 in B and T lymphocytes as well as macrophages 
and dendritic cells have been well established. MiR-155 expression is induced during 
activation of both macrophages and lymphocytes14, 15. In lymphocytes, miR-155 promotes 
Th1 responses as well as germinal center formation13, 14, while favoring proliferation and 
pro-inflammatory cytokine secretion in myeloid cells27, 31. MiR-155 also mediated crosstalk 
between innate and adaptive immune cells, as miR-155 deficient dendritic cells are less 
capable of activating T cells14, 26. This multitude of pro-inflammatory effects of miR-155 on 
both the innate and adaptive immune system is associated with a variety of anti-inflammatory 
protein targets, including proteins Suppressor of Cytokine Secretion 1 (SOCS1)32, 33, SH2-
containing Inositol-5-phosphatase (SHIP1)27, AID34, and the transcription factors PU.135 and 
c-MAF14. In line with these effects, miR-155 was shown to be protective during experimental 
autoimmune encephalitis (EAE)36 37 and rheumatoid arthritis28. 
Most of the immune mechanisms controlled by miR-155 are important in the pathogenesis 
of VM. However, because VM pathogenesis involves viral pathogens, protective effects 
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of anti-inflammatory manipulations are not trivial. In the current study, pharmacological 
inhibition of miR-155 reduced both cardiac damage and mortality during VM, indicating that 
miR-155 signaling contributes to an adverse rather than beneficial immune activation in 
the context of VM. AntimiR treatment reduced cardiac numbers of monocyte-macrophages 
and inhibited T lymphocyte activation, in parallel with down-regulation of both pro- and 
anti-inflammatory cytokines including TNF-α, Il-6, IL-10 and IFN-γ during the inflammatory 
phase. The increased percentage of naïve T cells in LNA-antimiR-155-treated animals was 
in line with the de-repression of PU.1, a direct miR-155 target that inhibits antigen 
presentation to lymphocytes in dendritic cells26. Cardiac protection by miR-155 inhibition 
was likely immune-cell autonomous, since miR-155 inhibition did not affect viral load, 
myocyte viability, or cytokine signaling by cardiac resident cells prior to infiltration by 
immune cells. Our results therefore suggest that therapeutic targeting of miR-155 may 
benefit myocarditis patients by dampening inflammation. Of note, miR-155 has been 
described to target the angiotensin II type 1 receptor (AT1R)38. Although we did not observe 
increased fibrosis after miR-155 inhibition, clinical studies are required to exclude short-
term side effects of antimiR-155 treatment. 
Beside miRNA-155, we identified a set of miRNAs that is consistently up-regulated during 
acute inflammation of both human and mouse VM, including miR-155, miR-146b and miR-
21, which all have central functions in immune activation and inflammation21, 39 and the less 
well-known miR-130b, a virus-induced inhibitor of target cell apoptosis in humans40. MiR-
106a, which was up-regulated in both C3H and C57Bl/6N at day 7 post-infection. MiR-106a 
has been shown to target interleukin-10, a central regulator of the immune system41, while 
the expression of miR-106a itself is regulated by the transcription factors Egr-1 and Sp-1, 
both key in cardiac processes41. Immune functions have also been described for consistently 
down-regulated candidates: miR-107 is down-regulated in multiple cell types in response 
to TLR-4 signaling and is required to facilitate macrophage adhesion42 whereas inhibition 
of miR-99b reduces dendritic cell differentiation22. In addition, we identified a set of miRNAs 
exclusively associated with viral infection in resistant C57Bl6/N mice, including miR-483*, 
miR-411, miR-135*, miR-300 and miR-140, miR-93* and miR-17*. While these miRNAs 
are relatively unknown, their likely involvement in the primary response to viral infection 
and disease susceptibility invites future studies.
In conclusion, VM induces marked miRNA expression changes in the mouse and human 
heart. MiRNA-155 is up-regulated in myeloid and lymphoid inflammatory cells during acute 
VM and is a mediator of adverse cardiac immune activation. In vivo inhibition of 
microRNA-155 after CVB3 infection attenuates myocardial inflammation and necrosis, 
reduces mortality and improves cardiac function. As such, this study identifies miRNA-155 
as a novel therapeutic target for treatment of viral myocarditis.
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Supplementary Figures
Supplementary Figure 1. MicroRNA (miRNA) expression profiles of viral myocarditis in susceptible 
(C3H) or non-susceptible (C57Bl/6N) mice. (A) Correlation plots of cardiac miRNA expression values 
in C3H versus C57Bl/6N animals in sham animals, and at days 4 and 7 after CVB3 infection. (B) Venn 
diagrams comparing numbers and overlaps of differentially expressed miRNAs in mice from day 4 to 7, and 
differences between mouse strains at days 0, 4, or 7. 
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Supplementary Figure 2. Differentially expressed miRNAs in murine viral myocarditis. (A) Volcano 
plots showing fold changes and p-values of individual miRNAs between C57Bl/6N and C3H mice at time 
points: sham, day 4 and day 7 after CVB3 infection. (B) Volcano plots of differential miRNA expression 
between sham and day 4 of either mouse strain. 
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Supplementary Figure 3. Quantitative RT-PCR validation of mouse array results. (A) Array results and 
(B) qRT-PCR results of selected miRNAs on day 4 or 7 versus sham levels (red line) (n=3 per group), showing 
reproducibility of the array-identified expression patterns. (C) Human array results for the miRNAs validated 
in panel A and B (VM n=4, controls n=6). *P < 0.05, **P < 0.01, ***P < 0.001.
Supplementary Figure 4. Quantitative RT-PCR validation of mouse array results for myomiRs.  (A) 
Array results and (B) qRT-PCR results of selected miRNAs on day 4 or 7 versus sham levels (red line) (n=3 
per group). qRT-PCR measurements show that myomiRs are not differentially regulated in C3H hearts at 
day 7, with the exception of miR-1, which is significantly down-regulated. In contrast, miR-1, miR-133a and 
miR-133b are up-regulated in C57Bl/6 hearts at day 7. *P < 0.05, **P < 0.01.
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Supplementary Figure 5. MiRNA-expression profiles of human viral 
myocarditis. (A) Heat map of differentially expressed microRNAs (p<0.05) 
between left ventricular biopsies of viral myocarditis patients compared 
to controls. (B) Correlation analysis of human-mouse-matched miRNA 
expression between human controls and C3H sham mice, showing a 
Pearson correlation coefficient of r=0.81. (C) miR-499-3p is strongly down-
regulated in human VM biopsies compared to controls. *P < 0.05.
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Supplementary Figure 6. MiR-155 is predominantly expressed by inflammatory cells in the mouse 
heart during viral myocarditis. (A) In situ hybridization of miR-155 (blue) on left ventricular sections of 
mouse VM (C3H 7 days). A triangular-shaped inflammatory patch stains dark blue after hybridization with 
a miR-155 detection probe while virtually no miR-155 is detected in adjacent normal myocardium. Only 
pink nuclear counterstaining is observed when using an LNA control probe. The inset shows perinuclear 
localization of miR-155 in inflammatory cells. (B) In situ hybridization for miR-155 in left ventricular biopsies 
of a human VM patient, again showing localization of miR-155 specifically in inflammatory cells in inflamed 
regions but not in adjacent myocardium. (C) MiR-155 expression in a cell panel of rat neonatal myocytes 
(RCM), fibroblasts (nRCF), adult mouse endothelial cells (SVEC), primary bone marrow-derived macrophages 
(BMM) and splenic T cells (TC), stimulated for 24 hours with pro-inflammatory stimuli (TNF-α for nRCM, 
nRCM and SVEC; LPS for BMM; Con A for TC). Expression levels are presented as relative to nRCM. Scale 
bars: 100µm. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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Supplementary Figure 7. Inhibition of miR-155 by LNA-antimiR-155 treatment. (A) Native Northern 
blot of spleen samples showing stable duplex formation between the LNA-antimiR and mature miR-
155, as evidenced by the band shift in both sham and VM animals. (B) qRT-PCR confirmed significant 
suppression of miR-155 in mouse spleens by LNA-antimiR-155 (n=6 per sham groups and n=11 per VM 
group). (C) De-repression of mRNAs with predicted 7-mer miR-155 seed sites in sham versus VM animals 
treated with LNA-antimiR-155 or LNA control. Cumulative distributions of mRNA changes in VM versus 
sham conditions demonstrate suppression of miR-155 targets upon up-regulation of miR-155 during VM 
(one-sided Kolmogorov-Smirnov test; control VM versus control sham: p=1.0*10-5; antimiR-155 VM versus 
antimiR-155 sham: p=1.4*10-3). ***P < 0.001. 
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Supplementary Figure 8. Inhibition of miR-155 suppresses inflammatory signaling in VM at day 7 after 
infection. MiR-155 inhibition reduced cardiac infiltration of Ly6G-immunoreactive neutrophil granulocytes 
(A) (scale bars: 100µm). (B) qRT-PCR measurements showing that miR-155 inhibition suppressed the cardiac 
expression of CD11b (macrophages), Ly6G (neutrophils) and CD3 (T lymphocytes) in VM. (C) A wide range 
of pro- and anti-inflammatory transcripts is suppressed during VM after treatment with LNA-antimiR-155. 
(n=6 per sham group and n=11 per VM group). Cytokine levels are shown as relative to sham. *P < 0.05, 
**P < 0.01, ***P < 0.001.
Supplementary Figure 9. Cardiac protein 
levels of direct miR-155 targets reflect 
intensity of inflammation. Western blots 
(A) and protein level quantifications (B) of 
the direct miR-155 targets PU.1 and SHIP1 
on left ventricular protein homogenates. 
Both proteins were hardly expressed in 
sham hearts and more abundant during viral 
myocarditis. Protein levels of PU.1 and SHIP1 
were not de-repressed by miR-155 inhibition, 
but were higher in control VM hearts, which 
contained more infiltrating inflammatory 
cells (n=3 per group). *P < 0.05. 
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Supplementary Figure 10. 
miR-155 inhibition does not affect 
cardiac viral load and cytokine ex-
pression at day 4 after infection.
 (A) qRT-PCR measurements of CVB3 
levels in the heart , spleen and liver 
are not affected by miR-155 inhibition 
at day 4, before infiltration of cardiac 
inflammatory cells. (B) Expression of 
TNF-α, Il-6, Il-12a, Il-10, IFN-β, IFN-γ, 
and the chemokine macrophage 
chemo-attractant protein-1 (MCP-1) 
(relative to sham) by cardiac resident 
cells is unchanged by miR-155 
inhibition at day 4 (n=6 per group).
Supplementary Figure 11. Mir-155 inhibition does not affect myocyte viability after CVB3 infection. 
To investigate whether the low levels of miR-155 expressed by cardiomyocytes influence myocyte viability 
after CVB3 infection, we knocked down miR-155 in vitro in neonatal rat cardiomyocytes (nRCM) (A) before 
infecting with CVB3 at MOI=1. (B) Viability was similarly decreased in antimiR-155 or control nRCM at 120 
hourse after infection (B) and the number of viral genome copies was not different between treatment 
groups (C). (D) Western blotting for cleaved caspase 3 (CC3) as a marker of apoptosis revealed that cleaved 
capsase 3 increases were not affected by miR-155 inhibition (n=3 per group). *P < 0.05, **P < 0.01.
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Supplementary Figure 12. Cardiac fibrosis at 1 and 7 weeks of viral myocarditis.  Cardiac collagen 
deposition as measured by sirius red staining was reduced by miR-155 inhibition at 1 week (A), but was not 
different between groups after 7 weeks if viral myocarditis (B). (1 week: n=6 per sham group and n=11 per 
VM group; 7 weeks: n=6 per sham group, n=14 for LNA control VM and n=19 for LNA-antimiR-155 VM). *P 
< 0.05, **P < 0.01, ***P < 0.001.
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Supplementary Methods
Animal studies
All mouse experiments were performed according to the guidelines for care and use of 
laboratory animals approved by the institutional animal care committee. For viral myocarditis 
(VM) experiments, 4-week-old male susceptible C3H mice or resistant N-strain C57Bl/6 
mice1 (Harlan, Boxmeer, The Netherlands) were inoculated intraperitoneally with 2x105 
plaque forming units of Coxsackievirus B3 (CVB3) or saline. To investigate cardiac microRNA 
expression longitudinally during VM, animals were euthanized and dissected for further 
molecular and histological analysis at days 0, 4 and 7 (n=3 animals per strain per time 
point). 
For microRNA knockdown in vivo, a 15-mer LNA-antimiR oligonucleotide targeting mmu-
miR-155 or an LNA control was administered to male 4-week-old C3H mice intravenously 
at a dose of 25 mg/kg per injection at days 1, 4 and 6 post-CVB3 infection. Group sizes 
were at least n=6 for sham, n=6 for VM groups at day 4 and n=11 for VM groups at day 
7. Chronic treatment for the 7-week-follow-up included 2 weeks of high dose treatment 
(25 mg/kg/injection iv) followed by 5 weeks of low dose treatment (5 mg/kg/injection ip). 
Group sizes were at least n=6 for sham and n=11 for VM groups in the 1-week analysis, 
n=6 per sham and n=8 for VM for flow cytometry, and n=6 for sham and n=20 for VM in 
the 7-week analysis. Echocardiography was performed with the Vevo770 (Visualsonics, 
Toronto, Canada) and probe RMV707B (15-45 MHz) at days 14 and 49. Organs were snap-
frozen or fixed for 4-6 hours in 1% paraformaldehyde for histology. Circulating leukocyte 
numbers were counted in fresh heparinized mouse blood samples using the Abbott (Waver, 
Belgium) Cell-Dyn 3700. Uptake of fluorescently labeled LNA-antimiRs in circulating 
leukocytes was evaluated using the FACS Canto II flow cytometer (Becton Dickenson, San 
Diego, CA) after removing erythrocytes by hypotonic lysis with ammonium chloride.
Patient material
All human material was obtained during routine sampling used for clinical purposes, stored 
in a coded way and available for research purposes in accordance with the Declaration of 
Helsinki and the ethical committee at Maastricht University Medical Center. For microRNA 
profiling, right ventricular septal biopsies were used, obtained during routine clinical 
sampling from patients with acute myocarditis (n=4). Patients with a definite clinical history 
of myocarditis were included2 (Supplementary Table 1). Patients presented with an episode 
of upper airway or gastro-intestinal infection, followed after 1-3 weeks by chest pain. All 
myocarditis patients had elevated troponin T plasma levels and immunohistochemically 
proven cardiac inflammation (n>14 CD45 positive cells/mm2). In all patients, virus presence 
was demonstrated in the cardiac biopsies (Supplementary Table 1). Coronary artery disease 
was excluded either by CAG or CT. Controls (n=6) consisted of age-matched patients with 
unexplained ventricular tachy-arrhythmias but with a normal ejection fraction and the 
absence of systemic or cardiac inflammation or virus presence at the time of biopsy 
(Supplementary Table 1). Cardiac biopsies were immediately snap-frozen for RNA analysis 
or formalin-fixed for histological examination. 
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In situ hybridization 
In situ hybridization was performed as described previously3, 4: 4 µm sections were prepared 
from 48hr 10% neutral buffered formalin fixed human or mouse cardiac biopsies. Sections 
were de-waxed, dehydrated, air-dried briefly and incubated in 1.3 mg/ml Pepsin/0.1mM 
HCl solution for 5 min at 37°C. After a brief wash in DEPC MQ, sections were incubated 
overnight at 42.5°C in 1x hybridisation buffer (ENZO Life sciences, Farmingdal, NY, #33808) 
with either 100 nM mmu-miR-155 DIG labeled probe (EXIQON, Vedbaek, Denmark, #39471-
01) or a scrambled control probe (#99004-01). The following day the sections were washed 
once in 5xSSC and twice in 0.2xSSC at hybridisation temperature. Subsequently, sections 
were blocked in DIG blocking buffer from the DIG Wash and Block Buffer Set (Roche, 
Woerden, The Netherlands, #11585762001) for 20 min followed by a 45 min incubation in 
1:500 anti-DIG-AP, Fab fragments (Roche, #11093274910). Sections were washed 3x5 min 
with TBS and incubated 3 min in DIG detection buffer at room temperature. AP signal was 
detected by using NBT/BCIP tablets (Roche cat.no.11697471001) for 4 hours at 30°C in 
darkness. Finally, sections were counterstained with fast red (Sigma, Zwijndrecht, The 
Netherlands) briefly washed in MQ, quickly dehydrated through an ethanol gradient and 
mounted with entellan (EMS, Hatfield, PA #14800).
Double stain for ISH/IHC was conducted as follows: For ISH, slides were dewaxed, 
dehydrated and briefly washed in PBS. Prot.K/PBS solution 15ug/ml (Ambion, #AM2546) 
was applied for 10min. at 37°C. Slides were washed twice in PBS for 5min., dehydrated 
and air dried for 15min. Subsequently slides were treated as described above. For the CD3 
IHC the ISH slides were treated with 1.3mg/ml Pepsin in 0.1mM HCl for 8min at 37°C 
followed with 2x5min PBS washes. Next, slides were blocked in 1%BSA/TBS and 10% 
goat serum. Slides were then incubated with primary CD3 antibody (Neomarkers, Fremont, 
CA, USA, #RM-9107-s) for 16hrs at 4°C. Next slides were incubated with secondary 
Supplementary Table 1. Acute viral myocarditis and control sample donor characteristics
Characteristic
Viral Myocarditis
(n=4)
Controls
(n=6) P*
Age, years  39 ± 20 38 ± 11 0.96
Women 0 (0) 2 (33.3) 0.52
Echocardiography
   LVEF (%) 25 ± 15 55 ± 7 0.002
   EDD (mm) 48 ± 10 56 ± 5 0.15
PVB19 > threshold † 4 (100)   0 (0) 0.005
PVB19 titer (c/µg DNA) 1855 ± 1508 79 ± 56 0.04
CD45 cell/mm2 80 ± 39 11 ± 4 0.005
Serum Troponin T, µg/L 2.9 ± 3.7 ND
Data are presented as mean ± SD, or n (%)
* P-values based on student t-test, Mann-Whitney test or Chi-square analysis, † 
Threshold value: 500 copies/µg cardiac DNA, LVEF Left Ventricular Ejection, EDD End 
diastolic Diameter, ND Not determined 
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PolyHRP antibody (Epitomics, Burlingame, CA, USA #3051-1) for 16hrs at 4°C, washed 3 
times with TBST and developed with DAB. No counterstain was applied; slides were 
dehydrated and mounted in entallan (EMS, Hatfield, PA, USA #14800).
RNA isolation, microRNA arrays, Northern blotting and quantitative RT-PCR
RNA was isolated from left ventricular mouse tissue samples and right ventricular septal 
biopsies using the miRVANA isolation kit (Ambion, Warrington, UK), according to the 
manufacturer’s instructions and without enrichment for small RNAs. Potential genomic 
DNA contamination was removed using the DNA-free kit (Ambion).
For Northern blot analysis total RNA was loaded on non-denaturing gels to show 
heteroduplex formation between the LNA-antimiR and mature miR-155. Briefly, 1-5 µg 
RNA per sample was loaded without pre-heating on a non-denaturing 20% acrylamide gel 
and ran for 2 hrs at 100 V, transferred to a nylon membrane (Roche, Mannheim, Germany) 
using a semi-dry blotting device (Biorad) for 15 minutes at 20V. Blots were hybridized at 
37°C with dual DIG-labeled LNA probes (Exiqon, Vedbaek, Denmark) and visualized using 
the DIG Wash and Block buffer set (Roche) and CDP-star reagent (Roche). 
For quantitative real-time PCR analysis, cDNA was generated using the miScript kit (Qiagen, 
Venlo, The Netherlands) and quantified using IQ SYBR-green supermix (Bio-Rad, Veenendal, 
The Netherlands) in a MyIQ iCycler (Bio-Rad). LNA-based primer assays (Exiqon) were used 
for detection of mature microRNAs. A complete list of primer sequences is provided in 
Supplementary Table 2. 
Supplementary Table 2. Primer sequences
Gene Forward primer Reverse primer
CVB3 ACGAATCCCAGTGTGTTTTGG TGCTCAAAAACGGTATGGACAT
mmu-Arginase CAAGACAGGGCTCCTTTCAG GCTTATGGTTACCCTCCCGT
mmu-CD3ε TATCACTCTGGGCTTGCTGA TAGTCTGGGTTGGGAACAGG
mmu-CD11b GGCAGGAGTCGTATGTGAGG CAGCAGTGATGAGAGCCAAG
mmu-CD68 CCAGCTGTTCACCTTGACCT CAATGATGAGAGGCAGCAAG
mmu-GAPDH GGTGGACCTCATGGCCTACA CTCTCTTGCTCAGTGTCCTTGCT
mmu-IFN-γ GCGTCATTGAATCACACCTG CTGGACCTGTGGGTTGTTG
mmu-IFN-β1 AGCACTGGGTGGAATGAGAC TCCCACGTCAATCTTTCCTC
mmu-interleukin-6 CAAAGCCAGAGTCCTTCAGAG GCCACTCCTTCTGTGACTCC
mmu-interleukin-10 ATCGATTTCTCCCCTGTGAA TGGCCTTGTAGACACCTTGG
mmu-interleukin-12a CTAGACAAGGGCATGCTGGT TCTCCCACAGGAGGTTTCTG
mmu-interleukin-17 TCCAGAAGGCCCTCAGACTA TGAGCTTCCCAGATCACAGA
mmu-iNOS GCAGCGGCTCCATGACTCCC AGGTGGTCCTCCTCCGGGTG
mmu-Ly6C TCTTGTGGCCCTACTGTGTG TGAGCAATGCAGAATCCATC
mmu-Ly6G GATGGATTTTGCGTTGCTCT GTCCAGAGTAGTGGGGCAGA
mmu-MCP-1 GTTGGCTCAGCCAGATGCA AGCCTACTCATTGGGATCATCTTG
mmu-MPO GCCTCATTGGCACTCAGTTT GTGGTGATGCCAGTGTTGTC
mmu-TNF-α CCACCACGCTCTTCTGTCTA AGGGTCTGGGCCATAGAACT
mmu-YM-1 TAAGACTGGAATTGGTGCCC CAGACCTCAGTGGCTCCTTC
rno-GAPDH GGTGGACCTCATGGCCTACA CTCTCTTGCTCTCAGTATCCTTGCT
2012100 proefschrift Maarten Corsten.indd   84 07-08-2012   08:38:51
MicroRNA-155 mediates cardiac injury in viral myocarditis
85
4
MicroRNA and Messenger RNA expression array analysis 
Total RNA from human biopsies was hybridized to Illumina Human miRNAv2 Expression 
Panel arrays by ServiceXS (Leiden, The Netherlands). These arrays contained 858 human 
microRNA sequences described in Sanger’s Institute miRBase release 17, plus novel 
content derived using Illumina’s sequencing technologies, making up a total of 1.146 assays 
per chip. Expression values were quantile normalized using the beadarray5 package in R. 
The limma package6 was used to identify differentially regulated microRNAs between 
experimental groups. MicroRNAs were considered differentially expressed with a p-Value 
of < 0.05. Raw data are available in the online Data Supplement.
Total RNA from mouse left ventricles was hybridized to µParaflo® arrays (LC Sciences, 
Houston, TX) based on miRBase Sequence Database Release 12.0 (Sept 2008) containing 
627 mouse microRNAs. In-depth data analysis was performed by LC Sciences. Similarity 
of mouse and human microRNA was determined by a global sequence alignment between 
the mature sequences as provided by miRBase. MicroRNAs were considered the same 
with a maximum of 1 mismatch or 2 gap extension to equalize their length.
RNA from hearts of LNA control- and LNA-antimiR-155-treated mice (sham and 7 days post 
CVB3 injection) was hybridized to Affymetrix GeneChip Mouse Gene 1.0 ST arrays 
(ArrayExpress accession: E-MEXP-3395). The chip quality was assessed using the 
affyQCReport in R. All chips passed the quality control. Expression values were normalized 
between chips using rma7 and the CustomCDF8 provided by the University of Michigan. 
The limma package was used to identify differentially regulated mRNAs (Benjamini & 
Hochberg adjusted p-Value < 0.05). De-repression of cardiac mRNAs with canonical 7-mer 
miR-155 seed match sites (Ensembl, February 2011) after LNA-antimiR treatment was 
evaluated using cumulative distribution functions and significance of the differences from 
mRNAs with no sites was determined using one-sided Kolmogorov-Smirnov tests. 
Unsupervised hierarchical clustering was based on Euclidean distance and Ward’s clustering 
method.
Design and synthesis of LNA oligonucleotides
The LNA-antimiRs were synthesized as unconjugated oligonucleotides with a complete 
phosphorothioate backbone. The perfectly matching LNA-antimiR-155 oligonucleotide 5’- 
TcAcAATtaGmCAtTA -3’ was complementary to nucleotides 2–16 in the mature murine 
miR-155 sequence while the LNA-control oligonucleotide was synthesized with the 
following sequence: 5’- TcAtamCTatAtGamCA -3’ (uppercase: LNA; lowercase: DNA; mC 
denotes LNA methylcytosine). 
Histology
Paraffin-embedded 4µm LV sections were stained with hematoxylin-eosin (HE) or Picrosirius 
red (Sigma). Left ventricular cryosections of 7µm were acetone-fixed and 
immunohistochemically stained with monoclonal rat-anti-mouse antibodies against CD11b 
(R&D systems, Minneapolis, MN, #MAB11124), Ly6G (BD Pharmingen, Breda The 
Netherlands, #551459) or a polyclonal rat anti-mouse antibody against CD3 (gift from Dr. 
Menno de Winther). Photomicrographs were obtained (Leitz DMRXE; Leica, Wetzlar, 
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Germany) and immunoreactivity was quantified as the number of positive cells per mm2, 
or when too many cells overlapped as stained area percentage, using QWin morphometry 
software (Leica).
For serial staining of leukocyte markers (Mac3, CD3 and CD45) on tissue fixed with 10% 
neutral buffered formalin for in situ hybridization, the following protocol was used. Slides 
were dewaxed and dehydrated through an Ethanol gradient and incubated in PBS. Next 
HIER was preformed in a pressure cooker with 10mM Citric Acid, 0,05% tween20, pH6,0 
for 5min. Slides were cooled down and incubated in PBS. Slides were then blocked in 
1%BSA/TBS with the appropriate normal serum for one hour. Next, slides were incubated 
in 1%BSA/TBS with antibody diluted 1:300 (CD45, BD #55039/ CD3, Neomarkers, #RM-
9107-s/ MAC3, BD #550292) overnight at 4°C. Slides were washed 3x5min. in TBST pH8.4 
and incubated in antibody solution 1%BSA/TBST with 1:500 of the appropriate antibody 
(Sigma; Goat-anti-Rat #A8438, Goat anti Rabbit #A3937). Subsequently slides were washed 
3x5min. in TBST pH 8.4 and developed in NBT/BCIP  (Roche cat.no.11697471001). Slides 
were counterstained in fast red (Sigma, Zwijndrecht, The Netherlands), dehydrated and 
mounted in entallan (EMS, Hatfield, PA #14800).
Western blotting
Protein extracts were obtained from left ventricular tissue, from the cardiac immune 
fraction, or from nRCMs, and were resolved by SDS-PAGE and immunoblotted to a PVDF 
membrane. Blots were incubated with antibodies against PU.1 (9G7 Cell Signaling 
Technology, Danvers, MA #2258), and SHIP1 (D-1163 Cell Signaling Technology, #2728). 
GAPDH (Fitzgerald, Acton, MA, RDI-TRK5G4-6C5) was used as a loading control.
Cardiac fractionation and flow cytometry
Animals were euthanized and the whole heart flushed with PBS by injecting a syringe in 
the left ventricle cavity and nicking the right atria. The heart was dissected out, the atria 
removed and placed in PBS, for isolation of the immune cell fraction. Briefly, the ventricles 
were minced into 1mm pieces with a sterile surgical blade, and placed in an enzymatic 
solution (125 U/ml collagenase type XI, 60 U/ml hyaluronidase type I-s, 60 U/ml DNase1, 
and 450 U/ml collagenase type I, Sigma-Aldrich) for 1hr at 37°C. After trituration, the single 
cell suspension was underlayed with Histopaque solution, in order to separate the immune 
from the non-immune fraction. The interphase (immune fraction) was rinsed with PBS and 
cell pellets were either lysed for further molecular analysis, or leukocyte analysis by FACS 
analysis. Leukocytes subpopulations were defined as follows; Regulatory T lymphocytes, 
(CD45+, CD3+, CD4+, CD25+, Foxp3+) Naïve T-helper lymphocytes (CD45+, CD3+, CD4+, 
CD62L+), Effector T-helper lymphocytes (CD45+, CD3+, CD4+, CD62L-), Naive Cytotoxic 
lymphocytes (CD45+, CD3+, CD8+, CD62L+), Effector Cytotoxic T lymphocytes (CD45+, 
CD3+, CD8+, CD62L-), B lymphocytes (CD45+, B220+), Granulocytes (CD45+, CD11b+ 
Ly6G+), Monocytes (CD45+, CD11b+ F4/80-), Pro-inflammatory monocytes (CD45+, 
CD11b+ F4/80-, Ly6C+), Macrophages (CD45+, CD11b+ F4/80+), with the following 
antibodies anti-CD45 (Biolegend clone 30-F11), CD62L (e-bioscience, clone mel-14), F4/80 
(Biolegend, clone BM8), CD3 (Ebioscience, clone 145-C11), CD45R/B220 (Ebioscience, 
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clone RA3-6B2), Ly6G (BD, clone 1A8) or CD11b (BD, clone M1/70), Ly6C (Miltenyi, 1G7.
G10), CD4 (BD, clone RM4-5), CD8 (BD, clone 53-6.7) and CD25 (Ebiosciencs, clone 
PC61.5), FoxP3 (regulatory T cells) (Ebiosciences, clone FJK-16s).
In vitro experiments
Neonatal rat ventricular cardiac myocytes (RCMs) and fibroblasts (RCFs) were isolated by 
enzymatic disassociation of 1-to-2-day-old pups, plated on gelatinized 6-well plates and 
cultured as previously described9. Per well, 106 RCMs or RCFs were grown on high serum 
media for 48 hours. They were then put on low serum media overnight before stimulation 
with 10 ng/mL TNF-α (cat. #315-01A, PeproTech, Rocky Hill, NJ, USA) for 24 hours. 
Experiments with murine endothelial cells (SVEC) were performed under similar conditions 
in 12-well plates, seeding 2.5*105 cells per well. Bone marrow-derived macrophages 
(BMMs) were harvested from the femurs and tibias of adult C3H mice and placed in R10 
(RPMI 1640 medium, containing 10% heat-inactivated fetal calf serum, 100 U/ml penicillin, 
100 µg/ml streptomycin, 2 mM L-glutamine, and 10 mM Hepes) supplemented with 15% 
L-929 cell-conditioned medium. After 7 days, cells were scraped and seeded in 6-wells at 
106 cells per well. After incubation overnight in low serum media, BMMs were stimulated 
with 10ng/mL lipopolysaccharide (from E. coli 055.B5; Sigma) for 24 hours. Primary T cells 
were isolated from adult mouse spleens by mechanical dissociation, followed by magnetic 
bead separation of CD4/8 positive cells by negative selection using the MACS Pan T cell 
isolation kit (Miltenyi Biotec, Auburn, CA, USA, #130-095-130). Cells were seeded in 6-wells 
at 106 cells per 6-well and stimulated with 5µg/mL concanavalin A (Sigma, #C5275) for 24 
hours. After stimulation RNA was isolated with miRVana (Ambion) and quantitative PCR 
was performed as described above.
To assess the effect of miR-155 inhibition in vitro on nRCM viability 106 RCMs per well in 
6-well plates were grown on high serum media for 24 hours before transfection using 
lipofectamine 2000 (Invitrogen, Breda, The Netherlands, #11668-019) according to 
manufacturer’s instructions. Cells were transfected with miRVANA inhibitors against mmu-
miR-155 (Ambion, #4464084-MH13058) or negative control (Ambion #4464076) at 40nM. 
After 6 hours, medium was replaced and cells were put on low serum media overnight 
before infection with CVB3 at MOI=1. After 72 hours, cells were harvested for protein 
extraction, or for RNA isolation as described above. Alternatively, after 120 hours, cells 
were washed twice with PBS following lysis using the CellTiter-Glo Limunscent Cell Viability 
Assay (Promega, Madison, WI, G7570) and read on a Spectramax L luminescent plate 
reader (Molecular Devices, Sunny Ville, CA).
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Supplementary Table 3a.  C57Bl/6N: 4 days versus sham
microRNA P value FC (log2) FC
mmu-miR-483* 0,044702563 -1,082 0,472
mmu-miR-503* 0,015530864 -0,940 0,521
mmu-miR-654-5p 0,03707061 -0,925 0,527
mmu-miR-494 0,048975676 -0,478 0,718
mmu-miR-151-5p 0,030107263 -0,302 0,811
mmu-miR-17* 0,017454267 0,407 1,326
mmu-miR-411 0,034315214 0,578 1,493
mmu-miR-135a* 0,007063276 0,810 1,753
mmu-miR-300 0,042411588 0,918 1,890
mmu-miR-140 0,048201516 1,007 2,009
mmu-miR-93* 0,032048773 1,149 2,217
Supplementary Table 3b.  C57Bl/6N: 4 days versus sham
microRNA P value FC (log2) FC
mmu-miR-541 0,02439305 -1,209 0,433
mmu-miR-151-5p 0,006003813 -0,751 0,594
mmu-miR-486 0,043727804 -0,729 0,603
mmu-miR-503* 0,03201153 -0,727 0,604
mmu-miR-320 0,025917845 -0,629 0,647
mmu-miR-351 0,042124193 -0,626 0,648
mmu-miR-361 0,006356742 -0,485 0,714
mmu-miR-378 0,03034244 -0,425 0,745
mmu-miR-324-5p 0,047891583 -0,216 0,861
mmu-miR-323-5p 0,021281615 0,308 1,238
mmu-miR-139-3p 0,029451575 0,334 1,260
mmu-miR-17* 0,019301327 0,507 1,422
mmu-miR-718 0,00689129 0,975 1,966
mmu-miR-93* 0,014088051 1,072 2,102
mmu-miR-223 0,034406003 1,453 2,738
mmu-miR-106a 0,013237868 1,624 3,083
mmu-miR-146b 0,01227604 1,759 3,384
mmu-miR-20b 0,03763973 1,943 3,846
mmu-miR-208b 0,001702103 2,613 6,118
Supplementary Table 3c.   C3H: 4 days versus sham
microRNA P value FC (log2) FC
mmu-miR-329 0,009322313 -0,723 0,606
mmu-miR-322* 0,045099653 -0,610 0,655
mmu-miR-370 0,020455325 -0,608 0,656
mmu-miR-361 0,035907492 -0,218 0,860
mmu-miR-324-3p 0,048320077 0,214 1,160
mmu-miR-181a-1* 0,002824315 0,386 1,307
mmu-miR-34b-3p 0,049852878 0,421 1,339
mmu-miR-615-5p 0,020096587 0,470 1,385
mmu-miR-374 0,02763182 0,509 1,423
mmu-miR-362-5p 0,02583122 0,647 1,566
mmu-miR-365 0,03683327 0,660 1,580
mmu-miR-467f 0,048136983 1,115 2,166
mmu-miR-223 0,04803933 1,236 2,356
mmu-miR-146b 0,019650105 1,267 2,407
mmu-miR-21 0,024212485 1,295 2,454
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Supplementary table 3d. C3H: 7 days versus sham
microRNA P value FC (log2) FC
mmu-miR-30e* 0,046358544 -2,351 0,196
mmu-miR-149 0,03397871 -2,174 0,222
mmu-miR-30a* 0,038407456 -2,094 0,234
mmu-miR-378* 0,026823249 -1,989 0,252
mmu-miR-181d 0,034686834 -1,977 0,254
mmu-miR-322* 0,004189921 -1,942 0,260
mmu-miR-486 0,032215957 -1,813 0,285
mmu-miR-181b 0,002808145 -1,781 0,291
mmu-miR-192 0,046755955 -1,676 0,313
mmu-miR-499 0,005804902 -1,426 0,372
mmu-miR-208a 0,049824037 -1,225 0,428
mmu-miR-574-3p 0,000201125 -1,184 0,440
mmu-miR-151-3p 0,011075961 -1,140 0,454
mmu-miR-128 0,02740018 -1,101 0,466
mmu-miR-125a-5p 0,038804565 -1,059 0,480
mmu-miR-676 0,00871934 -1,008 0,497
mmu-miR-145 0,019773467 -0,972 0,510
mmu-miR-185 0,013118264 -0,941 0,521
mmu-miR-329 0,019983388 -0,880 0,543
mmu-miR-151-5p 0,011855478 -0,868 0,548
mmu-miR-351 0,003871412 -0,864 0,550
mmu-miR-181a 0,014240269 -0,845 0,557
mmu-miR-22* 0,020532861 -0,842 0,558
mmu-miR-99b 0,03776402 -0,780 0,582
mmu-miR-24-2* 0,035912655 -0,761 0,590
mmu-miR-148a 0,035202067 -0,726 0,605
mmu-miR-455 0,019717637 -0,688 0,621
mmu-miR-361 0,016715042 -0,677 0,625
mmu-miR-320 0,03896415 -0,654 0,635
mmu-miR-195 0,03590963 -0,566 0,676
mmu-miR-107 0,0321193 -0,460 0,727
mmu-miR-744 0,045502525 -0,431 0,742
mmu-miR-103 0,04819953 -0,348 0,786
mmu-miR-143 0,023859914 -0,253 0,839
mmu-let-7a 0,030434748 0,178 1,131
mmu-miR-1 0,013920028 0,285 1,218
mmu-miR-126-3p 0,04826773 0,328 1,255
mmu-miR-23b 0,020723164 0,421 1,339
mmu-miR-106b 0,021067401 0,422 1,340
mmu-miR-23a 0,04349021 0,442 1,359
mmu-miR-16 0,02403476 0,568 1,483
mmu-miR-466f 0,038378604 0,598 1,513
mmu-miR-19b 0,026014028 0,657 1,577
mmu-miR-350 0,04972223 0,752 1,684
mmu-miR-17* 0,011749918 0,789 1,728
mmu-miR-15a 0,039716665 0,798 1,738
mmu-miR-532-5p 0,034992076 0,867 1,824
mmu-miR-15b 0,013798017 0,875 1,834
mmu-miR-425 0,013770207 0,888 1,851
mmu-miR-362-5p 0,002680239 0,923 1,897
mmu-miR-674 0,019204611 0,929 1,904
mmu-miR-210 0,018491874 0,988 1,983
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follow up of Supplementary table 3d
microRNA P value FC (log2) FC
mmu-miR-34a 0,01819858 1,013 2,018
mmu-miR-20a 0,024550011 1,081 2,116
mmu-miR-17 0,00604084 1,115 2,166
mmu-miR-146a 0,00706058 1,133 2,193
mmu-miR-494 0,04678588 1,211 2,315
mmu-miR-340-5p 0,037993435 1,466 2,762
mmu-miR-106a 0,001500131 1,518 2,863
mmu-miR-501-3p 0,016947836 1,578 2,985
mmu-miR-705 0,042335194 1,583 2,996
mmu-miR-1187 0,041873924 1,643 3,122
mmu-miR-714 0,03181346 1,883 3,689
mmu-miR-20b 0,02066468 1,903 3,741
mmu-miR-1224 0,024642378 1,954 3,874
mmu-miR-18a 0,009808551 2,156 4,456
mmu-miR-1892 0,032332353 2,302 4,931
mmu-miR-130b 0,006447384 2,377 5,193
mmu-miR-342-3p 0,011159668 2,596 6,046
mmu-miR-142-5p 0,036101244 2,838 7,149
mmu-miR-21 0,000807731 3,676 12,783
mmu-miR-155 0,010672883 3,906 14,986
mmu-miR-223 0,001946641 4,821 28,268
mmu-miR-146b 0,008104529 5,633 49,618
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Supplementary table 4a. C57Bl/6N versus C3H: sham
microRNA P value FC (log2) FC
mmu-miR-342-3p 0,023943413 -2,240 0,212
mmu-miR-491 0,035962764 -1,089 0,470
mmu-miR-805 0,032383937 -0,995 0,502
mmu-miR-503* 0,04833348 -0,874 0,546
mmu-miR-654-5p 0,034900457 -0,871 0,547
mmu-miR-434-3p 0,038859706 -0,774 0,585
mmu-miR-540-5p 0,002989688 -0,497 0,708
mmu-miR-29a 0,027615903 -0,451 0,732
mmu-miR-27b 0,020436365 0,319 1,247
mmu-miR-107 0,04304382 0,361 1,285
mmu-miR-135a* 0,048545305 0,393 1,313
mmu-miR-181a 0,02844735 0,489 1,404
mmu-miR-1899 0,046357077 0,615 1,531
mmu-miR-361 0,001403497 0,744 1,675
mmu-miR-140 0,032061037 1,137 2,200
mmu-miR-28* 0,031555235 1,383 2,609
mmu-miR-547 0,017727492 1,587 3,004
mmu-miR-208b 0,035234578 1,975 3,931
mmu-miR-582-5p 0,001915029 2,821 7,068
Supplementary table 4b. C57Bl/6N versus C3H: 4d
microRNA P value FC (log2) FC
mmu-miR-342-3p 0,004602955 -2,416 0,187
mmu-miR-204 0,045218993 -1,553 0,341
mmu-miR-155 0,036248315 -1,099 0,467
mmu-miR-34a 0,04637811 -1,051 0,483
mmu-miR-805 0,001562989 -1,001 0,500
mmu-miR-30c-1* 0,009433536 -0,846 0,556
mmu-miR-30a* 0,01951384 -0,771 0,586
mmu-miR-22* 0,0436794 -0,650 0,637
mmu-miR-146a 0,008665415 -0,632 0,645
mmu-miR-135a* 0,02008814 -0,609 0,656
mmu-miR-29c 0,035149448 -0,577 0,671
mmu-miR-150 0,008604468 -0,529 0,693
mmu-miR-29a 0,009543358 -0,445 0,734
mmu-miR-128 0,02925138 -0,318 0,802
mmu-miR-214 0,025768809 0,477 1,392
mmu-miR-207 0,038149375 0,481 1,396
mmu-miR-148a 0,012546075 0,487 1,401
mmu-miR-199a-3p 0,013693704 0,531 1,445
mmu-miR-499 0,039355725 0,684 1,606
mmu-miR-181b 0,032301154 0,690 1,613
mmu-miR-181a-1* 0,04342271 0,795 1,735
mmu-miR-361 0,012509491 0,850 1,803
mmu-miR-34b-3p 0,019788396 0,855 1,809
mmu-miR-28 0,005523557 1,161 2,237
mmu-miR-669f 0,03222844 1,344 2,539
mmu-miR-181c 0,006812654 1,378 2,600
mmu-miR-28* 0,02789194 1,397 2,634
mmu-miR-181d 0,000814127 1,508 2,845
mmu-miR-547 0,03526841 1,723 3,301
mmu-miR-335-5p 0,015183391 2,964 7,805
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Supplementary table 4c. C57Bl/6N versus C3H: 7d
microRNA P value FC (log2) FC
mmu-miR-30a* 0,02593803 -2,804 0,143
mmu-miR-30e* 0,02780424 -2,426 0,186
mmu-miR-98 0,048142307 -1,924 0,263
mmu-miR-805 0,037200842 -1,879 0,272
mmu-miR-145* 0,02535808 -1,767 0,294
mmu-miR-208a 0,03536968 -1,727 0,302
mmu-miR-188-5p 0,04030971 -1,672 0,314
mmu-miR-192 0,039125722 -1,618 0,326
mmu-miR-204 0,03919689 -1,609 0,328
mmu-miR-30c-2* 0,007318904 -1,499 0,354
mmu-miR-342-5p 0,027309835 -1,437 0,369
mmu-miR-101b 0,013836786 -1,381 0,384
mmu-miR-22* 0,018138826 -1,207 0,433
mmu-miR-128 0,027744314 -1,134 0,456
mmu-miR-30b* 0,02581216 -1,006 0,498
mmu-miR-872 0,04112682 -0,932 0,524
mmu-miR-504 0,015230159 -0,930 0,525
mmu-miR-574-3p 0,014991037 -0,833 0,561
mmu-miR-615-3p 0,04504323 -0,809 0,571
mmu-miR-24-2* 0,034350313 -0,755 0,593
mmu-miR-125a-5p 0,048810005 -0,748 0,595
mmu-miR-328 0,04480886 -0,747 0,596
mmu-miR-322* 0,008333288 -0,700 0,615
mmu-miR-26b 0,036034495 -0,677 0,625
mmu-miR-30d 0,0431715 -0,645 0,640
mmu-miR-196a* 0,012290002 -0,532 0,691
mmu-miR-365 0,019036058 -0,493 0,711
mmu-miR-151-3p 0,049959578 -0,409 0,753
mmu-miR-30c 0,02388088 -0,337 0,792
mmu-miR-29a 0,001371107 -0,286 0,820
mmu-miR-30b 0,010157838 -0,253 0,839
mmu-miR-27a 0,019476408 0,199 1,148
mmu-miR-27b 0,005049864 0,219 1,164
mmu-miR-191 0,03516194 0,306 1,237
mmu-miR-24 0,012635543 0,365 1,288
mmu-miR-23a 0,040018834 0,437 1,354
mmu-miR-23b 0,035773236 0,440 1,356
mmu-miR-106b 0,024372695 0,479 1,394
mmu-miR-361 0,009872661 0,552 1,466
mmu-miR-16 0,03980788 0,581 1,496
mmu-miR-690 0,017558878 0,649 1,568
mmu-miR-324-5p 0,046218343 0,665 1,586
mmu-miR-19b 0,047728945 0,687 1,610
mmu-miR-28 0,03340208 0,694 1,617
mmu-miR-199a-3p 0,011984071 0,799 1,740
mmu-miR-20a 0,019996602 0,849 1,802
mmu-miR-17 0,02529782 0,864 1,819
mmu-miR-28* 0,029774155 0,976 1,966
mmu-miR-425 0,009870599 0,982 1,976
mmu-miR-140* 0,04188976 0,997 1,996
mmu-miR-106a 0,030994477 1,005 2,006
mmu-miR-214 0,04392994 1,015 2,021
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follow up of Supplementary table 4c
microRNA P value FC (log2) FC
mmu-miR-709 0,040391672 1,030 2,042
mmu-miR-532-5p 0,007309648 1,116 2,167
mmu-miR-501-3p 0,04015988 1,140 2,204
mmu-miR-541 0,01138485 1,218 2,326
mmu-miR-376b 0,019579086 1,233 2,350
mmu-miR-210 0,003312363 1,284 2,435
mmu-miR-21 0,024541995 1,508 2,844
mmu-miR-184 0,03810928 1,535 2,898
mmu-miR-18a 0,005404913 1,739 3,338
mmu-miR-130b 0,006619324 2,079 4,226
mmu-miR-669a 0,026402878 2,265 4,807
mmu-miR-142-5p 0,043886542 2,794 6,935
mmu-miR-155 0,007051461 2,923 7,582
mmu-miR-223 0,008762343 3,024 8,135
mmu-miR-146b 0,014882721 4,237 18,850
Supplementary table 5. Human VM vs control
microRNA P value FC (log2) FC
hsa-miR-499-3p 0,01771 -1,653 0,318
hsa-miR-302b 0,01824 -1,464 0,362
hsa-miR-490-3p 0,00819 -1,436 0,370
hsa-miR-455-5p 0,00755 -1,347 0,393
hsa-miR-140-5p 0,02908 -1,324 0,399
hsa-miR-497 0,02668 -1,323 0,400
hsa-miR-361-3p 0,00029 -1,214 0,431
hsa-miR-106a 0,00139 -1,184 0,440
hsa-miR-20b 0,01424 -1,121 0,460
hsa-miR-302a 0,01833 -1,108 0,464
hsa-miR-652 0,00206 -1,096 0,468
hsa-miR-186 0,04768 -1,087 0,471
hsa-miR-133b 0,03597 -1,061 0,479
hsa-miR-1296 0,01056 -1,002 0,499
hsa-miR-221* 0,0052 -0,994 0,502
hsa-miR-193b 0,0398 -0,962 0,513
hsa-miR-9 0,0445 -0,956 0,515
hsa-miR-584 0,01509 -0,955 0,516
hsa-miR-302a* 0,04563 -0,954 0,516
hsa-miR-1271 0,01369 -0,906 0,534
hsa-miR-99b 0,00388 -0,904 0,534
hsa-miR-324-5p 0,00806 -0,883 0,542
hsa-miR-107 0,04434 -0,871 0,547
hsa-miR-30c-2* 0,01439 -0,871 0,547
hsa-miR-27b* 0,02178 -0,86 0,551
hsa-miR-30e 0,00866 -0,854 0,553
hsa-miR-149 0,02979 -0,823 0,565
hsa-miR-651 0,0138 -0,803 0,573
hsa-miR-29c* 0,0153 -0,765 0,588
hsa-miR-483-3p 0,01664 -0,751 0,594
hsa-miR-1237 0,01511 -0,697 0,617
hsa-miR-30a* 0,00307 -0,683 0,623
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follow up of Supplementary table 5
microRNA P value FC (log2) FC
hsa-miR-93 0,00006 -0,683 0,623
hsa-miR-103a 0,01541 -0,669 0,629
hsa-miR-147b 0,00409 -0,65 0,637
hsa-miR-24-1* 0,01616 -0,584 0,667
hsa-miR-190 0,03847 -0,575 0,671
hsa-miR-181a* 0,03631 -0,57 0,674
hsa-miR-545 0,00744 -0,559 0,679
hsa-miR-30a 0,01196 -0,498 0,708
hsa-miR-1287 0,0397 -0,493 0,711
hsa-miR-133a 0,00702 -0,437 0,739
hsa-miR-548b-3p 0,00115 -0,391 0,763
hsa-miR-182* 0,00314 -0,381 0,768
hsa-miR-1233 0,03365 -0,36 0,779
hsa-miR-30c 0,00565 -0,359 0,780
hsa-miR-30b 0,02737 -0,333 0,794
hsa-miR-921 0,00857 -0,329 0,796
hsa-miR-554 0,03872 -0,317 0,803
hsa-miR-1267 0,04009 -0,296 0,815
hsa-miR-885-5p 0,03958 -0,291 0,817
hsa-miR-30b* 0,02491 -0,285 0,821
hsa-miR-27b 0,03414 -0,225 0,856
hsa-miR-24 0,04245 -0,221 0,858
hsa-miR-30e* 0,02487 -0,149 0,902
hsa-miR-1266 0,00986 -0,127 0,916
hsa-miR-147 0,02309 -0,123 0,918
hsa-miR-1827 0,04579 -0,102 0,932
hsa-miR-146a* 0,01923 0,127 1,092
hsa-miR-1243 0,03945 0,134 1,097
hsa-miR-1253 0,02298 0,147 1,107
hsa-miR-552 0,01275 0,178 1,131
hsa-miR-202 0,0106 0,193 1,143
hsa-miR-323b-5p 0,00263 0,204 1,152
hsa-miR-155* 0,00218 0,22 1,165
hsa-miR-21 0,04875 0,228 1,171
hsa-miR-619 0,04981 0,252 1,191
hsa-miR-624 0,00783 0,271 1,207
hsa-miR-633 0,02698 0,326 1,254
hsa-miR-580 0,02838 0,349 1,274
hsa-miR-564 0,01807 0,362 1,285
hsa-miR-645 0,02141 0,368 1,291
hsa-miR-488 0,04594 0,379 1,300
hsa-miR-1263 0,01048 0,4 1,320
hsa-miR-1224-5p 0,02474 0,401 1,320
hsa-miR-217 0,03155 0,406 1,325
hsa-miR-452* 0,00034 0,423 1,341
hsa-miR-597 0,0391 0,467 1,382
hsa-miR-92b* 0,04421 0,471 1,386
hsa-miR-20b* 0,00053 0,485 1,400
hsa-miR-563 0,01002 0,511 1,425
hsa-miR-382 0,03068 0,521 1,435
hsa-miR-493* 0,04296 0,546 1,460
hsa-miR-501-3p 0,01185 0,556 1,470
hsa-miR-299-3p 0,00038 0,578 1,493
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follow up of Supplementary table 5
microRNA P value FC (log2) FC
hsa-miR-450b-3p 0,00956 0,592 1,507
hsa-miR-488* 0,01036 0,597 1,513
hsa-miR-132 0,0032 0,688 1,611
hsa-miR-302d* 0,02976 0,694 1,618
hsa-miR-629 0,00337 0,72 1,647
hsa-miR-892b 0,00783 0,741 1,671
hsa-miR-891a 0,00815 0,744 1,675
hsa-miR-631 0,03682 0,758 1,691
hsa-miR-558 0,01039 0,763 1,697
hsa-miR-1246 0,01835 0,883 1,844
hsa-miR-216a 0,03411 0,923 1,896
hsa-miR-432 0,03504 0,944 1,924
hsa-miR-92b 0,00738 0,995 1,993
hsa-miR-212 0,00231 1,002 2,003
hsa-miR-409-5p 0,00009 1,057 2,081
hsa-miR-889 0,0007 1,454 2,740
hsa-miR-155 0,00008 1,816 3,521
hsa-miR-511 0,00001 2,402 5,285
hsa-miR-146b-5p 0,0095 3,573 11,901
Bold microRNAs are significantly regulated in the same direction in murine VM 
(C3H mice day 7)
Supplementary Table 6. Biometrics of viral myocarditis mice treated with LNA-antimiR-155 or antimiR-
control 
Day 7 Day 50
LNA control
sham
LNA-155 
sham
LNA control
VM
LNA-155 
VM
LNA control 
sham
LNA-155
sham
LNA control
VM
LNA-155 
VM
Number 6 6 12 11 6 6 14 19
Body weight 
baseline (g)
21.4 ± 0.6 19.5 ± 0.4 20.3 ± 0.5 21.3 ± 0.3 17.1 ± 1.4 18.0 ± 0.3 17.7 ± 0.9 18.0 ± 0.8
Body weight 
at sacrifice (g)
24.1 ± 0.5 23.1 ± 0.5 20.5 ± 
0.8†††
23.2 ± 0.5** 30.2 ± 0.8 30.3 ± 0.5 28.2 ± 0.5† 29.2 ± 0.6
Heart weight / 
BW (mg/g)
3.9 ± 0.1 3.9 ± 0.1 5.7 ± 0.2††† 4.8 ± 0.3†* 5.4 ± 0.1 5.6 ± 0.1 6.5 ± 0.2† 6.3 ± 0.2
Lung weight / 
BW (mg/g)
6.9 ± 0.3 6.7 ± 0.2 7.2 ± 0.3 6.6 ± 0.1 8.6 ± 0.2 8.3 ± 0.1 9.7 ± 0.5 9.4 ± 0.4
Liver weight / 
BW (mg/g)
66.1 ± 2.2 71.4 ± 1.7 56.7 ± 4.0 63.7 ± 1.9† 77.0 ± 2.6 80.5 ± 2.2 82.2 ± 1.7 81.7 ± 1.6
Kidney weight / 
BW (mg/g)
8.7 ± 0.5 8.4 ± 0.3 7.1 ± 0.4† 9.1 ± 0.1* 11.9 ± 0.4 12.7 ± 0.3 12.0 ± 0.3 11.9 ± 0.3
Spleen weight / 
BW (mg/g)
4.6 ± 0.5 4.3 ± 0.2  7.9 ± 0.5†† 7.1 ± 0.4†† 4.4 ± 0.1 4.1 ± 0.1 4.8 ± 0.2 5.0 ± 0.2*
Fibrotic area (%) 1.25 ± 0.19 0.98 ± 0.06 7.7 ± 1.2†† 3.7 ± 0.6†** 0.61 ± 0.18 0.85 ± 0.30 8.9 ± 2.3†† 9.6 ± 2.3†
Data are presented as mean ± SEM; Organ weights were normalized for baseline body weights (BW)
*p<0.05; **p<0.01; ***<0.001 versus LNA control, †p<0.05; ††p<0.01; †††p<0.001 versus sham
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Supplementary Table 7. Flow Cytometric Analysis of the Cardiac Infiltrate at Day 7 Post-infection 
LNA control 
sham
LNA-155 
sham LNA control VM
LNA-155 
VM
Number 4 4 8 8
T lymphocytes % of CD45+ 12.4 ± 1.3 18.9 ± 0.8 ** 14.3 ± 0.7 16.3 ± 1.7
CD4+ lymphocytes 59.8 ± 0.9 69.0 ± 1.6 ** 75.3 ± 1.4 ††† 69.7 ± 1.8 *
Regulatory T lymphocytes 8.8 ± 0.8 6.4 ± 0.1 * 15.1 ± 1.3 †† 16.1 ± 1.0
Naive CD4+ lymphocytes 16.4 ± 4.7 25.8 ± 5.9 4.2 ± 0.9 †† 21.7 ± 7.7 *
Effector CD4+ lymphocytes 79.9 ± 5.0 68.6 ± 5.8 93.5 ± 1.1 †† 73.5 ± 8.4 *
CD8+ lymphocytes 13.5 ± 1.1 18.6 ± 1.6 * 14.6 ± 0.8 22.5 ± 1.4 ***
Naive CD8+ lymphocytes 21.1 ± 4.1 35.6 ± 7.6 10.0 ± 2.5 † 26.6 ± 8.8 *
Effector CD8+ lymphocytes 76.5 ± 4.7 61.3 ± 7.5 87.4 ± 2.9 70.3 ± 9.5
B lymphocytes 13.4 ± 0.6 12.1 ± 1.0 1.8 ± 0.2 ††† 3.2 ± 1.4
Granulocytes 2.8 ± 0.7 3.1 ± 0.5 0.2 ± 0.1 ††† 0.5 ± 0.2
Monocytes 30.8 ± 1.6 18.8 ± 0.5 *** 44.6 ± 2.3 †† 31.2 ± 3.2 **
Pro-inflammatory monocytes 21.2 ± 3.6 21.3 ± 5.1 67.3 ± 1.4 ††† 65.7 ± 7.3
Macrophages 13.8 ± 1.0 13.5 ± 2.3 2.5 ± 0.2 ††† 2.6 ± 0.7
Data are presented as mean percentage of parent population ± SEM
* p<0.05; ** p<0.01; *** p<0.001 versus LNA.control, † p<0.05; †† p<0.01; ††† p<0.001 versus sham
Supplementary Table 8. Serial echocardiographic analysis of LNA control and LNA-155 mice 
Day 14 Day 50
LNA control 
sham
LNA-155 
sham
LNA control
VM
LNA-155 
VM
LNA control 
sham
LNA-155
sham
LNA control
VM
LNA-155 
VM
Number 6 6 17 19 6 6 14 19
Heart rate 
(bpm)
486 ± 24 419 ± 23 578 ± 9† 500 ± 23** 421 ± 11 453 ± 34 422 ± 9 454 ± 11
Fractional 
shortening (%)
29.1 ± 2.7 24.6 ± 1.0 21.2 ± 1.1† 23.6 ± 0.9 25.6 ± 0.6 29.3 ± 1.8 18.4 ± 2.1† 23.4 ± 1.7*
LVID 
diastolic (mm)
3.96 ± 0.06 3.89 ± 0.05 3.97 ± 0.03 3.94 ± 0.37 3.97 ± 0.08 3.94 ± 0.11 4.19 + 0.09 4.19 ± 0.67
LVID 
systolic (mm)
2.81 ± 0.15 2.94 ± 0.06 3.13 ± 0.06 3.01 ± 0.04 2.96 ± 0.07 2.78 ± 0.10 3.42 ± 0.16 3.22 ± 0.12
Wall thickness 
diastolic (mm) ‡
0.61 ± 0.01 0.61 ± 0.01 0.68 ± 0.01† 0.66 ± 0.01 0.67 ± 0.01 0.66 ± 0.02 0.62 ± 0.03 0.66 ± 0.02
Wall thickness 
systolic (mm)‡
0.90 ± 0.03 0.86 ± 0.02 0.92 ± 0.01  0.92 ± 0.01 1.03 ± 0.03 1.02 ± 0.05 0.86 ± 0.04† 1.02 ± 0.03
Data are presented as mean ± SEM; LVID left ventricular internal dimension
*p<0.05; **p<0.01; ***<0.001 versus LNA control, †p<0.05; ††p<0.01; †††p<0.001 versus sham, ‡averaged anterior and posterior 
wall thickness
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ABSTRACT
Rationale  Viral myocarditis is an important cause of heart failure and sudden cardiac 
death in young adults. Our previous microRNA profiling study has shown that many microRNAs 
are differentially expressed in the heart during viral myocarditis, including the family members 
microRNA-221 (miR-221) and miR-222.
Objective To study the functional effects of miR-221 and miR-222 expression during 
enteroviral myocarditis in mice.
Methods & Results We measured cardiac microRNA levels during viral 
myocarditis with microRNA microarrays and qRT-PCR. Levels of miR-221 and miR-222 were 
significantly elevated during acute viral myocarditis in mice, and depressed in biopsies from 
viral myocarditis patients. In situ hybridization and in vitro experiments showed that both 
microRNAs are expressed by multiple cell types in the heart, including cardiomyocytes and 
endothelial cells, and are upregulated in neonatal rat cardiomyocytes (RCM) in response to 
enteroviral infection. In vivo inhibition of miR-221 and miRNA-222 by systemically delivered 
antagomirs aggravated cardiac injury and inflammation at day 7 post-infection, related to 
increased viral loads at day 4 post-infection. In line, overexpression of miRNA-221 and miR-
222 in RCM inhibited enteroviral replication. We identified and confirmed a set of conserved 
miR-221-222 targets, including the pro-inflammatory transcription factors ETS1, ETS2, the 
chemokine CXCL12, the type I interferon inhibitor IRF2, the T cell development factor TOX and 
the anti-apoptotic proteins BCL2L11 and BMF. De-repression of these targets following miR-
221-222 inhibition in VM may contribute to aggravated inflammation and cardiac injury. 
Conclusions Systemic inhibition of miR-221 and miR-222 increases cardiac viral 
loads and cardiac inflammation during acute viral myocarditis in mice.
In preparation
The MicroRNA-221-222 Family Controls Viral 
Replication and Cardiac Inflammation in Acute 
Enteroviral Myocarditis5
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Introduction
Viral myocarditis (VM) is an inflammatory condition of the heart that causes heart failure 
and sudden death in young, previously healthy individuals, and evidence-based therapies 
for VM are currently lacking1, 2. Myocarditis has been estimated to account for up to 12% 
of sudden cardiac deaths in patients below 40 years of age, and is found in almost 10% 
of biopsies from patients with unexplained heart failure3, 4. Cardiac injury in VM is caused 
by infection of the heart by cardiotropic viruses, such as the enteroviral Coxsackievirus B3 
(CVB3) or Parvovirus B19 (PVB19), which triggers an adverse immune response resulting 
in viral elimination as well as cardiac myocyte destruction, reparative fibrosis and heart 
failure. While immune activity is an important contributor to cardiac injury, broad inhibition 
of the immune response does not lead to clinical improvement in VM patients3, 5. In contrast, 
a range of preclinical studies has recently indicated that not all components of the immune 
response are equally beneficial or detrimental during VM, and that targeting specific 
signaling pathways may protect against cardiac inflammatory injury without compromising 
viral elimination2, 4. 
MicroRNAs (miRNAs) are important regulators of gene expression in a wide range of 
biological processes, including cardiac biology and the regulation of immune responses6-8. 
Recently, we studied miRNA expression profiles in the hearts of mice and humans during 
acute VM and identified a large number of up- and downregulated miRNAs at different 
time points of disease (this thesis, Chapter 4). Among the most strongly upregulated 
miRNAs were the miRNA family members microRNA-221 (miR-221) and miR-222. The 
co-transcribed miR-221-222 family was previously reported to promote tumor growth by 
targeting cell cycle inhibitors p27(kip1) and p57(kip2)9, 10 and to affect vasculature by 
promoting smooth muscle cell proliferation and inhibiting angiogenesis11-13. However, the 
roles of miR-221 and miR-222 in the heart or during viral infection have not been studied 
so far. In this study, we aimed to investigate which cells express miR-221-222 in the 
heart and whether cardiac miR-221-222 expression during viral myocarditis is functionally 
important for the pathogenesis of cardiac injury in VM. We found that miR-221 and miR-
222 are expressed by cardiomyocytes, fibroblasts and endothelial cells in the heart, as 
well as by infiltrating inflammatory cells, and directly target a range of inflammatory 
mediators, including the transcription factors Protein C-ets-1 (ETS1), ETS2 and the 
chemokine (C-X-C motif) ligand 12 (CXCL12). Both miRNAs are upregulated in 
cardiomyocytes in response to infection with CVB3 and overexpression of miR-221-222 
inhibited viral replication in cardiomyocytes in vitro. In vivo, systemic inhibition of miR-
221-222 by antagomirs aggravated cardiac injury and infiltration of T cells and macrophages 
in the heart during acute VM at day 7 post-infection, and caused increased early viral 
loads at day 4 post-infection. These data identify miR-221-222 expression as a protective 
factor in acute VM.
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Methods 
Animal studies
All mouse experiments were performed according to the local guidelines for care and use 
of laboratory animals approved by the institutional animal care committee. For viral 
myocarditis (VM) experiments, 4-weeks-old male susceptible C3H mice (Harlan, Boxmeer, 
The Netherlands) were inoculated intraperitoneally with 2x105 plaque forming units of 
Coxsackievirus B3 (CVB3) or saline. For microRNA knockdown in vivo, antagomirs were 
administered to male 4-week-old C3H mice intravenously at a dose of 40 mg/kg per injection 
(inhibition of miR-221-222 with 20/20 mg/kg versus 40 mg/kg control antagomiRs). 
Antagomirs were ordered from Fidelity Systems (Gaithersburg, MD) as fully 2’-O-methylated 
RNA oligonucleotides with perfect complementarity to the full mature sequences of miR-
221 or miR-222, a phosphorothioate backbone at both flanks, and a 3’ cholesterol 
modification. Sequences: anti-mmu-miR-221: 5’-G*A*AACCCAGCAGACAAUGUA*G*C*
U*Chol*T-3’; anti-mmu-miR-222: 5’-G*A*GACCCAGUAGCCAGAUGUA*G*C*U*Chol*T-3’ 
and anti-control 5’-C*A*GCUGAAGUAAAUACCGAC*C*A*G*Chol*T-3’ (* indicates 
phosphorothioate bond).
For analysis at day 7 post-infection, antagomiRs were given at days 1, 4 and 6 post-CVB3 
infection and group sizes were at least n=5 for sham groups, and at least n=10 for VM 
groups (n=20 for antagomiR-221-222 VM and, n=10 for antagomiR-control VM and n=20 
for PBS VM). For analysis at day 4 post-infection, antagomiRs were given at days 0, and 2 
post-CVB3 infection and group sizes were n=3 for sham groups and n=7 for VM groups. 
Organs were snap-frozen or fixed for 4-6 hours in 1% paraformaldehyde for histology. 
Circulating leukocyte numbers were counted in fresh heparinized mouse blood samples 
using the Abbott Cell-Dyn 3700 (Wavre, Belgium). 
Patient material 
All human material was obtained during routine sampling used for clinical purposes, stored 
in a coded way and available for research purposes in accordance with the Declaration of 
Helsinki and the ethical committee at Maastricht University Medical Center. For microRNA 
profiling, right ventricular septal biopsies were used, obtained during routine clinical 
sampling from patients with acute myocarditis, in view of its recurrence or lack of 
improvement within 48 hours  (n=4). Patients with a definite clinical history of myocarditis 
were included1 (Supplementary Table 1). Patients presented with an episode of upper 
airway or gastro-intestinal infection, followed after 1-3 weeks by chest pain. All myocarditis 
patients had elevated troponin T plasma levels and immunohistochemically proven cardiac 
inflammation (n>14 CD45 positive cells/mm2). In all patients, virus presence was 
demonstrated in the cardiac biopsies (Supplementary Table 1). Coronary artery disease 
was excluded either by CAG or CT. Controls (n=6) consisted of age-matched patients with 
unexplained ventricular tachy-arrhythmias but with a normal ejection fraction and the 
absence of systemic or cardiac inflammation or virus presence at the time of biopsy 
(Supplementary Table 1). Cardiac biopsies were immediately snap-frozen for RNA analysis 
or formalin-fixed for histological examination. 
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RNA isolation, microRNA arrays, northern blotting and quantitative RT-PCR
Total RNA was isolated from left ventricular mouse tissue samples and right ventricular 
septal biopsies using the miRVANA isolation kit (Ambion, Warrington, UK), according to 
the manufacturer’s instructions and without enrichment for small RNAs. Potential genomic 
DNA contamination was removed using the DNA-free kit (Ambion). For microRNA array 
analysis, total RNA from human biopsies was hybridized to Illumina Human miRNAv2 
Expression Panel arrays by ServiceXS (Leiden, The Netherlands) and total RNA from mouse 
left ventricles was hybridized to µParaflo® arrays (LC Sciences, Houston, TX). For Northern 
blot analysis, 1-5 µg total RNA per sample were heated at 85 degrees Celsius for 5 minutes, 
loaded on a denaturing 20% acrylamide gel and ran for 2 hrs at 100 V. RNA was transferred 
to a nylon membrane (Roche, Mannheim, Germany) using a semi-dry blotting device 
(Biorad, Veenendal, The Netherlands) for 15 minutes at 20V. Blots were hybridized at 37°C 
with dual DIG-labeled LNA probes (Exiqon, Vedbaek, Denmark) and visualized using the 
DIG Wash and Block buffer set (Roche) and CDP-star reagent (Roche). For quantitative 
real-time PCR analysis, cDNA was generated using the miScript kit (Qiagen, Venlo, The 
Netherlands) and quantified using IQ SYBR-green supermix (Bio-Rad) in a MyIQ iCycler 
(Bio-Rad). LNA-based primer assays (Exiqon) were used for detection of mature microRNAs. 
A complete list of primer sequences is provided in Supplementary Table 2. 
In situ hybridization
In situ hybridization was performed as described previously14, 15. 4 µm sections were 
prepared from 48hr 10% neutral buffered formalin fixed human or mouse cardiac biopsies. 
Sections were de-waxed, dehydrated, air-dried briefly and incubated in 1.3 mg/ml 
Pepsin/0.1mM HCl solution for 5 min at 37°C. After a brief wash in DEPC MQ, sections 
were incubated overnight at 42.5°C in 1x hybridisation buffer (ENZO Life sciences, 
Farmingdal, NY, #33808) with either 100 nM mmu-miR-221 or mmu-miR-222 DIG labeled 
probe (EXIQON, Vedbaek, Denmark, #39471-01) or a scrambled control probe (#99004-01). 
The following day the sections were washed once in 5xSSC and twice in 0.2xSSC at 
hybridisation temperature. Subsequently, sections were blocked in DIG blocking buffer 
from the DIG Wash and Block Buffer Set (Roche, Woerden, The Netherlands, #11585762001) 
for 20 min followed by a 45 min incubation in 1:500 anti-DIG-AP, Fab fragments (Roche, 
#11093274910). Sections were washed 3x5 min with TBS and incubated 3 min in DIG 
detection buffer at room temperature. AP signal was detected by using NBT/BCIP tablets 
(Roche, #11697471001) for 4 hours at 30°C in darkness. Finally, sections were counterstained 
with fast red (Sigma, Zwijndrecht, The Netherlands) briefly washed in MQ, quickly 
dehydrated through an ethanol gradient and mounted with entellan (EMS, Hatfield, PA, 
#14800).
Histology
Paraffin-embedded 4µm LV sections were stained with hematoxylin-eosin for microscopic 
analysis. Left ventricular cryosections of 7µm were acetone-fixed and immunohistochemically 
stained by incubation with a monoclonal rat-anti-mouse antibody against CD11b (R&D 
systems, Minneapolis, MN, #MAB11124), or a polyclonal rat anti-mouse antibody against 
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CD3 (gift from Dr. Menno de Winther). Photomicrographs were obtained (Leitz DMRXE; 
Leica, Wetzlar, Germany) and immunoreactivity was quantified as the number of positive 
cells per mm2, or when too many cells overlapped as stained area percentage, using QWin 
morphometry software (Leica).
In vitro experiments
Neonatal rat ventricular cardiac myocytes (RCMs) and fibroblasts (RCFs) were isolated 
by enzymatic disassociation of 1-to-2-day-old pups, plated on gelatinized 6-well plates 
and cultured as previously described16. Per well, 106 RCMs or 2*105 RCFs were grown 
on high serum media for 48 hours. They were then put on low serum media overnight 
before stimulation with 10 ng/mL TNF-α (PeproTech, Rocky Hill, NJ, #315-01A), 10ng/
mL Il-1β (PeproTech, #211-11B) for 6/24 hours, or infection with coxsackievirus B3 at 
an MOI of 1. Experiments with murine cardiac endothelial cells (MCEC) were performed 
under similar conditions in 12-well plates, seeding 2.5*105 cells per well. Bone marrow-
derived macrophages (BMMs) were harvested from the femurs and tibias of adult C3H 
mice and placed in R10 (RPMI 1640 medium, containing 10% heat-inactivated fetal calf 
serum, 100 U/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine, and 10 mM 
Hepes) supplemented with 15% L-929 cell-conditioned medium. After 7 days, cells 
were scraped and seeded in 6-wells at 106 cells per well. After incubation overnight in 
low serum media, BMMs were stimulated with 10ng/mL lipopolysaccharide (from E. 
coli 055.B5; Sigma) for 24 hours. Primary T cells were isolated from adult mouse spleens 
by mechanical dissociation, followed by magnetic bead separation of CD4/8 positive 
cells by negative selection using the MACS Pan T cell isolation kit (Miltenyi Biotec, 
Auburn, CA, USA, #130-095-130). Cells were seeded in 6-wells at 106 cells per well and 
stimulated with 5µg/mL concanavalin A (Sigma, #C5275) for 24 hours. After stimulation 
RNA was isolated with miRVana (Ambion) and quantitative PCR was performed as 
described above.
To assess the effect of miR-221-222 overexpression or inhibition in vitro, RCMs, RCFs, 
or MCECs were grown on high serum media for 24 hours before transfection using 
lipofectamine 2000 (Invitrogen, Breda, The Netherlands, #11668-019) according to 
manufacturer’s instructions. Cells were transfected with pre-miRs (MicroRNA mimics, 
Thermo Scientific Dharmacon, Lafayette, CO) for rno-miR-221 (C-032421-05), rno-miR-222 
(C-320420-03) or negative control (CN-002000-01) at 20/20nM for miR-221-222 and 40nM 
for control; or with miRNA inhibitors (miRVANA inhibitors against mmu-miR-221-3p 
(Ambion, #4464084-MH10337), mmu-miR-222-3p (Ambion, #4464084-MH11376), or 
negative control (Ambion #4464076) at 40/40nM for miR-221-222 and 80nM for control. 
After 6 hours, medium was replaced and cells were put on low serum media overnight 
before infection with CVB3 at MOI=1 or stimulation with TNF-α for 6/24 hours. To assess 
nRCM viability after CVB3 infection after 120 hours, cells were washed twice with PBS 
followed by lysis using the CellTiter-Glo Luminescent Cell Viability Assay (Promega, 
Madison, WI, G7570) and read on a Spectramax L luminescent plate reader (Molecular 
Devices, Sunny Ville, CA).
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Luciferase reporter assays
To confirm direct targeting of candidate targets by miR-221 and miR-222, we performed 
luciferase reporter assays. Mouse 3’UTR fragments (~1kb) were PCR amplified (Takara 
LA Taq, Clontech, Mountain View, CA) and cloned into the firefly luciferase 3’UTR of 
pMIR-REPORT (Applied Biosystems), using renilla luciferase as an internal control. Cloning 
primer sequences are provided in Supplementary Table 3. Mutations in th putative miR-
221-222 binding sites were introduced using site-directed mutagenesis (Quikchange II 
XL, Stratagene, La Jolla, CA), replacing the ATGTAGCA seed-binding sequence with 
ATGTCTAA (mutated bases underlined. Mutation primer sequences are given in 
Supplementary Table 4. Reporter plasmids were contransfected with premiRs (MicroRNA 
mimics, Thermo Scientific Dharmacon), into HEK293 cells using Lipofectamine 2000 
(Invitrogen) in 96-well plates (per well: 0.5 µL Lipofectamine 2000, 50ng plasmid, 1/1nM 
for pre-miR-221/pre-miR-222 versus 2nM for pre-miR-29b or pre-negative control (NC)). 
Luciferase was read after 24 hours using the Dual-Glo kit (Promega) on a Spectramax L 
luminescent plate reader (Molecular Devices). Measurements were performed in technical 
triplicates and were performed at least twice.
Electron microscopy 
Small tissue samples of the left ventricle were immersed in 3% glutaraldehyde in KH2PO4 
buffer (pH7.4), postfixed in 1% OsO4 in veronal acetate buffer (pH7.4) supplemented with 
1.5% ferricyanide and routinely processed for embedding in epoxy resin.
Statistical analyses
Statistical analyses for miRNA arrays were performed in R. Analyses for experimental 
work were performed using GraphPad Prism 5.0d for Macintosh (GraphPad Software Inc., 
La Jolla, CA, USA). Comparisons between 2 groups were performed with two-tailed 
Student’s t testing for Gaussian data or Mann-Whitney tests for non-Gaussian data. For 
comparisons of more than 2 groups, one-way ANOVA was used, followed by post hoc 
testing using Bonferroni correction for more groups. Probability values below 0.05 were 
considered statistically significant. Data are presented as mean ± SEM unless otherwise 
indicated. 
Results 
Cardiac expression of the miR-221-222 family is increased during acute VM in mice
We studied the cardiac expression of miRNAs during VM in two mouse models. C3H mice 
are susceptible to the development of VM after inoculation with CVB3, while C57Bl/6 mice 
are resistant to cardiac inflammation despite similar viral titers. MiRNA levels were analyzed 
at baseline (day 0), during high viral presence before the immune infiltration (day 4) (as 
described in Chapter 4), and during the acute inflammatory phase (day 7). Microarray results 
for cardiac miR-221 and miR-222 expression at these time points are shown in Figure 1A. 
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Levels of both miRNAs are significantly elevated at day 7 after CVB3 infection as compared 
to baseline in C57Bl/6 as well as in C3H mice, and were among the most strongly 
upregulated miRNAs in the C3H miRNA VM profile (Figure 1B). Quantitative real-time PCR 
(qRT-PCR) confirmed the elevation of both miRNAs in susceptible C3H mice at day 7 (miR-
221: 3.7-fold, p<0.01; miR-222: 5.9-fold, p<0.001) and of miR-221 in C57Bl/6 mice at day 
7 (3.5-fold, p<0.05) (Figure 1C). In addition, levels of miR-221 were already elevated in C3H 
mice at day 4 (1.3-fold, p<0.01) whereas miR-222 levels were elevated by trend (1.3-fold, 
p=0.09). Levels of both miRNAs remained elevated by trend in VM hearts after 50 days 
(miR-221: 2.7-fold, p=0.07; miR-222: 2.5-fold, p=0.07), after viral elimination and fibrotic 
remodeling (as described in Chapter 4). Together, these data indicate that miR-221 and 
miR-222 are strongly elevated during acute VM. 
Figure 1. MicroRNA-221 (miR-221) and miR-222 are upregulated in mouse viral myocarditis (VM), and 
downregulated in human VM. (A) Microarray signal fold changes compared to baseline of cardiac miR-221 
and miR-222 expression at day 4 (before cardiac immune infiltration) and day 7 (acute inflammation) post-
infection with Coxsackievirus B3 (CVB3). Data are shown for both VM-resistant C57Bl/6 and VM-susceptible 
C3H mice. (B) Volcano plots showing fold changes (log2 values) and p values (log10) compared to baseline 
for individual miRNAs in C3H mice at day 7 post-infection. (C) Quantitative real-time PCR measurement 
of miR-221 and miR-222 expression confirmed elevated levels of both miRNAs in C3H mice at day 7, and 
additionally showed elevation of miR-221 at day 4 in C3H mice and at day 7 in C57Bl/6 mice. (D) Microarray 
signal fold changes compared to control of cardiac miR-221 and miR-222 expression in cardiac biopsies from 
VM patients, showing trend-wise and significant downregulation of miR-221 and miR-222, respectively. *P 
< 0.05, **P < 0.01, ***P < 0.001.
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Cardiac expression of the miR-221-222 family is depressed in biopsies from patients 
with VM
In contrast to their elevation in mice, miR-221-222 were not elevated in cardiac biopsies 
of VM patients. MiR-221 levels were depressed by trend as compared to controls (0.8-fold, 
p=0.2) (Figure 1D), while miR-222 were significantly lower in VM (0.4-fold, p<0.01). Though 
the causative agent in the VM patients from Figure 1D was PVB19, both miRNAs are also 
depressed in biopsies from VM patients with other viral pathogens, including CVB3 and 
adenoviruses (personal communication, Wolfgang Poller), indicating that miR-221-222 
downregulation is not virus-specific. In fact, miR-221 and miR-222 downregulation was 
previously described in hearts of patients with ischemic cardiomyopathy and dilated 
cardiomyopathy17-19. While the difference between miR-221-222 regulation in humans and 
mice may indicate different sampling time-points during disease (acute in mice versus 
sub-acute/chronic in patients), it may also reflect non-conserved regulatory elements in 
the promoter. MiR-221 and miR-222 are located ~850 bases apart and are co-transcribed 
Figure 2. MiR-221 and miR-222 are expressed by multiple cell types in the heart. (A) In situ hybridization 
of miR-221 (blue) on left ventricular sections of a healthy mouse, VM mouse and a VM patient, showing 
blue cellular staining in multiple cardiac cell types, including cardiomyocytes (CM), endothelial cells (EC) 
and infiltrating white blood cells (WBC). Panel (B) shows miR-221 and miR-222 expression in responses to 
CVB3 infection or inflammatory stimulation in a cell panel including rat neonatal myocytes (RCM), fibroblasts 
(RCF), adult mouse cardiac endothelial cells (MCEC), primary bone marrow-derived macrophages (BMM) 
and splenic T cells.  Inflammatory stimuli were TNF-α for RCMs, RCFs and MCECs, lipopolysaccharide (LPS) 
for BMMs and Concanavalin A (ConA) for T cells (n=3 per group). Expression of miR-221 and miR-222 is 
significantly induced by CVB3 infection in RCM, and by TNF-α stimulation in RCFs. Expression levels are 
presented as relative to control. Scale bars: 50µm. *P < 0.05, **P < 0.01.
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from a large intergenic region on the X-chromosome. Mature miR-221-222 sequences are 
perfectly evolutionary conserved from zebrafish to rodents and humans (Supplementary 
Figure 1A). Regulatory elements for miR-221-222 transcription – identified by H3K27AC 
regulatory element footprints and DNAseI hypersensitivity clusters – are located over a 
region spanning from 80 kilobases (kb) upstream to 50 kb downstream of the miR-222 
transcription start site (UCSC Genome browser analysis shown in Supplementary Figure 
1B). This region includes no CpG islands but harbours >200 binding sites for transcription 
factors including several for nuclear factor kappa B (NF-κB), signal transducer and activator 
of transcription 3 (STAT3), and other inflammatory transcription factors (ENCODE Chip-seq 
data, not shown). Sequence conservation in this region is imperfect and may explain 
differential activation of miR-221 and miR-222 expression between different species. 
MiR-221-222 are expressed by multiple cardiac cell types and are upregulated in 
cardiomyocytes after CVB3 infection 
We next asked what cardiac cell types express miR-221 and miR-222 under basal and 
inflamed conditions, both in vivo and in vitro. In situ hybridization of miR-221 in the normal 
mouse heart revealed its expression by multiple cell types in the heart, including 
cardiomyocytes, endothelial cells, and interstitial cells (Figure 2A, miR-221 staining in dark 
blue) while no signal was detected using a scrambled probe (not shown). During VM (7 
days), staining was again apparent in cardiomyocytes and endothelial cells, and in addition 
in recruited inflammatory cells (Figure 2A). Similarly, in cardiac biopsies from VM patients, 
we observed miR-221 expression both in infiltrating inflammatory cells and in 
cardiomyocytes. Unfortunately, we could not detect miR-222 with the commercial probe 
indicated in the methods, but, given their similar expression behaviour and common 
promoter, a deviant expression profile for miR-222 is not expected.
To assess whether miR-221 and miR-222 are regulated by infectious or inflammatory 
conditions in vitro, we infected isolated RCM with increasing concentrations of CVB3. 
Alternatively, we stimulated rat neonatal cardiomyocytes (RCM), fibroblasts (RCF), or murine 
cardiac endothelial cells (MCEC), with Tumor Necrosis Factor-alpha (TNF-α) for 6 or 24 
hours, bone marrow-derived macrophages (BMM) with lipopolysaccharide (LPS) for 24 
hours, or splenic T lymphocytes with ConCanavalin A (ConA) for 6 or 24 hours. Cellular 
responses to stimuli were verified by measurement of responsive inflammatory genes 
(Supplementary Figure 2). We found that both miR-221 and miR-222 were upregulated by 
CVB3 infection in a dose dependent manner (CVB3 multiplicity of infection (MOI)=5; miR-
221: 2.3-fold, p<0.01; miR-222: 2.3-fold, p<0.01) (Figure 2B). In contrast, the expression 
of miR-1 and miR-208a was unchanged (Supplementary Figure 2A). MiR-221-222 expression 
responses to TNF-α stimulation in cardiac cell types were mild: both miRNAs were 
upregulated in RCFs after 24h of TNF-α (p<0.05) and slightly elevated by trend in RCMs. 
In contrast, TNF-α caused no miR-221-222 expression changes in endothelial cells, 
macrophages and T cells, in line with previous reports20, 21. Similar results were obtained 
by stimulation of RCMs, RCFs and MCECs with interleukin-1 beta (IL-1β), and after TNF-α 
stimulation of the fibroblast 3T3 cell line and the endothelial cell line SVEC (Supplementary 
Figure 3). In conclusion, miR-221 and miR-222 are expressed by cardiomyocytes, fibroblasts, 
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endothelial cells, and inflammatory cells in the VM heart. MiR-221-222 expression increases 
during murine VM likely reflect a combination of their upregulation in cardiomyocytes and 
fibroblasts, and of the influx of miR-221-222-expressing macrophages and T cells.
In vivo inhibition of miR-221-222 increases cardiac injury and immune cell infiltration 
during acute viral myocarditis 
To investigate whether expression of miR-221-222 affects the course of VM in mice, we 
systemically administered antagomirs against miR-221-222, a control sequence, or 
phosphate buffered saline (PBS), at 3 time points throughout the first 7 days of VM in male 
C3H mice (Figure 3A). qRT-PCR analysis of miR-221 and miR-222 expression confirmed 
upregulation of both miRNAs during VM in antagomir groups and revealed strong and 
significant knockdown of both miRNAs in sham and VM conditions after antagomir-221-222 
administration (Figure 3B). We observed no effects of the control antagomirs as compared 
to PBS treatment. Using northern blotting for mature miR-221 under denaturing conditions, 
we detected sharply reduced miR-221 levels after antagomir-221-222 treatment, indicative 
of knockdown by miRNA degradation (Figure 3C). While no mortality was observed in PBS 
or antagomir control-treated VM animals, 3 out of 20 antagomiR-221-222-treated VM 
animals died during the first week after infection (Supplementary Table 5). At day 7, 
Figure 3. In vivo inhibition of miR-221 and miR-222 aggravates cardiac injury during acute viral 
myocarditis. (A) Study design: antagomirs targeting miR-221 and miR-222 were administered by three 
intravenous injections throughout the first 7 days of CVB3-induced VM. (B) qRT-PCR analysis of cardiac miR-
221-222 expression, demonstrating significant knockdown of both miRNAs by antagomir treatment in both 
sham and VM groups. In agreement, northern blot analysis showed markedly reduced band intensity after 
antagomir treatment (C). (D) Left ventricular H&E stainings at day 7 of CVB3-induced VM showing aggravated 
cardiomyocyte necrosis after miR-221-222 inhibition (LV necrotic area 33.3% in antagomiR-221-222 VM, 
compared to 9.7% in PBS VM, p<0.01; and 13.4% in antagomir control VM, p<0.05). In addition, miR-221-
222 inhibition significantly promoted heart weight increase during VM as a marker of cardiac edema. (n≥5 
per sham group and n≥10 per VM group). Scale bar: 100 µm. *P < 0.05, **P < 0.01, ***P < 0.001.
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cardiac necrosis as measured on haematoxylin-eosin staining was significantly aggravated 
in antagomir-221-222 treated animals as compared to controls (33.3% of left ventricular 
area in antagomiR-221-222 VM, compared to 9.7% in PBS VM, p<0.01; and 13.4% in 
antagomir control VM, p<0.05) (Figure 3D). In addition, miR-221-222 inhibition significantly 
enhanced heart weight increases during VM, a marker of cardiac inflammatory edema 
(Figure 3D and Supplementary Table 6). Immunostainings revealed that miR-221-222 
inhibition promoted the infiltration of both CD3+ T cells and CD68+ macrophages in the 
heart after VM, while not affecting basal macrophage numbers in sham hearts (Figure 4A 
and Supplementary Figure 4B). In addition, miR-221-222 inhibition increased the white 
blood cell count in the circulation of VM mice (Supplementary Figure 4A). Electron 
microscopy confirmed necrotic degeneration of cardiomyocytes and influx of mononuclear 
cells in antagomir-221-222 VM hearts, while no ultrastructural differences were observed 
between sham hearts of different treatments (Supplementary Figure 5).
qRT-PCR revealed that miR-221-222-inhibited VM hearts contained more than 3-fold higher 
CVB3 genome copies (p=0.09) than VM controls, and expressed significantly higher 
amounts of both pro-inflammatory (interferon gamma, IFN-γ) as well as anti-inflammatory 
Figure 4. Inhibition of miR-221-222 promotes cardiac immune cell infiltration and inflammatory 
cytokine expression in VM. (A) MiR-221-222 inhibition promoted cardiac infiltration of CD68+ macrophages 
(p<0.05) and CD3+ T lymphocytes (p<0,05) during VM. (B) qRT-PCR analysis showing that miR-221-222-
inhibited VM hearts contained more than 3-fold higher CVB3 genome copies (p=0.09) than VM controls, 
and expressed significantly higher amounts of both pro-inflammatory (interferon gamma, IFN-γ) as well as 
anti-inflammatory (IL-10) T cell-cytokines. MiR-221-222 inhibition also caused significantly higher expression 
levels of the chemokine CXCL12 and Intercellular Adhesion Molecule-1 (ICAM1), and elevation by trend of 
IL-6, Macrophage Chemoattractant Protein-1 (MPC1), and P-selectin (PSEL), while not affecting TNF-α. (n≥5 
per sham group and n≥10 per VM group). Scale bars: 100 µm. *P < 0.05.
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(IL-10) T cell-cytokines (Figure 4B). MiR-221-222 inhibition also caused significantly higher 
expression levels of the chemokine CXCL12 and of Intercellular Adhesion Molecule-1 
(ICAM1), and elevation by trend of IL-6, Macrophage Chemoattractant Protein-1 (MCP1), 
and P-selectin (PSEL), while not affecting TNF-α and IL-4 levels (Figure 4B and Supplementary 
Figure 4C). Together, these data show that inhibition of miR-221 and miR-222 during VM 
in mice aggravates cardiac injury and inflammatory infiltration by macrophages and T cells, 
associated with increased expression of adhesion molecules, chemotaxis and viral load. 
Inhibition of miR-221-222 increases cardiac CVB3 load at day 4 post-infection 
Since miR-221-222-inhibited mice displayed higher cardiac CVB3 levels at day 7 of VM, we 
next investigated whether antagomirs against miR-221-222 directly affected viral loads in 
vivo. To circumvent possible confounding effects of inflammation on viral replication2, we 
analyzed the hearts of animals treated with antagomir-221-222 versus antagomir control at 
4 days post-infection, before the onset of inflammatory infiltration (Supplementary Table 6 
Table 2). Inflammatory patches were absent in all infected hearts, and both miR-221 and 
miR-222 were efficiently suppressed by antagomir administration (Figure 5A and B). At day 
4, miR-221-222 inhibition significantly increased CVB3 titers in the heart (2.7-fold, p<0.01), 
without affecting the number of apoptotic cells in the myocardium (Figure 5C and D). 
Figure 5. Inhibition of miR-221-222 increases cardiac CVB3 load at day 4 post-infection. (A) Left 
ventricular H&E stainings at day 4 of CVB3-induced VM show absence of inflammatory patches at this time 
point. (B) qRT-PCR measurements of cardiac miR-221 and miR-222 levels, showing significant knockdown 
for both miRNAs. (C) Photographs and quantification of Terminal deoxynucleotidyl transferase dUTP nick 
end labeling (TUNEL, green signal with DAPI nuclear counterstain in blue). No differences in the percentage 
of cardiac apoptotic cells were observed between antagomir treatments. (D) qRT-PCR showing significantly 
higher CVB3 levels in antagomir-221-222-treated VM hearts compared to controls (2.7-fold, p<0.01). In 
addition miR-221-222 inhibition caused significantly higher expression levels of IL-6, MCP1, IFN-β, and with 
a trend to higher expression of adhesion molecules ICAM1 and P-selectin, as well as CXCL12 and Il-1β, but 
not TNF-α. (n=5 per sham group and n=7 per VM group). *P < 0.05, **P < 0.01, ***P < 0.001.
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Increased viral loads after miR-221-222 inhibition were associated with significantly higher 
expression levels of IL-6, MCP1, IFN-β, and with a trend to higher expression of adhesion 
molecules ICAM1 and P-selectin, as well as CXCL12 and Il-1β, but not TNF-α or VCAM, in 
line with the fact that cardiomyocytes efficiently produce IL-6 and MCP1 but only minimal 
amounts of TNF-α (Figure 5D and Supplementary Figure 6). These data indicate that miR-
221-222 directly impacts viral replication and cardiac CVB3 load before the inflammatory 
phase in the heart.
The miR-221-222 family directly targets regulators of inflammation and apoptosis
To identify direct miR-221-222 targets that may explain the aggravated cardiac inflammation 
and injury after miR-221-222 inhibition, we queried predicted miR-221-222 targets in mouse 
and human using the Targetscan algorithm and searched the overlapping (conserved) gene 
set for putative targets with a potential role during VM. We selected 8 potential targets: 
the pro-inflammatory transcription factors ETS1 and ETS2 promote the expression of 
Figure 6. MiR-221 and miR-222 directly target multiple pro-inflammatory and anti-apoptotic proteins. 
Potential miR-221-222 targets were selected with evolutionary conserved predicted binding site for the 
miR-221-222 family in their 3’UTR, and with possible roles during viral myocarditis. Targets included the 
pro-inflammatory transcription factors ETS1 and ETS2, the inhibitor of type I interferons transcription IRF2, 
the chemokine CXCL12, the anti-apoptotic proteins BCL2L11 and BMF, and the T cell factors TOX and CD4. 
3’UTR fragments containing the predicted binding sequence were cloned into pmiR-REPORT downstream 
of firefly luciferase (Fluc), using renilla luciferase (Rluc) as an endogenous control. Arrowheads indicate 
the location of predicted binding sites and red crosses indicate mutated sites. All predicted targets except 
for CD4 were regulated by miR-221-222, as indicated by significantly lower Fluc/Rluc ratios in presence of 
miR-221-222 (pre-221-222) overexpression but not by overexpression of miR-29b (pre-29b) or a negative 
control mimic (pre-NC). Mutation of 3 bases in the predicted binding sites abrogated target repression by 
miR-221-222 overexpression. (n=3 per group; all experiment were performed at least twice). *P < 0.05, **P 
< 0.01, ***P < 0.001.
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cytokines, adhesion molecules and chemokines such as MCP122-24. In addition, ETS1 
promotes replication of the human immunodeficiency virus-1 (HIV1) and human T cell 
leukemia virus 1 (HTLV1) in lymphoid cells25-27. Interferon Regulatory Factor-2 (IRF2) inhibits 
the transcription of type I interferons, which are protective in VM28. The chemokine CXCL12 
is a strong lymphocyte attractant, while Thymocyte selection-associated high mobility group 
box protein (TOX) and CD4 are important in T cell biology. Finally we selected BCL2-like 
11 (BCL2L11) and BCL-2-modifying factor (BMF) as two anti-apoptotic proteins. All predicted 
targets harbor 1 3’UTR 8-mer conserved binding site, except for ETS1, which has a 7-mer 
conserved binding site and an additional 8-mer non-conserved binding site (Supplementary 
Figure 7A). Luciferase reporter assays revealed that the 3’UTRs of all putative targets 
except for CD4 were functional, as evidenced by suppression of the firefly luciferase signal 
by overexpression of miR-221-222 (~20-fold, data not shown) but not by overexpression 
of a control sequence or the unrelated miR-29b (Figure 6). Moreover, mutation of three 
single bases within the binding site for the miR-221-222 seed abrogated luciferase 
suppression by premiR-221-222 in all targets. For ETS1, both sites were functional as only 
double, but not single binding site mutation could rescue the reporter signal from miR-221-
222 repression (Supplementary Figure 7B). To see whether these confirmed miR-221-222 
targets were derepressed at the mRNA level by in vivo miR-221-222 inhibition, we measured 
their cardiac transcript levels using qRT-PCR at 7 days of VM in animals treated with miR-
221-222 or control antagomirs. Levels of CXCL12, BCL2L11 and TOX were significantly 
increased by miR-221-222 inhibition, while ETS1, ETS2, IRF2 and BCL2L11 were increased 
by trend (Supplementary Figure 4D).
MiR-221-222 overexpression suppresses viral replication in but not viability of 
cardiomyocytes in vitro
To assess whether targeting of inflammatory and apoptotic genes by miR-221-222 affects 
these processes in vitro, we overexpressed or inhibited miR-221 and miR-222 in 
cardiomyocytes, endothelial cells and fibroblasts. Transfection of premiR-221 and 
premiR-222 increased the levels of mature miR-221-222 in RCMs, while levels of the 
highly myocyte-expressed miR-133a were unaffected (Figure 7A and Supplementary 
Figure 8A). In agreement with the increased viral loads after antagomir-221-222 treatment 
in vivo, overexpression of miR-221-222 markedly and significantly suppressed viral 
replication, compared to control premiRs (5-fold after 48 hours, p<0.05) (Figure 7A). 
PremiR-221-222 treatment of RCMs did not efficiently activate interferon type I expression 
through IRF2 repression, as transcript levels of interferon-beta (IFN-β) were markedly 
higher in control RCMs, consistent with the higher viral loads in these cells. In line with 
the suppressive effects of miR-221-222 overexpression on CVB3 replication, inhibition of 
miR-221-222 resulted in higher viral loads in RCMs after 72 hours of infection (Figure 7B 
and Supplementary Figure 8B). We observed no differences in myocyte viability after 120 
hours of infection (Figure 7A), in agreement with the lack of effect on cardiac apoptosis 
observed in vivo after miR-221-222 antagomir treatment. Transcript levels of direct target 
ETS2 was not affected by premiR-221-222, while direct targets CXCL12, ETS1, and IRF2, 
as well as the chemokine MCP1 were by trend repressed by premiR-221-222 
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(Supplementary Figure 8A). Finally, overexpression or inhibition of miR-221-222 in 
endothelial cells (MCEC) did not reveal significant effects on MCEC cytokine or adhesion 
molecule expression to TNF-α stimulation (Supplementary Figure 9), and similarly 
overexpression of miR-221-222 in fibroblast did not suppress cytokine expression and 
interferon responses to TNF-α (Supplementary Figure 10). Together, these in vitro 
experiments indicate a potential role for miR-221-222 in CVB3 replication, while not 
supporting a role in cardiomyocyte apoptosis, endothelial cell adhesion molecule expression, 
or fibroblast interferon responses. 
Discussion 
In this study, we investigated the functional effects of miR-221-222 expression in the heart 
during VM in mice. We report that miR-221-222 levels are elevated in mouse VM but 
depressed in human VM, and that systemic inhibition of miR-221-222 in mice increases 
viral replication, cardiac injury and inflammation. These data add to our understanding of 
the role of miRNAs in VM and identify the miR-221-222 family as a protective factor in VM 
pathophysiology.
A striking finding from this study is the increased susceptibility of mice to VM-induced 
cardiac damage following miR-221-222 inhibition, suggesting that miR-221-222 upregulation 
is a compensatory molecular response during VM aiming to prevent virus-induced cardiac 
injury. In contrast, we previously reported that miR-155, which is also strongly upregulated 
during VM, contributes to cardiac inflammation, and that inhibition of miR-155 during VM 
Figure 7. MiR-221-222 overexpression suppresses viral replication but not viability in cardiomyocytes 
in vitro. RCMs were transfected with mimics for (A) or inhibitors (B) against miR-221-222 or control and 
infected with CVB3 (MOI=1). Mimics and inhibitors efficiently overexpressed and knocked-down miR-221-
222, respectively. Overexpression of miR-221-222 significantly suppressed CVB3 replication and IFN-β 
expression at 24 and 48 hours after infection (p<0.05 for both). Conversely, inhibition of miR-221-222 
caused higher CVB3 loads at 72 hours after infection (p<0.01). Viability was assayed after 120 hours and 
was not affected by miR-221-222 overexpression or knockdown. (n≥3 per group). *P < 0.05, **P < 0.01, 
***P < 0.001.
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in mice is protective against cardiac injury. Our data show that inhibition of miR-221-222 
directly increases viral loads in vivo, both at day 4 and 7 post-infection and causes an early 
increased expression of the chemokine MCP1, that is produced by myocytes in response 
to CVB3 infection29. This mechanism was supported by miR-221-222 overexpression in 
cardiomyocytes in vitro, which strongly reduced CVB3 replication. It is not clear what direct 
miR-221-222 targets are responsible for these effects on CVB3 replication. ETS1 has been 
shown to promote the replication of HIV1 and HTLV1 (which are both single stranded RNA 
viruses like CVB3) in lymphoid cells25-27. It is possible that ETS1 may also affect CVB3 
replication in cardiomyocytes, or additionally in lymphoid cells. Studies are underway to 
investigate these possibilities.
We identified a number of direct targets that suggest roles beyond viral replication for 
miR-221-222 in VM, including apoptosis (BCL2L11 and BMF), adhesion molecule expression 
(ETS1 and ETS2), cytokine secretion (ETS1 and ETS2, CXCL12), and T cell biology (TOX 
and CD4). Although we show that the pro-apoptotic factors BCL2L11 and BMF are bona 
fide targets of miR-221-222, miR-221-222 effects on viral load were not paralleled by 
differences in apoptosis, either in vitro or in vivo. It is well possible that the anti-apoptotic 
effects of miR-221-222 are cell type-dependent, as their expression has been reported to 
be anti-apoptotic or pro-apoptotic in different cellular contexts (hepatocytes and 
hepatocellular carcinoma cells, respectively)30, 31. In addition to targeting apoptotic genes, 
miR-221-222 directly target ETS1, which was previously shown to affect endothelial cell 
adhesion molecule expression and T cell adhesion in human umbilical vein endothelial 
cells32. Although we did not observe adhesion molecule upregulation in murine endothelial 
cells upon miR-221-222 manipulation, the biological activity of ICAM1 and VCAM molecules 
is at least as much determined by cellular localization as by expression levels, and our data 
do not exclude that cellular adhesion may be promoted in MCEC cells independent of 
adhesion molecule transcript abundance. 
We inhibited miR-221 and miR-222 expression levels in parallel in vivo, as we anticipated 
redundancy in target repression. Although the predicted target set of both miRNAs is highly 
overlapping (depending on the target prediction algorithm used), minor differences between 
their biological functions cannot be excluded from our experiments. Conversely, potential 
therapeutic strategies aimed at increasing miR-221 or miR-222 expression may not require 
overexpression of both family members. Additional experiments will be required to assess 
whether overexpression of both miRNAs is protective in vivo, and whether both family 
members possess differential efficacy for such purposes.
We observed divergent miR-221-222 expression response during VM in humans and mice. 
Previous studies reported downregulation of miR-221-222 in human ischemic and dilated 
cardiomyopathy18, 19, while  miR-221-222 upregulation in heterogenous acute murine heart 
disease33-36. The difference between mouse and human miR-221-222 expression during 
VM may thus reflect divergent transcriptional control of miR-221-222 expression, or may 
alternatively be caused by the fact that biopsies in human myocarditis are taken at a later 
time point after initial viral infection. Importantly, expression differences between species 
do not automatically imply differences in the cellular effects of miR-221-222 signaling 
between humans and mice. Rather, given the large number of direct and indirect targets 
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affected by single miRNAs and the marked conservation of miR-221 and miR-222 throughout 
evolution, comparable biological functions in humans and mice are expected. Therefore, 
our identification of miR-221-222 as protective in murine VM may have direct bearing on 
human disease, suggesting that promoting miR-221-222 signaling may benefit VM 
patients. 
In conclusion, miR-221 and miR-222 dysregulated in VM in humans and mice and miR-221-
222 inhibition in mice during VM leads to increased viral replication, cardiac injury and 
inflammatory infiltration. These data identify the miR-221-222 family as a protective 
component of the cardiac molecular response to CVB3 infection and as a potential 
therapeutic target in VM.
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Supplementary Figures and Tables
Supplementary Figure 1. Sequence conservation and genomic context of miR-221 and miR-222. (A) 
The mature sequences of miR-221 and miR-222 have been evolutionary conserved back to zebrafish. (B) 
UCSC Genome browser screen shot. MiR-221 and miR-222 are located ~850 bases apart and co-transcribed 
from a large intergenic region on the X-chromosome. Regulatory elements for miR-221-222 transcription – 
as indicated by H3K27AC regulatory element footprints and DNAseI hypersensitivity clusters – are located 
over a region spanning from 80 kilobases (kb) upstream to 50 kb downstream of the miR-222 transcription 
start site. Sequence conservation in this region is imperfect, which may explain differential activation of 
miR-221 and miR-222 expression between different species.
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Supplementary Figure 2. Control measurements for in vitro inflammatory stimulation experiments. 
(A) CVB3 infection in rat neonatal myocytes (RCM) leads to the upregulation of macrophage chemoattractant 
protein-1 (MCP1), while the expression of the highly myocyte-expressed miR-1 and miR-208a is not affected. 
(B) Positive control genes confirming cellular expression responses to CVB3 infection or inflammatory 
stimulation in a cell panel including RCMs, fibroblasts (RCFs), adult mouse cardiac endothelial cells (MCEC), 
primary bone marrow-derived macrophages (BMM) and splenic T cells.  Inflammatory stimuli were TNF-α 
for RCMs, RCFs and MCECs, lipopolysaccharide (LPS) for BMMs and Concanavalin A (ConA) for T cells (n=3 
per group). Expression levels are presented as relative to control. *P < 0.05, **P < 0.01, ***P < 0.001.
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Supplementary Figure 3. MiR-221 and miR-222 expression responses to IL-1β and TNF-α in cardiac 
cells in vitro. (A) MiR-221 and miR-222 expression in response to stimulation with IL-1β in rat neonatal 
myocytes (RCM), fibroblasts (RCF) and adult mouse cardiac endothelial cells (MCEC). (B) MiR-221 and 
miR-222 expression in response to stimulation with TNF-α a mouse fibroblast cell line (3T3), and mouse 
endothelial cell line (SVEC). Expression levels are presented as relative to control. *P < 0.05, **P < 0.01, 
***P < 0.001.
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Supplementary Figure 4. Inhibition of miR-221-222 inflammation during acute VM in mice. (A) MiR-
221-222 inhibition increased white blood cell (WBC) counts in the systemic circulation. (B) The number of 
CD68+ macrophages in sham hearts was not affected by antagomir-221-222 administration. (C) Cardiac IL-4 
transcript levels during VM were not affected by antagomir-221-222 administration. (D) Cardiac transcript 
levels of the direct miR-221-222 targets BCL2L11 and TOX were significantly increased by in vivo miR-221-
222 inhibition at VM day 7, while ETS1, ETS2 and IRF2 were increased by trend, and BMF was unaffected. 
Scale bars: 100 µm. *P < 0.05.
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Supplementary Figure 5. Transmission electron microscopy (TEM) analysis of the mouse left 
ventricle in sham and VM animals treated with antagomir-221-222 or antagomir control. Normal 
ultrastructural morphology of cardiomyocytes (CM) and capillary blood vessels (CAP) is observed in hearts 
of sham animals treated with antagomir-221-222 or control. In control VM hearts, several mononuclear cells 
(M) have infiltrated in the interstitial space between the cardiomyocytes (CM). In the VM heart treated with 
antagomir-221-222, several mononuclear cells (M) and a plasma cell (PC) are seen around the cardiomyocyte 
(CM), as well as degenerating cardiomyocytes (degCM). IC: interstitial cell.
Supplementary Figure 6. Effects of 
miR-221-222 inhibition on cardiac 
transcript levels at day 4 post-infection 
in mouse VM hearts. Cardiac transcript 
levels of IL-1β were elevated by trend in 
antagomir-221-222 treated VM hearts 
at day 4, while VCAM levels were not 
affected by miR-221-222 inhibition. (n=5 
per sham group and n=7 per VM group).
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Supplementary Figure 7. Conservation of miR-221-222 binding sites in the 3’UTR of inflammatory 
and anti-apoptotic protein targets.
(A) Schematic representation of the miR-221-222 seed sequence match with the 3’UTRs of 8 predicted 
miR-221-222 targets, including the pro-inflammatory transcription factors ETS1 and ETS2, the inhibitor of 
type I interferons transcription IRF2, the chemokine CXCL12, the anti-apoptotic proteins BCL2L11 and BMF, 
and the T cell factors TOX and CD4. The size of the 3’UTRs (mouse) is indicated above each target and 
arrowheads indicate the location of predicted binding sites within the 3’UTR. Watson-Crick complementarity 
in the seed region is indicated in black verticals, while an adenosine at the position across the first miRNA 
base (which outperform complementary bases for target prediction as described previously6) is indicated in 
green. (B) Luciferase experiments revealed that both predicted miR-221-222 binding sited in the ETS1 3’UTR 
are functional, as isolated mutation of either of the binding sites did not abrogate luciferase suppression by 
miR-221-222. **P < 0.01, ***P < 0.001.
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Supplementary Figure 7 (continued)
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Supplementary Figure 8. Effects of miR-221-222 overexpression and inhibition in cardiomyocytes in 
vitro. Neonatal rat cardiomyocytes were transfected with mimics (A) or inhibitors (B) against miR-221-222 
or control and infected with CVB3 (MOI=1). Mimics and inhibitors did not affect levels of miR-133a, and 
mimics did not significantly alter the expression levels of IL-6, CXCL12, MCP1, ETS1, ETS2 and IRF2. *P < 
0.05, **P < 0.01.
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Supplementary Figure 9. Overexpression or inhibition of miR-221-222 do not affect 
TNF-α-induced adhesion molecule expression in mouse cardiac endothelial cells 
(MCECs) in vitro. MCECs were transfected with mimics (A) or inhibitors (B) against miR-
221-222 or control and stimulated with TNF-α for 6 hours. Mimics and inhibitors efficiently 
overexpressed and knocked-down miR-221-222, respectively, but did not affect the 
induction of IL-6 or transcript levels of adhesion molecules ICAM1, VCAM and P-selectin 
in response to TNF-α stimulation. (n=4 per group). *P < 0.05, **P < 0.01, ***P < 0.001.
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Supplementary Figure 10. Overexpression of miR-221-222 does not affect TNF-α-induced cytokine 
responses in neonatal rat fibroblasts (RCFs) in vitro. MCECs were transfected with mimics against miR-
221-222 or control and stimulated with TNF-α for 24 hours. Mimics efficiently overexpressed miR-221- and 
miR-222, but did not significantly affect the transcripts levels of IL-6, MCP1, IFN-β, transforming growth 
factor-beta (TGF-β), CXCL12, or ETS1. (n=3 per group). *P < 0.05.
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Supplementary Table 1. Acute viral myocarditis and control sample donor characteristics
Viral Myocarditis Controls
Characteristic (n=4) (n=6) P*
Age, years  39 ± 20 38 ± 11 0.96
Women 0 (0) 2 (33.3) 0.52
Echocardiography
   LVEF (%) 25 ± 15 55 ± 7 0.002
   EDD (mm) 48 ± 10 56 ± 5 0.15
PVB19 > threshold † 4 (100)   0 (0) 0.005
PVB19 titer (c/µg DNA) 1855 ± 1508 79 ± 56 0.04
CD45 cell/mm2 80 ± 39 11 ± 4 0.005
Serum Troponin T, µg/L 2.9 ± 3.7 ND
Data are presented as mean ± SD, or n (%), * P-values based on student t-test, Mann-Whitney test or Chi-square 
analysis, † Threshold value: 500 copies/µg cardiac DNA, LVEF Left Ventricular Ejection, EDD End diastolic Diameter, 
ND Not determined 
Supplementary Table 2. Primer sequences
Gene Forward primer Reverse primer
CVB3 ACGAATCCCAGTGTGTTTTGG TGCTCAAAAACGGTATGGACAT
mmu-CXCL12 AGAGCCAACGTCAAGCATCT TAATTTCGGGTCAATGCACA
mmu-GAPDH GGTGGACCTCATGGCCTACA CTCTCTTGCTCAGTGTCCTTGCT
mmu-ICAM1 TGGAGACGCAGAGGACCTTA CGCTCAGAAGAACCACCTTC
mmu-IFN-γ GCGTCATTGAATCACACCTG CTGGACCTGTGGGTTGTTG
mmu-IFN-β1 AGCACTGGGTGGAATGAGAC TCCCACGTCAATCTTTCCTC
mmu-interleukin-4 CATGGGAAAACTCCATGCTT TGGACTCATTCATGGTGCAG
mmu-interleukin-6 CAAAGCCAGAGTCCTTCAGAG GCCACTCCTTCTGTGACTCC
mmu-interleukin-10 ATCGATTTCTCCCCTGTGAA TGGCCTTGTAGACACCTTGG
mmu-MCP1 GTTGGCTCAGCCAGATGCA AGCCTACTCATTGGGATCATCTTG
mmu-P-selectin TTCAGGACAATGGACAGCAG GAAGGTGCAGGTTGATCCAT
mmu-TNF-α CCACCACGCTCTTCTGTCTA AGGGTCTGGGCCATAGAACT
mmu-VCAM CCGGCATATACGAGTGTGAA GATGCGCAGTAGAGTGCAAG
rno-CXCL12 GCCAACGTCAAACATCTGAA TAATTTCGGGTCAATGCACA
rno-ETS1 GCTGTGGCAGTTTCTTCTGG TTCCTCTTTCCCCATCTCCT
rno-ETS2 CAGTAAGCCGACCATGTCCT AGAAACTGCCACAGCTGGAT
rno-IL-6 GCCAGAGTCATTCAGAGCAA GAGCATTGGAAGTTGGGGTA
rno-IRF2 CGAAACTACCGACAGTGTGC CCCCATGTTGCTGAGGTACT
rno-MCP1 ATGCAGTTAATGCCCCACTC TGCTGCTGGTGATTCTCTTG
rno-GAPDH GGTGGACCTCATGGCCTACA CTCTCTTGCTCTCAGTATCCTTGCT
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Supplementary Table 3. Cloning primer sequences
Gene
Seed 
match
Fragment 
(nt)
Forward 
primer*
Reverse 
primer†
mmu-ETS1 1x8mer, 1x7mer 961 ACTCCTCAGCGTGCTGACTT TGTGCCAGCATCAGCTACTT
mmu-ETS2 8mer 1000 TGAAGGGTGACCTGGTTTTT GCTCCAAGTCCCATGTCTGT
mmu-IRF2 8mer 749 GGCTGCTTCTGCACCTTATC TTCATTTATTATCAATCCACAGGA
mmu-CXCL12 8mer 832 CAGGAGGAGCCTAGGTCTGA ACCACCTTTCTTTGGGCTTT
mmu-BCL2L11 8mer 934 ACCCATCAAACCCATTTTTG TGAAAGCTAGTCGCAAGTTTTATTT
mmu-BMF 8mer 831 TTCAAAGTTTGGCTGTGCTG GGTCCCCATTCCTTTCCTTA
mmu-TOX 8mer 751 TTTCACCATGGATTGCTTTG AGTGAGCATTTGGCAGCTTT
mmu-CD4 8mer 957 CACCTGCGTCCTGTCTCAT CCATGTAGTGGCTTGGCTCT
* forward primers included a 5’ Pme1-site (GTTTAAAC), † reverse primers included a 5’denotes 5’ Nhe1-site 
(GCTAGC)
Supplementary Table 4. Mutation primer sequences
Gene Mutation primer*
mmu-ETS1 site #1 GGTTTATACACTGGAAATGTCTAAGCATTGCTGCATTGATGCT
mmu-ETS1 site #2 CTGAGGTAGCTTAGAGATGTCTAGATGTAAGTGTCTTAAATGT
mmu-ETS2 GGAAATATATGGGATTTATGTCTAAGCTATTTTTACTGCAAAAG
mmu-IRF2 CTTTTATGAGCTCATGTCTAAATCAAATTATCCTGTGGATTG
mmu-CXCL12 GCTGTACTTTCACATTTTATTATGTCTAAAGATACATGGTGATTT
mmu-BCL2L11 GTCAGAACCCAGCGTATGTCTAATTTGTATTGCAGTTTCCC
mmu-BMF GGGAGACCCAGCGAGATGTCTAATTTCCTTCATCCCCAGTC
mmu-TOX GACTTTTTAAATGGCTTGATGTCTAAGTCATAGCAAGTTTGTAA
* forward primers are shown, reverse primers were the perfect reverse complement of the forward primers.
The seed region is in bold, the mutate bases underlined (original seed: ATGTAGCA, mutated seed ATGTCTAA)
Supplementary Table 5. Biometrics of mice treated with antagomir-221-222 or antagomir control (VM day 7)
PBS
sham
anti-ctrl
sham
anti-221-2
sham
PBS
VM
anti-ctrl
VM
anti-221-2
VM
Number 11 5 11 20 10 20
Mortality 0 0 0 0 0 3
Body weight baseline (g) 20.0 ± 0.5 19.8 ± 1.0 20.0 ± 0.6 19.6 ± 0.6 19.8 ± 0.5 20.6 ± 0.6
Body weight at sacrifice (g) 24.6 ± 0.6 23.3 ± 0.4 22.4 ± 0.5 20.4 ± 0.7 21.8 ± 1.0 21.4 ± 0.7
Heart weight / BW (mg/g) 4.1 ± 0.1 3.9 ± 0.2 3.7 ± 0.04 4.6 ± 0.1 4.7 ± 0.3 5.6 ± 0.3*†††
Lung weight / BW (mg/g) 7.6 ± 0.1 7.8 ± 0.1 6.8 ± 0.1 6.8 ± 0.1 7.3 ± 0.2 7.3 ± 0.3
Liver weight / BW (mg/g) 79 ± 1 80 ± 3 76 ± 1 63 ± 1† 70 ± 1†† 69 ± 1†
Spleen weight / BW (mg/g) 5.6 ± 0.4 6.8 ± 0.5 5.0 ± 0.3 6.5 ± 0.4 7.9 ± 0.2 8.3 ± 0.5†††
Kidney weight / BW (mg/g) 8.9 ± 0.2 8.2 ± 0.2 7.9 ± 0.1 7.5 ± 0.2† 7.4 ± 0.2† 7.3 ± 0.2
Data are presented as mean ± SEM; Organ weights were normalized for baseline body weights (BW), *p<0.05; 
**p<0.01; ***<0.001 versus antagomir control, †p<0.05; ††p<0.01; †††p<0.001 versus sham
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Supplementary Table 6. Biometrics of mice treated with antagomir-221-222 or antagomir control (VM day 4)
anti-control 
sham
anti-221-222 
sham
anti-control 
VM day 4
anti-221-222 
VM day 4
Number 3 3 7 7
Body weight baseline (g) 20.4 ± 1.0 21.1 ± 0.3 21.3 ± 0.3 21.2 ± 0.6
Body weight at sacrifice (g) 21.6 ± 1.1 22.6 ± 0.1 21.0 ± 0.6 21.0 ± 0.6
Heart weight / BW (mg/g) 3.6 ± 0.1 3.6 ± 0.1 3.2 ± 0.05† 3.4 ± 0.05
Liver weight / BW (mg/g) 72 ± 1 74 ± 2 63 ± 2 61 ± 2†
Spleen weight / BW (mg/g) 5.8 ± 0.5 4.7 ± 0.2 6.1 ± 0.3 5.4 ± 0.3
Data are presented as mean ± SEM; Organ weights were normalized for baseline body weights (BW), *p<0.05; 
**p<0.01; ***<0.001 versus antagomir control, †p<0.05; ††p<0.01; †††p<0.001 versus sham
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ABSTRACT
Hypertension triggers hypertrophic remodeling of the cardiac muscle and subsequent heart 
failure, representing one of the major challenges for cardiovascular research in the twenty-first 
century. While neurohormonal and myocyte signaling are well-established underlying 
mechanisms, the implication of the inflammatory system is increasingly gaining interest. Here, 
we show that genetic loss or pharmacological inhibition of the leukocyte-derived microRNA-155 
in mice reduces cardiac inflammation, hypertrophy and dysfunction in pressure-overloaded 
hearts. The contribution of microRNA-155 expression in macrophages to myocyte growth was 
confirmed in vitro, where medium of microRNA-155 knockout macrophages did not allow the 
hypertrophic growth of cardiomyocytes. In vivo cardiac myocyte-specific microRNA-155 over-
expression did not affect cardiac hypertrophy or dysfunction, whereas bone marrow 
transplantation from wild type into microRNA-155 knockout animals rescued the cardiac 
myocytes’ hypertrophic response. These effects were at least partly mediated by the direct 
microRNA-155 target Suppressor of Cytokine Signaling 1 (Socs1), as Socs1 knockdown in 
microRNA-155 knockout macrophages rescued the hypertrophic response. 
These findings reveal that the inhibition of the inflammatory cell-derived microRNA-155 
prevents cardiac hypertrophy and dysfunction, and demonstrate a causative relation between 
inflammatory signaling and heart failure.  
Submitted
Macrophage MicroRNA-155 Controls Cardiac 
Hypertrophy and Failure6
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Introduction
Cardiac hypertrophy and consequent heart failure in response to chronic hypertension 
represent one of the major health challenges in Western societies1. Over the past decade, 
inflammatory mediators have become well-recognized contributors to heart failure2-4. 
Conversely, the role of inflammatory cells during pressure overload-induced hypertrophy 
and heart failure is less well established despite the notion that Angiotensin II (Ang II), one 
of the major mediators of hypertension-induced target organ damage and hypertrophy, is 
a powerful promoter of inflammation5. In this study, we show that microRNA-155 (miR-
155) expression by macrophages contributes to cardiac hypertrophy and failure, through 
up-regulation of pro-inflammatory paracrine signaling.
MicroRNAs are small non-coding RNAs that inhibit gene expression of complementary 
target genes at the post-transcriptional level6. Whereas others have studied the implication 
of cardiac myocyte- or fibroblast-derived microRNAs in cardiac hypertrophy and failure7-10, 
inflammatory microRNAs have hitherto remained unaddressed in cardiac disease. MiR-155 
is one of the first described inflammatory microRNAs, whose expression is induced rapidly 
in myeloid and lymphoid cells upon exposure to a variety of inflammatory stimuli11, and 
whose upregulation has been observed in a multitude of inflammatory diseases, including 
rheumatoid arthritis and multiple sclerosis12-15. MiR-155-deficient mice generate normal 
leukocyte populations under steady-state conditions, but they display defective B-cell 
responses upon immunization and resistance to T cell-dependent experimental autoimmune 
encephalomyelitis16-18. Conversely, forced expression of miR-155 in the hematopoietic 
system dysbalances inflammation-driven granulocyte/monocyte expansion and causes a 
myeloproliferative disorder19, in line with its increased expression in human myeloid 
cancers20. In light of these accounts, miR-155 is highly likely to be of functional importance 
in innate immunity. However, in vivo evidence to support this conclusion or for a role of 
miR-155 in heart disease is so far lacking.   
The purpose of our study was to determine whether macrophage-derived miR-155 has a 
role in cardiac disease. We demonstrate that miR-155 is a mediator of cardiac hypertrophy 
and failure in response to pressure overload. Absence of miR-155 leads to decreased pro-
inflammatory cytokine production through its de-repressed target Suppressor of cytokine 
signaling 1 (Socs1). Consequently, pro-inflammatory and pro-hypertrophic signaling through 
the downstream pathway Signal Transducer and Activator of Transcription 3 (Stat3) 
decreases both in cardiac myocytes and macrophages in the absence of miR-155. Our data 
demonstrate that local inflammation in the myocardium is driven by miR-155 and aggravates 
cardiac remodeling, and support a role for miR-155 in innate immunity.
Methods
Mouse models
All animal experiments were approved by the Committees for Animal Welfare of Maastricht 
and Leuven Universities, and performed adhering to Dutch and Belgian law. Ten to twelve 
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weeks-old male miR-155 KO and WT C57Bl/6J mice weighing 20-25 grams were used17. 
Angiotensin II (Ang II, 2.5 µg/g/day) was infused subcutaneously by Alzet osmotic minipump 
2004 (Cupertino, CA) for 7 and 28 days. Echocardiography was performed with the Vevo770 
(Visualsonics, Toronto, Canada) and probe RMV707B (15-45 MHz) at days 0 and 28. At day 
21, blood pressure was monitored with tail cuff (CODA, Kent Scientific, Torrington, CT). At 
day 7 or 28, mice were sacrificed and hearts were isolated for histological and molecular 
analyses. Total RNA was isolated with RNeasy mini kit (Qiagen, Valencia, CA) and SYBR 
Green quantitative PCR analysis was performed on a Bio-Rad iCycler (Hercules, CA) to 
determine Acta1, Nppa, Nppb, Il6 and Gapdh expression (primers in Supplementary Table 
3). Cardiac protein extracts (50µg) were immunoblotted with antibodies to Agtr1 (Abcam, 
Cambridge, UK), Stat3 (C-20 Santa Cruz Biotechnology, Santa Cruz, CA), P-Stat3 (Tyr705, 
Cell Signaling Technology, Danvers, MA) and Gapdh (Fitzgerald, Acton, MA). At day 7, 
peripheral blood was taken for FACS analysis as previously described44. 
For bone marrow transplantation, eight weeks-old male miR-155 KO and WT mice received 
water supplemented with neomycin (100 mg/l) and polymyxin B sulfate (60.000U/l). One 
day before transplantation, mice were irradiated with a lethal dose of 6 Gy röntgen. Bone 
marrow cells of male miR-155 WT and KO littermates were derived by flushing the femur 
and tibia, and cells (107) were injected in the tail vein of each recipient. After eight weeks, 
mice were treated with Ang II for 28 days as described above.
Eight weeks-old male WT C57Bl/6J mice were tail vein-injected on three consecutive days 
with a total of 10mg/kg LNA-modified antimiR-155 or control antimiR (Ribotask, Denmark). 
On the last day of injection, Ang II administration started as described above for 28 days. 
RNA was isolated from hearts with the miRVana microRNA isolation kit (Ambion, Austin, 
TX) and the miScript PCR system (Qiagen) was used to determine miR-155 expression. 
Eight weeks-old male WT C57Bl/6J mice were tail vein-injected with 2.5x1011 viral genome 
particles of adeno-associated virus serotype 9 (AAV9) in 100µl PBS. AAV9-pre-hsa-miR-155 
and -scrambled vectors, and AAV9-sponge-miR-155 and sponge-control vectors were 
produced at high-titer as previously described45, 46. The AAV9-sponge-miR-155 vector 
contained 4 imperfect binding sites for mmu-miR-155 (acccctatcacgtcaagcattaa; imperfect 
binding sites in bold, while the AAV9-sponge-control vector contained 3 mutated binding 
sites for miR-122 (acaaacaccattgtcagattcga; mutations in seed region in bold). Rescue 
efficiency of the sponge-miR-155 construct was tested in a luciferase assay. HEK293T 
cells were co-transfected with 1) sponge-miR-155 or sponge-control vector, 2) psiCheck2 
luciferase vector (Promega) containing an imperfect miR-155 target sequence (the same 
also contained in the sponge) in the Renilla luciferase 3’UTR, and 3) either mmu-pre-
miR-155 in pCDM vector (System Biosciences, Mountain View, CA) or pBluescriptII control 
vector (Stratagene, Santa Clara, CA). In vivo AAV9-mediated gene transfer and CMV-driven 
expression of pre-miR-155, scrambled, sponge-miR-155 and sponge-control was allowed 
for 3 weeks. Then, mice were treated with Ang II as described above. 
Histology
Paraffin-embedded 4µm LV sections were stained with hematoxylin-eosin (HE) and Picro 
Sirious red (SR) as described before47, or were immunohistochemically stained at RT using 
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Horse Reddish Peroxidase/DAB with monoclonal rat anti-mouse CD45 Leukocyte Common 
Antigen Ly-5 (BD-Biosciences Pharmingen, San Diego, CA) and monoclonal mouse anti-
human desmin (Dako Cytomation, Denmark). Left ventricular cryo-sections of 7µm were 
immunohistochemically stained at RT using Alkaline Phosphatase/Fast Red with polyclonal 
rat anti-mouse antibodies against CD68, CD3 and Nimp1 (kind gift from Dr Menno de 
Winther). Morphometric analyses were performed using a microscope (Leica DM2000; 
Leica, Wetzlar, Germany), camera (Leica DFC295 3Mpix CMOS color), and LAS Image 
Analysis and QWin morphometry software (Leica). The number of positive cells was 
measured per mm2. 
In situ hybridization was preformed as described48, 49. In brief, 12µm cryo-sections were 
prepared from 4% paraformaldehyde-fixed hearts from WT and KO AngII-treated animals. 
Sections were air-dried for 30min, incubated in 1.3mg/ml Pepsin/0.1mM HCl solution for 
20min at room temperature, and incubated overnight at 37ºC in 1x hybridization buffer 
(ENZO Life sciences, Farmingdale, NY) with 40nM mmu-miR-155 double DIG-labeled probe 
(Exiqon, Vedbaek, Denmark). The following day the sections were washed twice in 5xSSC, 
1xSSC and 0.2xSSC at hybridization temperature, and then blocked in DIG blocking buffer 
(Roche, Basel, Switzerland) for 20min followed by a 45min incubation in 1:800 anti-DIG-AP, 
Fab fragments (Roche). Sections were washed 3x5min with DIG wash buffer and incubated 
3min in DIG detection buffer at RT. DIG signal was detected by using NBT/BCIP tablets 
(Roche) for 4hrs at 30C in darkness. Finally, sections were briefly washed in MQ, quickly 
dehydrated through an ethanol gradient and mounted with Entellan (EMS, Hatfield, PA).
FACS
Peripheral blood was analyzed using FACS CantoII flow cytometer (Becton Dickenson, San 
Diego, CA). Erythrocytes were removed by hypotonic lysis with NH4Cl. Cells were first 
incubated with anti-CD16/32 (eBioscience, San Diego, CA) to block Fc receptor binding 
and stained with anti-CD3e-FITC, anti-CD8a-eFLUO450, anti-CD25-APC, anti-B220-PE-Cy7 
(eBioscience) and anti-CD4-PerCp (BD-Biosciences Pharmingen). Foxp3-positive cells were 
detected with PE anti-mouse/rat Foxp3 Staining Set (eBioscience). Leukocytes were further 
incubated with anti-CD11b-PE-Cy7, anti-ly6G-PE and NK1.1 PerCp-Cy5.5 (BD-Biosciences 
Pharmingen) to detect monocytes (CD11b+ly6G-NK1.1-) and granulocytes 
(CD11b+ly6G+NK1.1-).
In vitro experiments 
Rat ventricular cardiac myocytes (RCMs) and fibroblasts (RCFs) were isolated by enzymatic 
dissociation of 1- to 2-day-old neonatal rats, plated on gelatinized 6-well plates and cultured 
as described previously50. Per well, 5*105 RCMs were grown on low serum media and 
transfected with 35nM miR-155 antagomiR or scrambled control (Ambion). After 24 hours, 
cells were treated with 100nM endothelin-1 (Et-1, Sigma, St. Louis, MO) or control for 24 
hours, after which RNA was isolated with miRVana (Ambion) and quantitative PCR was 
performed as described above.
Bone marrow macrophages (BMMs) were obtained and cultured from miR-155 KO and 
WT mice as described previously51, 52. Cells were stimulated with 10ng/ml LPS (from E. 
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coli 055.B5; Sigma) for 0, 1, 6 and 24 hours, or transfected with siSocs1 or siControl 
(Ambion) by electroporation as previously described53. Then media were collected, residual 
cells removed by centrifugation for 10min at 300g, and media were stored at -80°C. BMMs 
were harvested for protein extraction or RNA isolation with miRVana RNA isolation kit. 
SOCS1 knockdown was assessed by RT-PCR using forward primer 
CCTCCTCGTCCTCGTCTTC and reverse primer AAGGTGCGGAAGTGAGTGTC, yielding a 
103 nucleotides RT-PCR product, with GAPDH as a loading control (F- 
GGTGGACCTCATGGCCTACA; R-CTCTCTTGCTCAGTGTCCTTGCT; 82 nucleotides). BMM 
proteins were blotted for Socs1 (Cell Signaling Technology). Media were subjected to Il6 
ELISA (kindly provided by Dr. Frank Stassen). 
KO and WT BMM-conditioned media were dialyzed in low serum RCM media using slide-
a-lyzer dialysis cassettes (1/100, 3.5kDa, Thermo Fisher Scientific, Waltham, MA). RCMs 
were incubated with dialyzed conditioned media for 24 hours, treated with endothelin-1 
or PBS for 24 hours, and either stained with rhodamin-phalloidin (Molecular probes, 
Invitrogen, Paisley, UK) or processed for RNA extraction (RNeasy) and qPCR as described 
above. 
Proteomics
BMM media were subjected to mass spectroscopic proteomics analyses as previously 
described54. In brief, BMM media were concentrated using Amicon 3kD MWCO spin 
columns (Millipore) and precipitated by 2D Clean-up kit (Bio-Rad). After that, protein samples 
were denatured with 2X sample buffer (Invitrogen) at 97ºC for 5 min. and separated in 
4%-12% NuPAGE Bis-Tris gels (Invitrogen). Gels were stained using Coomassie G-250 
overnight and destained. Each lane was cut into 16 gel bands without any gap and tryptic 
digestion was performed using the ProGest robot (Genomic Solutions) with sequencing 
grade modified trypsin (Promega) overnight. Digested peptides were lyophilized and 
resuspended with 0.05% TFA then separated by nano-flow liquid chromatography on a 
reverse-phase column (Acclaim PepMap100, C18, 3µm, 100Å, 25cm; Dionex). The 
separated peptides were directly injected to a high mass accuracy ion trap tandem mass 
spectrometer (LTQ Orbitrap XL, Thermo). Spectra were collected from the mass analyzer 
using full ion scan mode over the m/z range 450-1600. Six dependent MS/MS scans were 
performed using dynamic exclusion. The MS/MS data were matched to SwissProt mouse 
database (version 57.15, 16230 protein entries) using Mascot version 2.3.0 (Proteome 
Discoverer 1.1, Thermo Scientific). Carboxyamidomethylation of cysteine was used as a 
fixed modification, and oxidation of methionine was used as a variable modification. The 
mass tolerance was set at 10 ppm for the precursor ions and 0.8 Da for fragment ions. 
Two missed cleavage were allowed. Search results were loaded into Scaffold software 
(version 3.0.8, Proteome Software). Assignments were accepted with >99.0% protein 
probability, >95.0% peptide probability, and a minimum of two peptides. 
Statistical analyses
Group numbers are given in Supplementary Table 1. Data are presented as average±SEM 
unless indicated otherwise. Comparisons between 2 groups were performed with two-
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tailed Student’s t testing for Gaussian data or Mann-Whitney tests for non-Gaussian data. 
For comparisons of more than 2 groups, one-way ANOVA was used, followed by post 
hoc testing using Bonferroni correction for more groups. P<0.05 was considered 
statistically significant. 
Results
Absence of miR-155 protects from heart failure following pressure overload
We addressed the biological role of miR-155 in a pre-clinical model of heart failure, where 
we infused miR-155 KO and WT mice with a pressor-dose of Angiotensin II (Ang II) for 
4 weeks. All mice survived the observation period. Whereas miR-155 WT mice developed 
impaired systolic function after Ang II, the absence of miR-155 protected against cardiac 
dysfunction (Figure 1A and Supplementary Table 1). Remarkably, miR-155 KO Ang II 
hearts showed dramatically decreased hypertrophy as compared to WT Ang II hearts 
(Figure 1B and C (upper panels)), despite similar blood pressure responses to Ang II 
(Figure 1D). This protection against cardiac hypertrophy was confirmed on the individual 
myocyte level (Figure 1C (lower panels), E) and by echocardiographically measured wall 
thickness (Figure 1F). Concordantly, transcript levels of cardiac stress markers alpha 
skeletal actin (Acta1), natriuretic peptide type A (Nppa) and natriuretic peptide type B 
(Nppb) remained low in Ang II treated miR-155 KO mice as compared to WT animals 
(Figure 1G). Capillary density was similar in untreated miR-155 KO and WT sham hearts 
(Figure 2A), and could therefore not explain differences in hypertrophy. In addition, as 
expected, vascularization increased with hypertrophy in WT mice. Interstitial fibrosis, 
quantified as percentage of Sirius red-stained area of the left ventricle, was increased in 
both WT and KO mice upon Ang II, indicating that Ang II-induced cardiac matrix deposition 
was unaffected by miR-155 deficiency (Figure 2b and Supplementary Table 1). Desmin 
staining as a marker of cardiac myocyte stress21, 22 was dramatically reduced in LV sections 
of miR-155 KO Ang II compared to WT Ang II (Figure 2C). Cardiac protein levels of the 
angiotensin II type 1 receptor (Agtr1), which has been reported to be a miR-155 target 
in humans23 but is not conserved in mice, were not different between WT and KO mice 
(Figure 2D). Therefore, miR-155 KO mice are protected against AngII-induced cardiac 
hypertrophy and dysfunction by a mechanism that is independent of its target Agtr1, of 
blood pressure, of vascularization, and of cardiac fibrosis.
To confirm these findings in another model of pressure overload, we subjected miR-155 
KO and WT mice to transverse aortic constriction (TAC). Again, miR-155 KO mice were 
protected from hypertrophy and heart failure (Figure 3A-D and Supplementary Table 1), and 
their induction of hypertrophic markers Acta1, Nppa and Nppb was blunted (Figure 3E). Both 
strains had trans-stenotic pressure gradients above 50 mmHg on average (not shown) and 
interstitial fibrosis was not different between WT and KO mice after TAC (Figure 3F and 
Supplementary Table 1). Additionally, to ensure that the observed protection against heart 
failure was not due to differences inherent to embryologic development between miR-155 
KO and WT mice, we injected LNA-modified antimiRs against miR-155 (antimiR-155) into 
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adult WT mice followed by Ang II treatment for 4 weeks. We obtained a cardiac knockdown 
of 81±4% in antimiR-155-treated mice as compared to mice treated with control antimiR 
(Figure 4A). Similar to the miR-155 KO mice, antimiR-155-treated mice were protected from 
hypertrophy and heart failure following Ang II. MiR-155 inhibition was accompanied by 
preserved systolic function (Figure 4B), decreased cardiac weight and wall thickness (Figure 
4C-E and Supplementary Table 1), and decreased induction of Acta1, Nppa and Nppb (Figure 
4F) compared to LNA-control Ang II. Again, interstitial fibrosis induced by Ang II did not 
significantly differ in both groups (Figure 4G and Supplementary Table 1). 
Together, these data show that, in the absence of miR-155, cardiac myocytes do not 
respond to pressure overload-induced stress by pathological remodeling, and are protected 
from cardiac dysfunction in response to both pharmacological and physical pressure 
overload. Therefore, we conclude that miR-155 mediates cardiac function under pathological 
conditions.
Figure 1: MiR-155 KO mice are protected from Ang II-induced cardiac hypertrophy and failure. 
(A) Fractional shortening as a measure of cardiac function shows no significant differences between miR-
155 WT and KO mice at baseline. WT mice develop systolic dysfunction after 4 weeks of Ang II, while KO 
mice are protected. (B) Heart weight to body weight ratios of miR-155 WT and KO mice are not different 
at baseline. WT mice but not KO mice develop cardiac hypertrophy following Ang II, already apparent at 
week 1 and pronounced after 4 weeks. (C) Representative images of whole hearts (top panels, scale bar: 
5mm) and H&E-stained sections of the left ventricles (lower panels, scale bar: 50µm) of miR-155 WT and 
KO mice. (D) Tail cuff measurements of arterial blood pressure in WT and KO mice after 3 weeks of Ang II 
infusion reveal a comparable development of hypertension in both genotypes measured under similar heart 
rates. Quantifications of myocyte cross-sectional area (E), diastolic averaged wall thickness (F) and cardiac 
expression of the fetal hypertrophy marker genes Acta1, Nppa and Nppb (G) all show an increase in Ang 
II-treated miR-155 WT mice, but to a significantly lesser extent in KO mice. WT sham, n=13; WT Ang II 1w, 
n=4; WT Ang II 4w, n=11; KO sham, n=11; KO Ang II 1w, n=5; KO Ang II 4w, n=14; all error bars represent 
s.e.m.; *P < 0.05, **P < 0.01, ***P < 0.005.
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MiR-155 controls cardiac monocyte/macrophage infiltration upon pressure 
overload
To establish the cellular origin of miR-155 in the heart, we visualized cardiac miR-155 
distribution by in situ hybridization. Almost no miR-155 signal was observed in cardiac 
myocytes and the interstitial compartment of sham hearts. However, following Ang II-
treatment we observed marked miR-155 induction localized to infiltrating patches of 
interstitial leukocytes in miR-155 WT but not KO hearts (Figure 5A). Given its well-known 
immune role and its expression in cardiac inflammatory cells during pressure overload, we 
hypothesized that miR-155 may influence the function of leukocytes in the heart during 
stress. Immunostaining for inflammatory cell markers revealed that, following Ang II 
treatment, WT hearts experienced an influx of macrophages and - to a much lesser extent 
- T cells already after 1 week and lasting for at least 4 weeks (Figure 5B-E and Supplementary 
Figure 1A). However, absence of miR-155 largely abrogated this influx both in miR-155 KO 
and antimiR-155-treated mice (Figure 5B-E and Supplementary Figure 1A). Similarly, TAC 
triggered a significant recruitment of leukocytes to WT but not to KO hearts (Supplementary 
Figure 1B). Baseline numbers of interstitial leukocytes were not affected by absence of 
miR-155. These observations point towards a role for miR-155 to drive macrophage 
mobilization and infiltration upon pressure overload. 
Figure 2: Protection from cardiac hypertrophy in the absence of miR-155 is independent of 
vascularization, fibrosis and Agtr1 expression. (A) The number of CD31-positive vessels per myocyte is 
similar between miR-155 WT and KO hearts at baseline, but increases only in WT hearts in response to Ang 
II. (B) Quantification of Sirius red staining shows comparable fibrosis in response to Ang II-induced pressure 
overload in both genotypes (scale bar: 100µm) while (C) desmin staining as a marker of cardiac stress shows 
a marked increase in WT hearts but not KO hearts subjected to Ang II (scale bar: 100µm). (D) Protein levels 
of the Agtr1 are not significantly different between the hearts of WT and KO mice both at baseline and in 
response to Ang II infusion. WT sham, n=13; WT Ang II 4w, n=11; KO sham, n=11; KO Ang II 4w, n=14; all 
error bars represent s.e.m.; *P < 0.05, **P < 0.01. 
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In line with these data, the secretome of LPS-activated miR-155 KO macrophages showed 
a broadly reduced activation status as compared to WT macrophages. Levels of proteins 
indicative of macrophage activation or important for tissue infiltration, including the 
macrophage receptor mac1, the adhesion-mediating integrins LFA1 and VLA4a, and the 
inflammatory cytokines TNFa, IL1B and IL12, were significantly lower in the miR-155 KO 
macrophage secretome, suggesting compromised macrophage function upon activation 
in the absence of miR-155 (Figure 6A). 
Figure 3: MiR-155 KO mice are protected from TAC-induced cardiac hypertrophy and failure. (A) 
Echocardiographic analysis shows that miR-155 KO but not WT mice are protected from systolic dysfunction 
following transverse aortic constriction (TAC) for 4 weeks. (B) Both WT and KO mice develop cardiac 
hypertrophy following TAC, but this response is significantly blunted in KO mice. (C) Both WT and KO mice 
significantly increase averaged diastolic wall thicknesses following TAC with a trend to lower wall thickness 
in KO mice. (D) Representative images of H&E-stained sections of the left ventricles of miR-155 WT and KO 
mice at baseline and after 4 weeks of TAC (scale bar: 50µm). (E) Induction of cardiac Acta1, Nppa and Nppb 
expression is significantly blunted in KO mice following TAC. (F) Quantification of Sirius red staining shows 
comparable fibrosis in response to TAC-induced pressure overload in both genotypes (scale bar: 100µm). 
WT sham, n=5; WT TAC, n=6; KO sham, n=11; KO TAC, n=11; all error bars represent s.e.m.; *P < 0.05, 
**P < 0.01, ***P < 0.005.
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Finally, flow cytometry of circulating leukocytes revealed that 1 week Ang II failed to 
mobilize CD11b+/Ly6G- monocytes in the absence of miR-155 (Figure 6B), while CD11b+/
Ly6G+ granulocytes were equally mobilized by Ang II in WT and KO (Supplementary Table 
2). Again, baseline numbers of circulating monocytes and granulocytes were similar in WT 
and KO mice. In agreement with previous findings24, KO mice were found to have a reduced 
number of regulatory T cells. In conclusion, these data show that monocyte mobilization, 
cardiac macrophage infiltration and macrophage activity are hampered in response to 
pressure overload in miR-155-deficient mice. Combined with the protection of miR-155 
Figure 4: AntimiR-155 treatment protects against Ang II-induced cardiac hypertrophy and failure. 
(A) qRT-PCR analysis of miR-155 levels in mouse hearts 4 weeks after treatment with antagomiRs shows 
significant knockdown by antagomiRs against miR-155. AntimiR-mediated miR-155 inhibition protects 
WT mice from Ang II-induced systolic dysfunction (B) and cardiac hypertrophy (C, D). (E) Representative 
images of H&E-stained sections of the left ventricles of miR-155 WT and KO mice at baseline and after 4 
weeks of Ang II infusion (scale bar: 50µm). (F) Induction of cardiac hypertrophic marker genes Acta1 and 
Nppa is significantly reduced in antimiR-155 treated mice following Ang II, while Nppb induction does not 
differ significantly. (G) Quantification of Sirius red staining shows comparable fibrosis in response to Ang 
II-induced pressure overload after control and anti-miR-155 antagomirs (scale bar: 100µm). WT scrambled 
sham, n=6; WT scrambled Ang II, n=8; KO scrambled sham, n=6; KO scrambled Ang II, n=6; all error bars 
represent s.e.m., *P < 0.05, **P < 0.01, ***P < 0.005. 
2012100 proefschrift Maarten Corsten.indd   142 07-08-2012   08:39:47
MicroRNA-221-222 signaling is protective in acute viral myocarditis
143
6
KO mice against pressure overload-induced HF, these data suggest that macrophage 
presence and activity are important pathogenic factors during the cardiac hypertrophic 
response and the progression to HF. 
Macrophages influence hypertrophic growth of cardiac myocytes via miR-155
To pursue the hypothesis that macrophage miR-155 promotes cardiac hypertrophy, we 
undertook two distinct approaches. First, we investigated the myocyte hypertrophic 
response both in vivo and in vitro with miR-155 specifically absent in inflammatory cells. 
In vivo, we adoptively transferred WT bone marrow into miR-155 KO mice (WT to KO) and 
vice versa (KO to WT) and infused Ang II for 4 weeks. The presence of WT macrophages 
in miR-155 KO mice increased the cardiac hypertrophic response (Figure 7A). 
Figure 5: MiR-155 is required for pressure overload-induced influx of macrophages in the heart. 
(A) In situ hybridization of miR-155 in cardiac sections. While miR-155 expression is hardly detected in myocytes 
and interstitium of sham hearts, miR-155 signal is readily detected in patchy infiltrates of inflammatory 
cells after Ang II treatment. No signal was observed in KO hearts (scale bars: 50µm). Quantification of 
immunoreactive cells using antibodies against CD45 (all leukocytes; B), CD68 (macrophages; C), CD3 
(T-cells; D) or NIMP-1 (neutrophils; E). Macrophages have infiltrated the heart after 1 and 4 weeks of Ang 
II-induced pressure overload in WT mice, but this is significantly depressed in hearts of miR-155 KO mice. 
In addition, infiltration of T-cells – though substantially lower in number as compared to macrophages - is 
significantly reduced in miR-155 KO versus WT hearts, while numbers of NIMP-1-positive neutrophils are 
not different at baseline and 4 weeks of Ang II and show higher numbers of infiltrating cells in KO hearts 
after 1 week. All error bars represent s.e.m.; n=4/group; *P < 0.05, **P < 0.01, ***P < 0.005. Scale bars: 
100µm.
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Also the expression of cardiac stress markers Nppa and Nppb – but not Acta1 - was 
rescued by the replacement of KO macrophages by WT (Figure 7B). Vice versa, the 
removal of macrophage miR-155 from WT mice compromised hypertrophic growth 
following Ang II (Figure 7A), and cardiac stress markers Nppa, Nppb and Acta1 decreased 
towards full KO levels (Figure 7B). Although we did not accomplish a full rescue of 
hypertrophy, which is possibly due to a fraction of host macrophages remaining after 
irradiation25, these findings suggest that miR-155 controls pro-hypertrophic signaling by 
macrophages. To independently confirm this mechanism in vitro, we grew neonatal rat 
cardiac myocytes in conditioned culture media of LPS-activated WT and KO bone marrow-
derived macrophages. Interestingly, cardiac myocytes cultured in miR-155 KO macrophage 
media displayed a limited hypertrophic response to endothelin-1 as compared to WT 
macrophage media-cultured cardiac myocytes, demonstrated by Acta1 and Nppa gene 
expression and myocyte size (Figure 7C). 
Second, though the expression of miR-155 by cardiac myocytes is low (Figure 5A), we ruled 
out a possible role of cardiac myocyte miR-155 to drive hypertrophy both in vivo and in vitro. 
Figure 6: MiR-155 controls macrophage mobilization and activity. (A) Secreted abundance of selected 
macrophage proteins in WT LPS BMM media is significantly higher than in KO LPS BMM media (n=3/
group). (B, C) Flow cytometry of circulating blood cells after 1 week of Ang II treatment shows impaired 
mobilization of CD11b+/Ly6G-/NK1.1-monocytes in KO animals, while CD11b+/Ly6G+/NK1.1- granulocyte 
mobilization following Ang II is unaffected by miR-155 (n=6/group). Panel C shows the gating strategy and 
representative flow cytometry pictures with averages and standard errors of immune cell subpopulations. 
All error bars represent s.e.m.; *P < 0.05, **P < 0.01, ***P < 0.005.
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In vivo, we introduced hsa-pre-miR-155 in WT mice specifically into cardiac myocytes using 
an adeno-associated virus serotype 9 (AAV9)-vector and observed no difference in cardiac 
hypertrophy neither at baseline nor following Ang II (Figure 8A-C). Vice versa, inhibition of 
cardiac myocyte miR-155 function using AAV9-introduced miR-155 sponges demonstrated 
again similar cardiac mass and hypertrophic marker responses following Ang II infusion in 
control sponge and miR-155 sponge treated WT mice (Figure 8D-F). In addition, we knocked 
down miR-155 in vitro in cardiac myocytes and induced hypertrophy with endothelin-1, 
after which we could not observe differences in induction of hypertrophic markers (Figure 
8G-H). Together, these data show that macrophage- but not myocyte-expression of miR-
155 regulates hypertrophic cardiomyocyte growth in a paracrine fashion. 
The Socs1/Il6/Stat3 signaling axis links macrophage miR-155 to cardiac myocyte 
hypertrophic growth
We next addressed how miR-155 expression in macrophages influences macrophage 
paracrine activity. Direct miR-155 targets that potentially modulate macrophage activity 
and could explain the observed phenotype include Src homology 2-containing inositol 
Figure 7: Macrophages influence hypertrophic growth of cardiac myocytes via miR-155. Heart weight 
to body weight ratios (A) and cardiac Acta1, Nppa and Nppb (B) expression of Ang II- or sham-treated 
mice following adoptive bone marrow transfer between miR-155 WT and KO mice show partial rescue 
of the hypertrophic response of KO mice reconstituted with WT bone marrow as well as blunting of the 
hypertrophic response in WT mice reconstituted with KO bone marrow. (C) Phalloidin staining (red) of 
actin filaments in cultured neonatal rat cardiac myocytes (scale bar: 50µm). The hypertrophic growth and 
Acta1 gene expression response of myocytes to Et-1 is significantly blunted by addition of culture media 
from miR-155 KO bone marrow-derived macrophages. All error bars represent s.e.m.; WT>WT sham, n=7; 
WT>WT AngII, n=13; KO>KO sham, n=7; KO>KO AngII, n=7; WT>KO sham, n=7; WT>KO AngII, n=11; 
KO>WT sham, n=5; KO>WT AngII, n=12; *P < 0.05, **P < 0.01, ***P < 0.005. All quantitative in vitro data 
were generated from a minimum of three replicates.
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phosphatase-1 (Ship-1)26 and Socs127. We found that in the absence of miR-155, Socs1 
protein expression is indeed elevated in untreated as well as LPS-activated macrophages 
as compared to WT macrophages, while Ship1 was found mildly derepressed only in 
unstimulated macrophages (Figure 9A-B). Therefore, we focused on Socs1, which inhibits 
macrophage inflammatory responses by targeting the Jak/Stat axis 28 29. In agreement, we 
found that the elevated Socs1 levels in LPS-treated miR-155-deficient macrophages were 
associated with diminished Stat3 phosphorylation at baseline and at 6 and 24 hours 
following LPS stimulation (Figure 9A and C), consistent with diminished pro-inflammatory 
Figure 8: Myocyte-specific manipulation of miR-155 has no influence on the development of cardiac 
hypertrophy. In vivo cardiac myocyte miR-155 overexpression using AAV9-hsa-miR-155 leads to similar 
induction of cardiac hypertrophy (A) and of the fetal genes Nppa and Acta1 (B), as compared to both PBS 
and AAV9-scrambled treatment. (C) Human miR-155 was detected only in AAV9-hsa-miR-treated mouse 
groups. Note that human and mouse miR-155 differ by one nucleotide outside the seed region, enabling 
human-specific miR-155 detection. Vice versa, in vivo cardiac myocyte miR-155 inhibition using AAV9-
sponge-miR-155 also induces similar levels of cardiac hypertrophy (D) and of hypertrophic gene expression 
(E). (F) Luciferase validation of sponge efficiency shows a knockdown of the luciferase target to 23%±3 
(left panel). Co-expression of sponge-miR-155 rescued this knockdown (>90%) whereas expression of a 
sponge containing 4 mutated binding sites had no influence. In vivo, AAV9-sponge-miR-155 reduced miR-
155 expression by 57%±7 (right panel). Knockdown of miR-155 in neonatal rat cardiac myocytes with 
antagomiRs (G) does not influence induction of the fetal genes Acta1 and Nppb (H). All error bars represent 
s.e.m.; PBS sham, n=8; PBS Ang II, n=8; AAV-scram sham, n=8; AAV-scram Ang II, n=12; AAV-155 sham, 
n=6; AAV-155 Ang II, n=8; *P < 0.05, **P < 0.01; ND, not detected. All quantitative in vitro data were 
generated from a minimum of three replicates.
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responses in the absence of miR-155. Activated miR-155 deficient macrophages secrete 
less pro-inflammatory and pro-hypertrophic cytokines, including interleukin-6 (Il-6) (Figure 
9D) and tumor necrosis factor-alpha (Tnfa) (Figure 6A). Interestingly, both are involved in 
hypertrophic and inflammatory signaling; Il-6 via Stat3 and Tnfa by activation of nuclear 
factor-kappaB (Nf-κB) 30-32. 
Hypothesizing that Il6-dependent activation of Stat3 in myocytes could mediate the pro-
hypertrophic effects of activated macrophages, we studied Stat3 activation in cardiac 
myocytes subjected to conditioned macrophage media. We found decreased P-Stat3 levels 
in the cardiac myocytes grown in miR-155-deficient macrophage media (Figure 9E). Similar 
results were obtained in vivo, where miR-155-deficient hearts showed dramatically reduced 
Figure 9: MiR-155 controls inflammatory signaling through its target Socs1. (A-C) Representative 
Western blot images and quantification of Ship1, Socs1 and Stat3 phosphorylation (P-Stat3) in bone-marrow 
derived macrophages from miR-155 WT or KO mice stimulated with LPS. MiR-155 KO macrophages 
show higher Socs1 levels and lower Stat3 activation (P-Stat3/Stat3 levels) in response to LPS versus WT 
macrophages. (D) Levels of Il6 are higher in WT versus KO macrophages in response to LPS (ELISA), and 
in WT versus KO mouse hearts following 1 and 4 weeks of Ang II infusion (mRNA). Levels of Tnfa are not 
affected by absence of miR-155 in macrophages, and are even temporarily and slightly elevated shortly 
after LPS stimulation, while cardiac mRNA levels are temporarily and slightly down-regulated after Ang II 
infusion. (E) Adding culture media from KO macrophages to neonatal cardiac myocytes inhibits their Stat3 
phosphorylation in response to Et-1 stimulation. (F) Stat-3 phosphorylation is significantly lower in KO versus 
WT mouse hearts after 1 and 4 weeks of Ang II infusion (WT sham, n=5; WT AngII 1w, n=4; WT AngII 4w, 
n=6; KO sham, n=6; KO AngII 1w, n=4; KO AngII 4w, n=4). All error bars represent s.e.m., *P < 0.05, **P 
< 0.01, ***P < 0.005. Western blot images are representative. All quantitative in vitro data were generated 
from a minimum of three replicates.
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Stat3 activities upon pressure overload (Figure 9F). We found no evidence for involvement 
of Nf-κB signaling in limiting hypertrophy in the absence of miR-155 (not shown). Together, 
these data support a central role for Stat3 signaling in miR-155-driven cardiac hypertrophy 
and failure. 
To confirm that macrophage-expressed miR-155 mediates cardiac hypertrophy via Socs1, 
we prevented the de-repression of Socs1 in miR-155 KO macrophages with siRNAs 
(Figure 10A). 
Figure 10: Socs1 knockdown in macrophages rescues paracrine hypertrophic stimulation to myocytes. 
(A) Knockdown of Socs1 transcripts in bone marrow-derived macrophages from miR-155 WT and KO mice. 
Socs1 is repressed by miR-155 on the translational level; therefore transcript levels are similar between 
WT and KO cells. (B) Phalloidin staining (red) of actin filaments in cultured neonatal rat cardiac myocytes 
stimulated with Et-1 and grown in culture media from WT or KO bone marrow-derived macrophages that 
were treated with siRNAs against Socs1 or control (scale bar: 50µm). Quantification of cross-sectional 
myocyte areas (C) and expression of hypertrophic markers Acta1, Nppa and Nppb (D) show that the blunting 
of hypertrophy by media from KO macrophages is rescued by Socs1 knockdown in macrophages. (E) 
Schematic representation of the cardiac miR-155 signaling pathway. MiR-155 inhibits Socs1, enabling the 
pressure overload-induced increase in Il6 levels as well as directly relieving Socs1-mediated repression of 
macrophage Stat3 activity. Il6 signals to macrophages and cardiac myocytes to induce Stat3 activity, leading 
to inflammatory activation and cardiac myocyte hypertrophy. All error bars represent s.e.m., *P < 0.05, **P 
< 0.01, ***P < 0.005. All quantitative in vitro data were generated from a minimum of three replicates.
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Socs1 knockdown in macrophages largely rescued the limited hypertrophic response of 
myocytes grown in miR-155 KO macrophage-conditioned media both at the level of 
myocyte growth and gene expression (Figure 10B-E). Therefore, we conclude that the 
paracrine effects of miR-155 on myocyte hypertrophy are mediated at least in part by its 
direct target Socs1. 
Discussion
In this study, we identify a role for the macrophage-derived miR-155 in cardiac hypertrophy 
and failure in response to pressure overload. Gene inactivation or pharmacological inhibition 
of miR-155 significantly reduced the hypertrophic growth and prevented systolic dysfunction 
in pressure overloaded hearts. A role for miR-155 specifically derived from macrophages 
was indicated by the fact that transplantation of miR-155 KO bone marrow into irradiated 
WT mice blunted the hypertrophic response, whereas reconstitution of WT macrophages 
in miR-155 KO mice largely rescued the hypertrophic response. In line with these findings, 
miR-155 in situ hybridization co-localized with the areas of interstitial inflammation in the 
pressure overloaded WT hearts. Moreover, we specifically exclude a role for cardiomyocyte-
derived miR-155 in cardiac hypertrophy, since both AAV9-mediated cardiomyocytic over-
expression and knockdown of miR-155 had no effect on the in vivo cardiac hypertrophic 
response. As additional proof in vitro, macrophage medium derived from miR-155 KO 
animals blunted the hypertrophic growth of cardiomyocytes, while medium from WT 
macrophages did allow hypertrophy. 
 The mechanism responsible for cardioprotection of miR-155 KO mice was partly mediated 
by de-repression of the translational miR-155 target Socs1 in inflammatory cells.  In vitro, 
Socs1 knockdown in miR-155 KO macrophages rescued the lack of cardiomyocyte 
hypertrophy. Socs1 increase in the absence of miR-155 reduces the release of pro-
hypertrophic and -inflammatory cytokines such as Il6 and Tnfa, thereby protecting cardiac 
cells from chronic cytokine-mediated activation of pro-hypertrophic signaling pathways. As 
such, miR-155 links hypertension-induced interstitial cardiac inflammation to myocyte 
hypertrophy and function (a diagram of the proposed signaling pathway is provided in Figure 
10E). Our finding that leukocytes may regulate cardiac hypertrophy is in line with previous 
studies revealing a role for leukocyte-derived galectin-3 and PI3 kinase in cardiac hypertrophic 
remodeling5, 33, 34. Furthermore, reduction of cardiac monocyte infiltration by administration 
of immune-inhibitory regulatory T cells prevented cardiac hypertrophy and damage during 
Ang II-mediated pressure overload35, and Il6-null mice are protected from cardiac hypertrophy 
irrespective of blood pressure changes36. These studies and the current work imply that 
inflammatory signaling may be necessary for hypertrophic remodeling during pressure 
overload. Importantly, the cardiac influx of inflammatory cells upon pressure overload 
precedes signs of hypertrophy and heart failure (Figure 5B), suggesting a direct contribution 
to cardiac pathophysiology.  
Cardioprotection of miR-155 KO mice was associated with reduced Stat3 activation and 
decreased Il6 levels in cardiac myocytes as well as macrophages, in line with the de-
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repression of Socs1. On the one hand, Socs1 is an endogenous inhibitor of Stat3 activation, 
and on the other hand it is a potent inhibitor of cytokine production and release30. In turn, 
cytokines - including Il6 - induce Stat3 signaling, that has both pro-hypertrophic and pro-
inflammatory effects31, 32. We propose that increased Socs1 levels and resulting decreased 
Stat3 signaling reduce the production of cytokines in miR-155-deficient cardiac macrophages 
during pressure overload. This altered milieu of secreted factors blunts the hypertrophic 
response of miR-155-deficient myocytes, as evidenced by decreased Stat3 activation and 
decreased production of hypertrophic markers. The observed chronically reduced Stat3 
activation during pressure overload in the absence of miR-155 was associated with 
improved cardiac function. Whereas rapid Stat3 activation in acute heart failure is cardio-
protective37-39, chronic activation of this signaling pathway during pressure overload40 is 
detrimental and causes increased cardiac inflammation and failure37. This is reminiscent of 
other inflammatory pathways such as Toll-like receptor, Nuclear factor of activated T cells 
(NFAT) and NF-κB signaling, whose acute expression during cardiac disease is protective, 
while sustained expression is detrimental41-43. Therefore, chronic pressure overload may 
cause a prolonged, unbalanced Stat3 activation leading to adverse effects. In line, sustained 
activation of Stat3 following chronic Ang II infusion was associated with heart failure in our 
WT mice, and reduced Stat3 signaling in the absence of miR-155 may therefore in part 
contribute to the cardiac protection observed. Our data emphasize that cardiac function 
– like many other physiological processes - depends on balanced signaling activities.
In the present study, three essential components of the cardiac inflammatory effects of 
Ang II are affected by miR-155 deficiency: (1) Ang II-induced mobilization of leukocytes to 
the circulation; (2) leukocyte infiltration into the heart; and (3) production of pro-inflammatory 
and pro-hypertrophic factors by activated interstitial cardiac leukocytes. This study is the 
first to dissect the pro-inflammatory effects of Ang II during pressure overload. Our results 
indicate that miR-155 is crucial for leukocyte mobilization, tissue infiltration and activation 
upon pressure overload. Of note, while absence of miR-155 blunted pressure overload-
induced cardiac hypertrophy and inflammation, the cardiac fibrotic response remained 
intact, indicating that pressure overload-induced fibrotic remodeling was independent of 
miR-155 function in leukocytes. Damilano et al. show that leukocyte PI3Kγ does influence 
cardiac fibrotic responses to TAC34. However, in agreement with our findings, these authors 
show that cardiac function is independent of fibrotic remodeling. 
In conclusion, inflammatory signaling through miR-155 modulates cardiac hypertrophy and 
failure during pressure overload. Whereas pharmacological inhibition of miR-155 prevented 
cardiac hypertrophy and failure, its over-expression or knockdown in cardiomyocytes did 
not affect the hypertrophic response. Our data stress the importance of cardio-inflammatory 
crosstalk and identify miR-155 as a potential therapeutic target in heart failure.
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Supplementary Figures and Tables
Supplementary Figure 1. MiR-155 absence reduces pressure overload-induced influx of inflammatory 
cells in the heart. (a) Quantification of immunoreactive cells for antibodies against CD45 (all leukocytes) 
in hearts of antagomiR-treated WT mice after AngII infusion shows blunting of cardiac infiltration by 
inflammatory cells in absence of miR-155. (b) Quantification of immunoreactive cells for antibodies against 
CD45 (all leukocytes) in miR-155 WT and KO hearts after TAC reveals blunting of cardiac infiltration by 
inflammatory cells in KO animals. Scale bars: 100µm. All error bars represent s.e.m., *P < 0.05, **P < 0.01, 
***P < 0.005.
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Supplementary Table 2. Peripheral blood flow cytometry in sham and AngII-treated miR-155 WT and KO 
mice
Marker WT sham WT Ang KO sham KO Ang
T cell CD3+ 26.4±1.6 24.8±2.8 27.0±1.5 25.8±1.3
CD4+1 62.0±0.4 54.3±0.7$$$ 57.8±0.9** 55.7±1.0
CD25+ 
Foxp3+2
8.2±0.3 10.2±0.4$$ 4.9±0.4*** 5.5±0.3***
CD8+1 35.2±0.4 42.7±0.6$$$ 39.1±0.8** 41.0±0.8
B cell B220+ 30.7±4.2 20.7±2.2 36.9±3.8 27.4±3.9
Monocyte CD11b+ 
Ly6G-
11.9±0.8 18.7±2.3$ 11.3±1.8 11.4±1.0*
Ly6Chigh3 31.2±2.9 45.0±2.2$$ 27.1±5.4 35.6±4.6
Granulocyte CD11b+Ly6G+ 18.6±2.8 29.7±2.0$ 19.1±2.1 29.2±3.4$
NK NK1-1+ 6.3±0.6 6.8±1.4 6.4±0.8 5.4±0.3
Data are provided as average % ± s.e.m. of life or parent; n=6/group; 1% of CD3+; 2% of CD4+; 3% of 
CD11b+Ly6G-, *P<0.05, **P<0.01, ***P<0.001 versus WT, $P<0.05, $$P<0.01, $$$P<0.001 versus sham
Supplementary Table 3. Primers for quantitative real-time PCR
Gene Forward primer Reverse primer
mmu-Acta1 TGAGACCACCTACAACAGCA CCAGAGCTGTGATCTCCTTC
mmu-Nppa ATTGACAGGATTGGAGCCCAGAGT TGACACACCACAAGGGCTTAGGAT
mmu-Nppb GTTTGGGCTGTAACGCACTGA GAAAGAGACCCAGGCAGAGTCA
mmu-Il-6 CAAAGCCAGAGTCCTTCAGAG GCCACTCCTTCTGTGACTCC
mmu-GAPDH GGTGGACCTCATGGCCTACA CTCTCTTGCTCAGTGTCCTTGCT
rno-Acta1 ATCACCAAGGGCTTCTTCCT CCGCCGATCCACACTGA
rno-Nppa ATCACCAAGGGCTTCTTCCT TGTTGGACACCGCACTGTAT
rno-Nppb GCTGCTTTGGGCAGAAGATAGA GCCAGGAGGTCTTCCTAAAACA
rno-GAPDH GGTGGACCTCATGGCCTACA CTCTCTTGCTCTCAGTATCCTTGCT
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ABSTRACT
Background  Small RNA molecules, called microRNAs, freely circulate in human 
plasma and correlate with varying pathologies. In this study, we have explored their diagnostic 
potential in a selection of prevalent cardiovascular disorders.
Methods and Results MicroRNAs were isolated from plasmas from well-
characterized patients with varying degrees of cardiac damage: a) acute myocardial infarction 
(AMI), b) viral myocarditis (VM), c) diastolic dysfunction, and d) acute heart failure (AHF). 
Plasma levels of selected microRNAs, including heart-associated (miR-1, -133a, -208b and 
-499), fibrosis-associated (miR-21 and miR-29b) and leukocyte-associated (miR-146, -155 and 
-223) candidates, were subsequently assessed using real-time PCR. Strikingly, in plasma from 
AMI patients, cardiac myocyte-associated miRs-208b and -499 were highly elevated, 1600-fold 
(p<0.005) and 100-fold (p<0.0005) respectively, as compared with controls. ROC-curve analysis 
revealed an AUC of 0.94 (p<10-10) for miR-208b and 0.92 (p<10-9) for miR-499. Both microRNAs 
correlated with plasma troponin T, indicating release of microRNAs from injured cardiomyocytes. 
In VM, we observed a milder but significant elevation of these microRNAs, 30- and 6-fold 
respectively. Plasma levels of leukocyte-expressed microRNAs were not significantly increased 
in AMI or VM patients, despite elevated white blood cell counts. In AHF patients, only miR-499 
was significantly elevated (2-fold), while no significant changes in microRNAs studied could 
be observed in diastolic dysfunction. Remarkably, plasma microRNA levels were not affected 
by a wide range of clinical confounders, including age, gender, BMI, kidney function, systolic 
blood pressure, and white blood cell count. 
Conclusions  Cardiac damage initiates the detectable release of cardiomyocyte-
specific microRNAs-208b and -499 into the circulation.
Modified from Circulation Cardiovascular Genetics 2010;3:499-506 [IF 4.0]
Circulating MicroRNA-208b and MicroRNA-499 
Reflect Myocardial Damage in Cardiovascular 
Disease 7
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Clinical perspective
It was recently discovered that small RNAs, called microRNAs, circulate freely and stably in 
human plasma. This finding has sparked interest in the potential of microRNAs as biomarkers, 
because microRNAs are strongly implicated in cardiovascular disease and RNA molecules 
can be detected with high specificity and sensitivity using novel molecular techniques. We 
report profiles of microRNAs in varying cardiovascular disorders: acute myocardial infarction 
(AMI), acute viral myocarditis (VM), diastolic dysfunction and acute heart failure. Most 
strikingly, 2 cardiomyocyte-specific microRNAs (miR-208b and miR-499) are markedly elevated 
upon cardiac damage and correlate to circulating levels of troponin T. Our findings suggest a 
potential role for microRNAs as biomarkers in cardiology and mandate subsequent 
investigations to define their clinical applicability in early detection of myocardial damage.
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Introduction
MicroRNAs (miRNAs) form a class of small (~22 nucleotides) non-coding RNAs that 
negatively regulate gene expression by recognizing complementary messenger RNAs 
(mRNAs) and prohibiting their translation into functional protein1. Their critical (patho)
physiological importance is evidenced by their marked evolutionary conservation and current 
estimates are that they fin-tune expression of up to 50% of protein-coding genes2, 3. 
MiRNAs are crucial for virtually all cellular processes and are a prerequisite for normal 
cardiac function4-7. Consequently, aberrant miRNA expression profiles are associated with 
various cardiovascular conditions such as hypertrophy, fibrosis, heart failure, and 
arrhythmias8-11. 
Recently, different groups reported that non-cell associated miRNAs are circulating freely 
in mammalian blood with marked biostability, and can be detected with high sensitivity 
and specificity in human plasma and serum12, 13. Though the biological meaning of these 
miRNAs is unclear, pioneer profiling studies have attributed specific serum miRNA 
signatures to conditions varying from pregnancy to drug-induced liver injury, sepsis, and 
a variety of malignancies12-16. The diagnostic potential of miRNA detection in human plasma 
for cardiovascular disorders is beginning to be explored: Ai et al. studied plasmas of 93 
AMI patients and found miR-1 increased17; Adachi et al. found elevated miR-499 in plasmas 
of 9 AMI patients18; increased plasma levels of miR-208a were reported by Wang et al. 
for 33 AMI patients19; Cheng et al. reported increased plasma miR-1 levels in 31 AMI 
patients20; and finally in a total of 42 heart failure patients, miR-423-5p was found increased 
by Tijsen et al. and correlated with proBNP levels21. Cardiovascular disease populations 
typically are elderly, overweight, and are associated with possible confounding factors 
such as age, gender, body-mass-index, and kidney and liver function. The importance of 
these clinical confounders for multiple plasma miRNA levels has, to our knowledge, not 
been investigated to date.
Methods 
Clinical samples 
All clinical samples were obtained with approval of the local Human Research Ethical 
Committees and stored at -80 degrees Celsius. They were subjected to freeze-thawing 
once.
Acute myocardial infarction (AMI)
Citrate plasma samples were obtained from patients presenting with AMI (n=32) and 
patients with atypical chest pain, positive stress testing but with normal coronary angiograms 
(n=36). All patients with acute MI were enrolled in the Luxembourg acute MI registry and 
treated with primary percutaneous coronary intervention. All patients had successful 
mechanical reperfusion and stenting of the infarct artery within 12 hours of chest pain 
onset. All patients received Aspirin, Clopidogrel, Heparin and Abciximab. Acute MI was 
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defined by the presence of chest pain < 12 hours with significant ST elevation and increase 
in creatine kinase and troponin I to greater than 2-fold upper limit of normal. Blood samples 
were obtained at the time of mechanical reperfusion. More details are provided in 
Supplementary Table 1.
Viral myocarditis (VM)
Ethylenediaminetetraacetic acid (EDTA) plasma samples were obtained from patients with 
acute VM during hospitalization in the acute phase (n=14), post-VM phase (ranging from 
1 to 12 months after the acute inflammatory phase, n=20) and from age-matched healthy 
controls (n=20) at the Cardiology Department of the Maastricht University Medical Center 
between 2007 and 2009. Acute VM patients were further subdivided into mild VM (troponin 
T<0.01µg/L and normal left ventricular ejection fraction (LVEF), n=4), moderate VM 
(elevated troponin T or LVEF<50%, n=5) and severe VM (LVEF<30%, n=5). See 
Supplementary Table 2.
Diastolic dysfunction
We examined EDTA plasma samples from 79 individuals at ages of 42-85, originally selected 
from a general Flemish population for the FLemisch Study on Enviromnent, Genes, and 
Health Outcomes (FLEMENGHO22), and thoroughly examined including echocardiographic 
analysis and detailed epidemiological characterization, as described previously23. 
Asmptomatic individuals were age-matched and divided into three groups. Group 1: controls 
(n=20) with normal cardiac function and no risk factors, corresponding to AHA stage 0 of 
Heart Failure24. Group 2: hypertensive individuals (n=20) without structural of functional 
cardiac involvement, corresponding to AHA stage A of HF. Group 3: hypertensive individuals 
with clear signs of cardiac involvement (n=39) with impaired left ventricle (LV) relaxation, 
or elevated end-diastolic LV pressures, corresponding the AHA stage B of HF. Full details 
are provided in Supplementary Table 3.
Acute heart failure (AHF)
EDTA plasma samples were collected from patients that were admitted with acute 
decompensation of congestive heart failure according to predefined Framingham-based 
criteria25 and an elevated plasma NT-proBNP (>200pmol/L) (n=33), and from healthy staff-
members as controls (n=34) at the Cardiology Department of the Maastricht University 
Medical Center. For additional details, see Supplementary Table 4.
Whole blood samples
To compare miRNA levels in matched plasma and leukocyte-rich whole blood, whole blood 
samples were used from 12 individuals from the Diastolic dysfunction cohort.
Urine samples
To investigate whether plasma miRs are excreted from the blood through glomerular 
filtration, simultaneous urine and EDTA plasma samples were taken from healthy volunteers 
(n=5) from the VM healthy control group in Maastricht in November 2009. 
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RNA extraction 
Total RNA was extracted from 100 µL of plasma, whole blood or urine, using the mirVana 
PARIS kit (Ambion, Warrington, UK), according to the manufacturer’s instructions and 
without enrichment for small RNAs, and subsequently eluted in 50 µL nuclease-free water. 
Subsequently, potential genomic DNA contamination was eliminated using DNA-free kit 
(Ambion).
cDNA synthesis and qRT-PCR 
15 µL of RNA was used per 20-µL reaction to generate cDNA using the miScript kit (Qiagen, 
Venlo, The Netherlands) that is designed to specifically detect mature microRNAs. The 20 
µL reaction mix was then diluted 4x in nuclease free water and 2 µL of cDNA was added 
per qPCR reaction, using BR SYBR-green supermix for IQ (Quanta Biosciences, Amsterdam, 
The Netherlands) in a MyIQ iCycler (Bio-Rad, Veenendal, The Netherlands) device using 
MiScript primers sets (Qiagen). The selection of miRNA candidates to be tested was based 
on intellectual choice for each disease cohort. The following miRNAs were assayed: AMI: 
miR-1, -122, -133a, -208b, -223, -499; VM: miR-1, -133a, -146a, -146b, -155, -208b, -223, 
-499; Diastolic Dysfunction: miR-1, -21, -29b, -122, -126, -133a, -146a, -146b, -155, -208b, 
-223, -499 and AHF: miR-1, -122, -133a, -208b, -223, -499.
Normalization of experimental data 
Quantitative qPCR measurements of miRNA levels were normalized for isolation efficiency 
using a mix of three spiked-in synthetic C. elegans miRNAs (Eurogentec, Maastricht, The 
Netherlands), lacking sequence homology to human miRNAs, as described previously13. 
Oligonucleotides were spiked into the samples during RNA isolation following plasma 
incubation with the provided 2x denaturing solution. We have chosen to correct for spikes 
rather than for endogenous “stable” miRNAs, since there is no consensus in the literature 
regarding stable microRNAs for correction.
Statistical analyses 
Statistical analyses were performed using GraphPad Prism 4.0a for Macintosh (GraphPad 
Software Inc., La Jolla, CA, USA),. Data are presented as mean ± SEM unless indicated 
otherwise and plasma miRNA levels are presented as fold-change relative to controls. 
Linear regression analyses were used to correlate quantitative variables following 
normalization of non-Gaussian variables by log-transformation. Regression analyses of 
miRNA levels versus clinical parameters in the diastolic dysfunction database involved 
n=79 patient plasmas, resulting in a power of 80% to demonstrate a Pearson correlation 
of 0.31. Comparisons between 2 groups were performed with Student’s t tests for Gaussian 
data or Mann-Whitney tests for non-Gaussian data. For comparisons of more than 2 groups, 
one-way ANOVA was used, followed by post hoc testing using Bonferroni correction for 
more groups. Receiver operating characteristic curves were generated with PASW 18.0 
for Macintosh, using nonparametric analyses to estimate error margins for the area under 
the curve.
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Results 
Plasma miRNA-208b and -499 levels are highly elevated after acute myocardial 
infarction and correlate with cardiac injury markers 
We first established miRNA plasma levels in AMI patients as compared to patients 
presenting with atypical chest pain and no cardiac disease. Heart-associated miRNAs, 
but not liver-specific miR-122 or leukocyte-associated miR-223, were elevated in AMI 
patients compared to controls (Figure 1). While miR-133a (p<0.05) and miR-1 (non 
significant) levels were mildly increased, we found a robust elevation of plasma miR-208b 
and miR-499 levels by ~1600-fold (p<0.005) and ~100-fold (P<0.0005), respectively. 
Receiver operating characteristic (ROC) curves generated for both miRNAs revealed an 
area under the curve of 0.944 for miR-208b (95% confidence interval = 0.863-1.000, 
p<10-10) and 0.918 for miR-499 (95% confidence interval = 0.842-0.995, p<10-9) (Figure 
2). Subsequently, we assessed the correlation between plasma levels of miR-208b and 
miR-499 with serum levels of cardiac injury markers troponin T (Figure 2C and D) and 
creatine phosphokinase (CPK) in the AMI group (Supplementary Figure 1). Both miR-208b 
and miR-499 correlated significantly to troponin T and CPK levels, with the highest degree 
of correlation observed for miR-499 (CPK: regression coefficient R=0.41, p<0.0001; and 
troponin T: R=0.69, p<0.0001). 
Intriguingly, miR-223 was mildly but significantly decreased in AMI patients as compared 
to controls. We found no correlation between miR-223 levels and Troponin T levels or 
WBC counts (Supplementary Figure 1). Wang et al. also report decreased miR-223 levels 
in patients with sepsis26. Future research will need to establish if there is a rationale for 
the diminished presence of this predominantly granulocyte-originating miRNA in 
inflammation-related pathologies. 
Cardiomyocyte-associated but not inflammatory microRNAs are significantly elevated 
in the acute stage of viral myocarditis 
We subsequently investigated plasma miRNA levels in patients with acute VM, patients 
in the post VM phase, and healthy controls. Again, levels of miR-208b and miR-499 
were significantly elevated (30- and 6-fold, respectively, p<0.01 versus controls for 
both) during the acute phase of VM (Figure 3 and Supplementary Figure 2). Their 
expression levels significantly correlated with the severity of VM: subgroup analysis 
within the acute VM patients revealed normal values of miRs-208b and -499 in mild 
VM patients (with no troponin T elevation), and increasing levels for moderate and 
severe VM (~20-fold and 50-fold higher, respectively, than control levels for miR-208b, 
and ~5-fold and 10-fold for miR-499) (Supplementary Figure 2). Of note, the more 
accentuated rise in miRNA plasma levels in AMI compared to VM paralleled the higher 
troponin T levels in AMI patients (Supplementary Tables 1 and 2). Levels of miR-1, 
-133a and leukocyte-associated miRs-146a, -146b, -155 and -223 were not significantly 
different between groups (Figure 3), despite significant leukocytosis in the acute VM 
group (Supplementary Table 2).
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Cardiomyocyte- and leukocyte-expressed plasma miRNAs are not diagnostic for 
diastolic dysfunction 
None of the muscular or leukocytic miRNAs studied showed significantly different levels 
between the healthy controls, patients with hypertension without cardiac changes and 
patients with evident myocardial diastolic dysfunction (Figure 4 and Supplementary Figure 
3). Also levels of miR-21 and -29b, which are both involved in the pathophysiology of cardiac 
fibrosis and upregulated in failing human hearts27-29, were not elevated in diastolic 
dysfunction plasmas. We then investigated correlations of the individual miRNA levels to 
Figure 1. Cardiomyocyte miRNA levels mark acute myocardial infarction (AMI). Compared to microRNA 
levels in controls with atypical chest pain and no cardiac disease (n=36), AMI patient plasmas (n=32) show a 
sharp rise in levels of heart-associated microRNAs miR-208b (1600-fold, p<0.005), -499 (100 fold, p<0,0005) 
and to a lesser extent miR-133a (p<0.05) and miR-1 (p=0.12) (panels A through D). Plasma levels of liver-
specific miR-122 were not different between groups (F) and miR-223 levels were even decreased in AMI 
plasmas (p<0.005) (E). 
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cardiovascular indices. Intriguingly, the myocardium-associated miR-133a correlated 
significantly and positively to serum NT-proBNP levels (R=0.43, p=0.001, see Figure 4H), 
However, this correlation was independent of cardiac diastolic function, as miR-133a was 
not elevated in patients with diastolic dysfunction (Figure 4D). In addition, the NT-proBNP 
levels in this cohort were very mildly elevated, as opposed to the NT-proBNP levels in the 
acute heart failure cohort, where no correlation was found (Figure 5G).
Figure 2. MiR-208b and miR-499 are potential circulating biomarkers for acute myocardial infarction 
(AMI). (A and B) Scatter plots of plasma miR levels in controls (n=36) versus AMI patients (n=32), revealing 
a 1500-fold increase for miR-208b (p<0.005) and 90-fold increase for miR-499 (p<0.001) in AMI. MiR-208b 
was not detected in 32 out of 36 controls and 3 our of 32 AMI patients. (C and D) Within the AMI groups 
levels of miR-208b and miR-499 correlated significantly with circulating troponin T levels (miR-208b: R=0.59, 
p=0.0005 and miR-499: R=0.69, p<0.0001). Panels A-D show that a few AMI patients had relatively low miR-
208 and miR-499 levels. This was reproducible and not due to technical issues. (E and F) Receiver operating 
characteristic (ROC) curves revealing an area under the curve of 0.944 for miR-208b (95% confidence 
interval: 0.863-1.00, p<10-10) and 0.918 for miR-499 (95% CI: 0.842-0.995, p<10-9).
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Tijsen et al. also found no association between miR-133a plasma levels and NT-proBNP 
levels in heart failure patients21. No correlations were observed between miRNA plasma 
levels and systolic blood pressure, or left ventricular mass index (Supplementary Table 5). 
Finally, no differences were found in plasma microRNA levels of smokers and non-smokers, 
with exception of miR-29b, which was significantly higher in smokers (p=0.02).
Figure 3. Plasma miRNA levels reflect myocardial damage but not inflammation in acute viral myocarditis. 
(A and B) MiR-208b and -499, which were the strongest indicators of myocardial damage in myocardial 
infarction, are significantly elevated in plasmas from acute VM patients (n=14), compared to post VM 
patients (n=20, p<0.05 for miR-208b and p<0.01 for miR-499) or healthy controls (n=20, p<0.01 for 
both miRNAs). MiRs-1 and -133a levels were not significantly different between groups (C and D). (E-H) 
Leukocyte-associated miRs-146a, -146b, -155, and -223 showed a non-significant trend to higher levels 
during the acute phase of VM.
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Figure 4. Plasma miRNA levels in a cohort of diastolic dysfunction. Levels of our plasma microRNA 
panel did not discriminate between diastolic dysfunction patients (n=39) and hypertensive (n=20) or 
normotensive (n=20) controls. Panels A through G depict levels of the muscle-associated miRs-208b, -499, 
-1 and -133 (A-D), fibrosis associated miRs-21 and -29b (E and F), and the leukocyte-associated miR-223 (G). 
(H) The striated muscle associated miR-133a correlates significantly to serum N-terminal prohormone brain 
natriuretic peptide (NT-proBNP) levels in patients with diastolic dysfunction (R=0.43, p=0.001). Color-coding 
of data points in 4H is as follows: controls black, hypertensive patients grey, and patients with diastolic 
dysfunction white.
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Acute heart failure provokes mild differences in heart-associated miRNAs 
We subsequently assessed plasma miRNA levels in patients with acutely decompensated 
AHF. All heart-associated miRNAs showed a trend towards mildly higher plasma levels in 
the AHF group, reaching significance for miR-499 (2-fold; p<0.05) (Figure 5). Of note, 
significance might have been masked for miR-1, by the mild negative correlation of miR-1 
with age (Supplementary Table 1, R=-0.25, p=0.04) and the higher mean age of AHF 
patients versus controls. Additionally, the liver-specific miR-122, that is known to correlate 
with hepatic damage16, was significantly elevated in AHF patients (Figure 5), possibly 
reflecting hepatic venous congestion. In this patient group, we found no positive correlation 
of miR-133a with NT-pro-BNP levels (Figure 5G), nor with troponin T levels (Figure 5H).
Circulating plasma miRNAs are markedly robust against clinical confounders 
including age, gender, and renal function  
To determine to which extent plasma miRNA levels are confounded by the baseline 
characteristics of plasma donors, we selected 79 samples from the extensively characterized 
diastolic dysfunction patient database to evaluate the potential impact of a set of clinical 
confounders on miRNA levels (See Supplementary Table 5). Linear regression analyses 
revealed that plasma miRNA levels were not affected by the evaluated parameters. Patient 
gender and body mass index did not correlate with any of the plasma miRNAs 
(Supplementary Table 5). Plasma sample age, ranging from 11 to 49 months also had no 
influence on detected levels, indicating that miRNAs are not degraded when stored at -80 
degrees Celsius. Patient age did not significantly correlate with 10 out of 12 miRNAs, and 
only showed weak negative correlation with miRNAs -1 and -29b (R=-0.25 and -0.26, 
respectively and p<0.05 for both). Interestingly, glomerular filtration rate did not correlate 
with plasma miRNA levels.  In addition, we investigated matched plasma and urine levels 
of miR-122 (liver) and -223 (granulocytes), and found that while both miRNAs were well 
detected in both sample types, levels in plasma compared to urine were ~1000-fold higher 
for miR-122 and ~100 fold for miR-223 (Supplementary Figure 4). Together, these data 
indicate that freely circulating miRNAs are not renally cleared.
Plasma levels of the liver-specific miR-122 correlated with levels of the liver-specific marker 
gamma glutamyl transferase (gamma GT) (Supplementary Table 5), in agreement with the 
elevated levels of miR-122 in AHF (Figure 5E). Finally, levels of miR-133a correlated with 
NT-proBNP levels in this patient group, as described above.
Leukocyte-associated miRNAs do not reflect white blood cell count or leukocytic 
miRNA levels 
To investigate whether leukocyte-associated miRNAs could serve as markers for mild 
inflammatory processes, we compared plasma levels of inflammatory miRNAs to WBC 
counts. Plasma levels did not correlate with circulating numbers of leukocytes, indicating 
that secretion of miRNAs from circulating leukocytes is not the main determinant of their 
plasma levels (Supplementary Figure 5 and Supplementary Table 5). This lack of correlation 
was independently confirmed in our plasma databases of acute VM and AMI plasmas with 
leukocytosis (Supplementary Figure 1 and data not shown). We subsequently compared 
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Figure 5. Plasma miRNA levels in patients with acutely heart failure AHF. (A-D) Plasma levels of the 
heart-associated miRs-208b, -499, -1, and -133a were higher in AHF patients (n=33) than in controls (n=20), 
although only miR-499 level differences were significantly elevated (p<0.05). The liver-specific miR-122 
was elevated in AHF patients (E), while granulocyte-specific miR-223 was not different for AHF patients 
and controls (F). (G) In AHF patients, miR-133a failed to correlate with NT-proBNP (R=-0.32, p=0.09) as was 
observed in diastolic dysfunction patients. This lack of correlation could not be explained by a correlation 
with circulating troponin T levels (R=0.27, p=0.23) (H).
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the levels of plasma miRNA with whole blood miRNA levels (containing leukocytes) across 
patients, but again did not find a significant correlation (Supplementary Figure 4), indicating 
that plasma miRNAs reflect neither WBC count nor leukocytic miRNA expression. However, 
we did notice a striking quantitative correlation between leukocyte-associated but not 
cardiac miRNAs within samples (Supplementary Table 6A and B), pointing towards a 
common etiology. We also found highly identical patterns of these miRNAs in plasma and 
whole blood (Supplementary Figure 6) within individuals, with levels always 1000-fold 
higher in whole blood, suggesting that leukocytes are indeed the primary source of these 
miRNAs in plasma. The paradoxical lack of correlation with WBC counts and whole blood 
miRNA might be explained by variable leakage between patients, compromising their 
diagnostic accuracy.
Discussion 
Recent evidence that freely circulating miRNAs may be informative of human pathology 
has ignited wide interest in their diagnostic potential13, 16. Our study demonstrates that in 
humans, diverse conditions of myocardial damage are associated with striking perturbations 
of plasma levels of heart-associated miRNAs-208b and -499. These are increasingly elevated 
during acute heart failure (minimal), viral myocarditis (marked), and acute myocardial 
infarction (extensive). In AMI, where cardiac damage was most severe, ROC-curves for 
AMI detection by miR-208b or -499 levels revealed a pronounced diagnostic accuracy, 
evidenced by an area under the curve of >0.91 with p<10-9 for both individual miRNAs. 
Encouragingly, these data are in agreement with a recent report published during the 
preparation of this manuscript, that examined plasma levels of muscle-specific miRNAs in 
AMI patients and also identified miRs-208(a) and -499 as the most sensitive biomarkers of 
AMI19. Supplementary Table 7 provides an overview of the plasma miRNA changes reported 
in cardiovascular disease thus far. In addition, our study uniquely shows that miR-208b and 
-499 release is not exclusive for AMI and occurs independently of ischemia and ejection 
fraction. Biologically, these data evoke tantalizing questions about potential functions for 
circulating miR-208b and -499, which modulate cardiomyocyte performance by shifting the 
balance between slow and fast muscle fibre gene programs towards the slow type7, 30. 
There is currently no evidence demonstrating a functional role for plasma miRNAs through 
affecting distant gene expression in vivo. Interestingly, it was reported that following drug-
induced liver injury, miRNAs elevated in plasma were consistently downregulated in 
corresponding livers16 suggesting the intriguing possibility of a cellular survival mechanism 
in which, during stress, undesirable miRNAs are actively excreted. However, miR-208 is 
elevated in acutely infarcted human hearts31 and additional research is required to address 
the biological role of plasma miRNAs after cardiac damage.
Interestingly, the profound increases of miRNAs -208b and -499 in patients with AMI (1600- 
and 100-fold, respectively) are in contrast with the mild elevations observed for heart-
associated miRs-1 and -133a (3- and 4-fold, respectively). This could be a reflection of the 
higher specificity of miR-208b and -499 for cardiac muscle, or higher baseline levels of 
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miR-1 and -133a in serum, due to turnover of skeletal muscle19. An alternative possibility 
is that these miRNAs might be trapped in structural complexes in cardiomyocytes, 
preventing leakage.  Three groups previously reported that plasma miR-1 levels are elevated 
in AMI patients17, 19, 20, but also in these studies this elevation was milder than observed 
for miR-208b and -499. Our data generally support their conclusions but extend on their 
findings by identifying miRs -208b and -499 as far more sensitive markers for myocardial 
damage not only in AMI but also in VM. An intruiging observation from our study was the 
correlation of miR-133a plasma levels with with NT-proBNP in asymptomatic patients with 
diastolic dysfunction, which was not observed in AHF patients. Additional research in larger 
patient populations will be required to unveil the significance of this phenomenon.
The influence of potentially confounding patient characteristics has so far remained largely 
unexplored. We present evidence that the investigated plasma miRNA levels are highly 
robust to a variety of patient parameters including age, gender, body mass index, systolic 
blood pressure, smoking, and glomerular filtration rate. Further, the liver-specific miR-122 
was the only miRNA mildly correlating with gamma GT levels, in agreement with the recent 
report that plasma miR-122 parallels levels of aminotransferase levels during hepatic 
damage16. These findings are of vital importance for the diagnostic applicability of plasma 
miRNAs in clinical settings, and in particular cardiovascular medicine, where skewed 
distributions of age and biometry, combined with comorbidities such as renal failure are 
common. Our data indicate caution to use leukocyte-expressed plasma miRNAs as 
diagnostic targets in conditions of mild inflammation, as their levels may be subject to 
variable leakage from circulating leukocytes, eg caused by venipuncture.  On the other 
hand, the significant decrease in miR-223 levels following AMI has potential biological and/
or diagnostic significance, given the study by Wang et al.26 who find decreased miR-223 
levels during sepsis. Therefore, the value of miR-223 for AMI needs to be investigated 
further. 
In conclusion, we report that cardiac damage in diverse cardiac diseases initiates massive 
release of cardiomyocyte-specific microRNAs into the circulation, and that these microRNAs 
are highly insensitive to clinical characteristics in a cardiovascular patient population. 
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Supplementary Figures and Tables
Supplementary Figure 1. Plasma miRNA levels in AMI. Plasma levels of miR-208b (panel A) and miR-499 
(B) correlate with circulating levels of cardiac damage marker creatine phosphokinase (CPK) in AMI patients 
(miR-208b: R=0.40, p=0.03 and miR-499: R=0.41, p=0.01). Regression analysis between plasma levels 
of the granulocyte-specific miR-223 and white blood cell count (panel C) revealed no correlation (R=0.10, 
p=0.63). MiR-223 levels also did not correlate with levels of troponin T (panel D; R=0.03, p=0.88).
Supplementary Figure 2. Plasma miR-208b and miR-499 elevation in viral myocarditis reflects VM 
severity. Plasma levels of miR-208b (panel A) and miR-499 (panel B) are elevated in acute viral myocarditis 
in relation to disease severity, as classified into mild VM (troponin T<0.01µg/L and normal left ventricular 
ejection fraction (LVEF), n=4), moderate VM (elevated troponin T or LVEF<50%, n=5) and severe VM 
(LVEF<30%, n=5). MiR-208b was detected in only 4 out of 20 control patients and none of the patients in 
the mild VM group (that per definition does not include patients with troponin T elevation). MiR-499 was 
detected in all patients and levels were comparably low in the control and mild V group. Moderate VM 
samples display a trend towards elevation of both microRNAs and in severe VM, both miR-208b and miR-
499 are significantly elevated (p<0.001).
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Supplementary Figure 4. Plasma miRNAs are 
not subject to efficient glomerular filtration. 
MicroRNA detection in matched plasma and urine 
samples revealed substantially higher levels in 
plasmas for all investigated microRNAs, which, 
together with he lack of correlation of with 
glomerular filtration rate, indicates that microRNAs 
are not renally cleared. Displayed microRNAs were 
selected for predominant preglomerular origin (miR-
122: liver-specific; miR-223: granulocyte-specific). 
Error bars represent standard deviations.
Supplementary Figure 3. Plasma miRNA levels in patients with myocardial Diastolic Dysfunction. 
Panels A through F depict plasma miRNA levels in controls without hypertension or cardiovascular risk 
factors, hypertensive patients without cardiac involvement, and patients with evident diastolic dysfunction. 
MiRNAs studies included miRNAs associated with liver (miR-122), endothelium (miR-126), and leukocytes 
(miRs-146a, 146b, -155, 223). Panel F depicts NT-proBNP levels for all three groups (not significantly 
different).
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Supplementary Figure 5. Plasma microRNAs do not reflect white blood cell count or leukocytic 
microRNA fraction in Diastolic Dysfunction. Plasma levels of leukocyte-associated microRNAs-146a, 
-155 and -223 fail to correlate with circulating white blood cell counts (n=79) (A, C and E). Plasma levels of 
leukocyte-associated microRNAs additionally do not correlate with measured microRNA levels from whole 
blood (n=12) (B, D and F).
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Supplementary Figure 6. Plasma microRNA profiles mirror microRNA profiles in the leukocyte blood 
fraction and might be skewed by leakage. (A) Average threshold cycle (Ct) values for qRT-PCR detection 
of microRNAs in paired plasma and whole blood samples (n=12), showing the highest whole blood levels 
(lowest Ct values) in leukocyte-associated microRNAs-21, -29b, -126 and -223. Panel (B) displays the 
difference between plasma and whole blood Ct per patient. The liver-specific miR-122 is not detected 
earlier in whole blood, as expected due to its exclusive liver specificity. Interestingly, leukocyte-associated 
microRNAs show highly similar patterns in plasma and whole blood (all were detected ~11 cycles earlier 
in whole blood than plasma regardless of expression level), indicating that these plasma microRNA are 
predominantly derived from leukocytes. Since plasma microRNAs did not correlate with leukocyte counts 
at the individual patient level (Supplementary Figure 5), these findings may suggest that variable leakage 
of microRNAs from leukocytes distorts the diagnostic accuracy of plasma microRNAs. Error bars represent 
standard deviations.
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Supplementary Table 1. Acute Myocardial Infarction Database Patient Characteristics
Acute Myocardial Infarction Controls
Characteristic (n=36) (n=36) P*
Age, years 62 ± 13 62 ± 13 0.95
Women 12 (33.3) 13 (36.1) 0.86
Sample age, months 80 ± 10 94 ± 1 <0.0001
Serum Troponin T, µg/L 3.5 ± 4.8 < 0.01 <0.0001
NT-proBNP, pmol/L 615 ± 678 366 ± 835 0.36
Serum hs-CRP, mg/L 0.74 ± 0.80 0.46 ± 0.79 0.23
PTCA, n 36 (100) 1 (2.8) <0.0001
Data are presented as mean ± SD, or n (%), * P-values based on student t-test or Chi-square analysis, CPK Creatine 
Phosphokinase NT-proBNP, hs-CRP High-Sensitivity C-Reactive Protein, N-terminal Prohormone Brain Natriuretic 
Peptide, PTCA Percutaneous Transluminal Coronary Angioplasty
Supplementary Table 2. Viral Myocarditis Database Patient Characteristics 
Acute VM Post VM Controls
Characteristic (n=14) (n=20) (n=20) P
Age, years 32.7 ± 16.3 37.3 ± 19.4 32.1 ± 7.3 0.51*
Women 2 (14.2) 3 (15) 8 (40) 0.96†
Sample age, months 19 ± 13 22 ± 6    6 ± 0.4 <0.001*
Serum CRP, mg/L 95 ± 92 11 ± 14 ND <0.005‡
Serum troponin T, µg/L 1.1 ± 1.6 <0.01 ND <0.05‡
Blood leukocytes, x109/L 12.5 ± 5.5 7.1 ± 3.1 ND <0.005‡
LVEF, % 48.3 ± 14.1 57.2 ± 7.6 ND <0.001*
Data are presented as mean ± SD, or n (%), P-values based on *One-way ANOVA, † Chi-square analysis or ‡ 
Student’s t-test or Mann-Whitney test, CRP C-Reactive Protein, LVEF Left Ventricular Ejection Fraction, ND Not 
determined
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Supplementary Table 3. Diastolic Dysfunction Patient Baseline Characteristics
Controls Hypertension Diastolic
Dysfunction
Characteristic (n=20) (n=20) (n=39) P*
Age, years 63 ± 7 60 ± 8 69 ± 8 <0.001
Women 9 (45) 8 (40) 17 (44) 0.95
Sample age, months 33 ± 11 33 ± 11 37 ± 11 0.31
BMI, kg/m2 24.8 ± 2.3 27.3 ± 4.3 28.8 ± 3.4 <0.001
SBP, mm Hg 121 ± 8 157 ± 15 150 ± 13 <0.0001
Creatinine, µmol/L 86 ± 17 90 ± 14 90 ± 16 0.86
GFR†, mL/min 73 ± 17 80 ± 16 72 ± 21 0.29
γGT, units/L 31 ± 20 36 ± 21 32 ± 25 0.78
WBC count, x109/L 6.1 ± 2.1 5.6 ± 1.4 5.7 ± 1.7 0.66
Glucose, mmol/L 4.9 ± 0.3 5.1 ± 0.8 5.2 ± 1.7 0.55
NT-proBNP, pmol/L 245 ± 118 268 ± 155 337 ± 159 0.09
LVMI, g/m2 88 ± 12 100 ± 18 117 ± 22 <0.0001
Current smoker 6 (30) 5 (25) 4 (10) 0.14
Data are presented as mean ± SD, or n (%), * P-values based on One-way ANOVA or Chi-square analysis, † 
Glomerular filtration rates were calculated using the Cockroft-Gault formula, BMI Body Mass Index, EDP End Diastolic 
Pressure, GFR Glomerular Filtration Rate, LVMI Left Ventricular Mass Index, NT-proBNP N-terminal Prohormone 
Brain Natriuretic Peptide, SBP Systolic Blood Pressure
Supplementary Table 4. Acute Heart Failure Database Patient Characteristics
Acute Decompensation Healthy Controls
Characteristic (n=33) (n=24) P*
Age, years 76.3 ± 8.4 34.8 ± 17.1 <0.0001
Women 20 (60.1) 16 (59.6) 0.82
Sample age, months 6.5 ± 2.4 6.9 ± 2.0 0.50
NT-proBNP, pmol/L 1590 ± 2022 ND
LVEF, % 37.0 ± 15.0 ND
Preserved LVEF > 45% 15 (45) ND
Underlying pathology
   CAD 19 (57.5)
   Valvular 6 (18.2)
Data are presented as mean ± SD, or n (%), * P-values based on student t-test or Chi-square analysis, CAD Coronary 
Artery Disease, CRP C-Reactive Protein, LVEF Left Ventricular Ejection Fraction, ND Not determined, NT-proBNP 
N-terminal Prohormone Brain Natriuretic Peptide
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Supplementary Table 6a. MicroRNA level intercorrelations in Diastolic Dysfunction Plasmas (correlation 
coefficient R)
R values miR-21 miR-29b miR-126 miR-146a miR-146b miR-223 miR-133a* miR-208b*
miR-21 X
miR-29b >0.75 X
miR-126 >0.75 >0.75 X
miR-146a >0.75 >0.75 >0.75 X
miR-146b >0.75 >0.75 >0.75 >0.75 X
miR-223 >0.75 >0.75 >0.75 >0.75 >0.75 X
miR-133a* <0.2 <0.2 <0.2 <0.2 <0.2 <0.2 X
miR-208b* <0.2 <0.2 <0.2 <0.2 <0.2 <0.2 <0.2 X
* Non-leukocyte associated microRNAs
Supplementary Table 6b. MicroRNA level inter-correlations in Diastolic Dysfunction Plasmas (P values)
P-value miR-21 miR-29b miR-126 miR-146a miR-146b miR-223 miR-133a* miR-208b*
miR-21 X
miR-29b <0.0001 X
miR-126 <0.0001 <0.0001 X
miR-146a <0.0001 <0.0001 <0.0001 X
miR-146b <0.0001 <0.0001 <0.0001 <0.0001 X
miR-223 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 X
miR-133a* 0.24 0.69 0.11 0.17 0.34 0.30 X
miR-208b* 0.16 0.54 0.55 0.39 0.89 0.97 0.42 X
* Non-leukocyte associated microRNAs
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MicroRNAs (miRNAs) are important regulators of pre-mammalian and mammalian gene 
expression and their involvement in cardiovascular disease has been well documented1-3. 
Most studies have focused on the role of miRNAs in processes such as cardiomyocyte 
hypertrophy, angiogenesis, apoptosis and fibrosis4-7. In contrast, miRNA regulation of cardiac 
inflammation, which is critically involved in the pathogenesis of heart failure, has hitherto 
not been addressed8, 9. Therefore, the first aim of this thesis was to study miRNA signaling 
in cardiac inflammation during different forms of heart failure. We approached this question 
by (1) screening for cardiac miRNA expression alterations during acute viral myocarditis 
and next by (2) addressing the cardiac response to pressure overload in mice deficient for 
the pro-inflammatory microRNA-155 (miR-155). The main conclusions from these studies 
are that miRNAs are important contributors to inflammatory signaling and heart failure 
development in both myocarditis and hypertensive heart failure, and that their adverse 
effects can be therapeutically targeted by pharmacological inhibition in rodents. During 
viral myocarditis, many miRNAs are dysregulated in the hearts of human patients and mice 
(Chapter 4). Among them, miR-155 is consistently and strongly upregulated during the 
acute inflammatory phase. Pharmacological inhibition of miR-155 reduces cardiac injury in 
the acute phase and improves survival (Chapter 4). In contrast, signaling by the miR-221-
miR-222 family is protective against viral replication, cardiac injury, and inflammatory 
infiltration during acute viral myocarditis (Chapter 5). Following pressure overload, miR-155 
controls the activation and cardiac infiltration of immune cells. Absence or inhibition of 
miR-155 attenuates pro-hypertrophic signaling by cardiac macrophages and diminishes 
cardiac hypertrophy as well as systolic dysfunction (Chapter 6).  
The second aim of this thesis was to explore the potential of using miRNAs as biomarkers 
for cardiovascular diseases in patients. By studying levels of individual miRNAs in plasma 
samples from patients suffering from acute myocardial infarction, viral myocarditis, heart 
failure, and from controls, we discovered that the cardiac-enriched miRNAs miR-208b and 
miR-499 are sensitive indicators of myocardial damage (Chapter 7). Levels of these miRNAs 
are strongly elevated in patients with acute myocardial infarction and viral myocarditis, and 
correlate tightly with biochemical markers of cardiomyocytes death, such as cardiac troponin 
T. These alterations were independent of clinical characteristics such as age, gender, body 
mass index, and renal function, and may therefore be clinically applicable in the diagnosis 
of acute myocardial infarction.
MicroRNAs as mediators of viral myocarditis
Viral infection is the most prevalent cause of acute myocarditis in Western society and the 
treatment of virus-induced myocarditis represents a difficult clinical problem30. Since both 
the virus and the immune response against it contribute to cardiac injury and the 
development of dilated cardiomyopathy, broad inhibition of inflammation does not lead to 
patient benefit as it does in non-viral myocarditis31-34. Over the past decade, accumulating 
insights into the beneficial versus detrimental nature of specific immune response 
components (cellular or molecular) suggest that targeted treatment of viral myocarditis 
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may be feasible, as reviewed in Chapter 3. For instance, toll-like receptor-3 signaling through 
TRIF is necessary for efficient antiviral defence and cardiac protection, while TLR-4 and 
TLR-9 signaling through the molecular adapter MyD88 promote cardiac injury and 
mortality35-37. Similarly, endogenous inhibitors of inflammation, such as alternatively activated 
macrophages or regulatory T cells, attenuate viral replication as well as myocarditis in 
mice38, 39. While such findings establish a clear rationale for targeted treatment, development 
and testing of specific inhibitors is a challenging and time-consuming endeavour. 
MiRNAs play important roles in numerous diseases and can efficiently be targeted in vivo 
in mice and primates through a variety of chemistries40-42. They are attractive therapeutic 
targets due to the straightforward design of antimiRs – based on Watson-Crick 
complementarity – and the generally subtle effects of miRNAs on signaling networks2, 43, 
44. To map the behaviour of miRNAs during viral myocarditis, we have longitudinally profiled 
miRNA alterations in the hearts of human patients as well as myocarditis-susceptible and 
-resistant mouse strains (Chapter 4). A large number of miRNAs is up or downregulated 
during acute myocarditis, including miR-155 that is elevated in the hearts of both mice and 
humans during myocarditis. Inhibition of miR-155 in mice suppresses T cell activation and 
cardiac infiltration by myeloid cells, which reduces cardiac necrosis in the acute phase and 
mortality in the long run (Chapter 4 and Figure 1). Previous studies have demonstrated that 
miR-155 suppression ameliorates autoimmune diseases, such as experimental autoimmune 
encephalitis and rheumatoid arthritis45, 46. The therapeutic benefit of miR-155 suppression 
in a combined infectious-autoimmune disease such as viral myocarditis complements these 
observations and shows that miR-155 may be a molecularly targetable switch to improve 
outcome in viral myocarditis patients. In contrast to miR-155, inhibition of the miR-221-222 
family severely aggravates cardiac inflammation and injury in mice, at least in part by 
promoting viral replication in the heart (Chapter 5 and Figure 1). Since cardiac miR-221 and 
miR-222 are upregulated in mouse myocarditis, but downregulated in cardiac biopsies of 
humans during viral myocarditis, restoring their expression levels in the hearts of human 
patients may be of therapeutic benefit.
In addition to miRNA dysregulation during acute myocarditis, we studied the different 
response in early miRNA signaling between myocarditis susceptible (C3H) and resistant 
(C57Bl/6) mice. Intriguingly, profiles of dysregulated miRNAs at day 4 after infection with 
the cardiotropic Coxsackievirus B3 were markedly divergent between these strains, despite 
equal viral replication in the heart. These differences may be responsible for the differential 
generation of immune responses and provide clues about the determinants of myocarditis 
susceptibility between humans. 
While our study is the first do describe the expression and functional roles of miRNAs 
during viral myocarditis, we have likely uncovered the mere tip of the iceberg and the study 
generates several important questions. During what phases of disease is modulation of 
miRNAs such as miR-155 and miR-221/miR-222 effective and how long should treatment 
continue? Which miRNAs are involved in the progression of acute into chronic myocarditis? 
Can miRNA function during enteroviral myocarditis be extrapolated to other increasingly 
prevalent viral causes of myocarditis, such as parvovirus B19 and human herpes virus 6? 
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Systematic investigation of the last question requires analysis of endomyocardial biopsies 
(EMB). EMB is infrequently performed in patients with acute viral myocarditis since many 
patients with acute myocarditis spontaneously recover. Unfortunately, this complicates the 
association of therapeutic outcomes with molecular disease markers (viral, miRNA) that is 
needed to develop more targeted treatments for this heterogeneous group of patients. In 
addition, non-standardized EMB performance across institutions fosters variation between 
clinical studies. Recent discoveries provide arguments in favor of more frequent EMB 
performance. First, specific treatments benefit EMB-identifiable patient subgroups, such 
as immunosuppression and interferon-beta administration in non-viral and viral myocarditis, 
respectively33, 48. Secondly, the establishment of non-invasive prognostic parameters during 
the acute phase allows to restrict EMB sampling to patients at risk for poor outcome, such 
as those with late gadolinium enhancement on cardiac magnetic resonance imaging49. 
These findings help pave the way towards integration of lessons from cardiac miRNA 
biology into patient care.
Figure 1. Effects of microRNA-155 (miR-155) and miR-221-222 in the heart during cardiac inflammation. 
Inflammatory injury to the heart during viral myocarditis is mediated by the pro-inflammatory effects of miR-
155. MiR-155 is expressed by immune cells, including macrophages and T lymphocytes, and stimulates T 
cell activation by targeting genes involved in the regulation of immune responses, such as PU.1. In addition, 
miR-155 promotes macrophage recruitment to the heart, thereby augmenting the local inflammatory activity. 
The miR-221-222 family inhibits replication of Coxsackievirus B3 (CVB3) in cardiomyocytes and protects 
against virus accumulation and cardiac inflammation. This effect may be mediated by the direct miR-221-
222 target ETS1, that is known to promote the replication RNA viruses. In addition to viral myocarditis, 
inflammation is also a hallmark of pressure overload-induced cardiac disease, which is mediated partly by 
activation of the pro-inflammatory vasoconstrictor hormone Angiotensin II (AngII). During pressure-induced 
cardiac inflammation, miR-155 promotes the recruitment of monocyte-macrophages into the blood, their 
infiltration into the heart, and stimulates their secretion of pro-inflammatory and pro-hypertrophic cytokines 
through targeting the inhibitor of cytokine secretion SOCS1.
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Inflammation and miR-155 in the pressure-overloaded heart
Chronic arterial hypertension increases cardiac workload and ventricular wall stress. The 
human heart accommodates for such changes by adapting its shape and function in a 
process called hypertrophic remodeling. In this process, cardiac enlargement is associated 
with increased size and contractile organization of individual myocytes10. In the short run 
this is an adaptive, compensatory response that results in wall stress normalization. 
However, in the long run, cardiac hypertrophy is associated with progression to heart failure, 
arrhythmias, and sudden death, independent of the underlying trigger10, 11. In line with these 
observations, inhibition or reversal of hypertrophy in patients by treatment with angiotensin-
converting enzyme inhibitors lowers their risk for death and heart failure progression, while 
persistent hypertrophy predicts adverse outcomes independent from blood pressure 
responses12. Hypertrophic remodeling is therefore considered a therapeutic target in 
cardiovascular medicine. The molecular mechanism of myocyte hypertrophy is complex 
and involves activation of hypertrophic gene programs through biomechanical stress or 
extracellular triggers including neurohormones (angiotensin II, endothelin-1, catecholamines) 
and peptide growth factors (such as epidermal growth factor, fibroblast growth factor-2 
(FGF2), insulin-like growth factor-1)13. Over the past decade it has become well accepted 
that signaling by adjacent cardiac cells, such as fibroblasts and endothelial cells, is of critical 
importance for hypertrophy. For instance, fibroblasts stimulate myocyte hypertrophy by 
secreting pro-hypertrophic factors including transforming growth factor-beta (TGF-β), FGF2 
and members of the interleukin 6 (Il-6) family14. 
In line with the pro-hypertrophic effects of the inflammatory cytokine Il-6, the immune 
system is also emerging as a contributor to hypertrophic signaling, as supported by a 
number of observations. First, pressure overload causes cardiac infiltration of activated 
immune cells, which precedes hypertrophic remodeling (Chapter 4). Second, myocyte 
hypertrophy can be triggered by multiple cytokines secreted from infiltrated immune cells, 
including Il-6, Il-1β, tumor necrosis factor, and TGF-β10, 13, 15-17. Third, several pro-hypertrophic 
signal transduction pathways are also essential pro-inflammatory pathways in immune 
cells, such as calcineurin-nuclear factor of activated T cells (NFAT), nuclear factor kappa B 
(NF-κB), signal transducer and activator of transcription 3 (STAT3), and phosphoinositide 3 
kinase gamma (PI3Kγ) signaling18-20. Finally, infusion with regulatory T cells (a class of T cells 
with broad anti-inflammatory effects) blunts cardiac hypertrophy during angiotensin-induced 
pressure overload in mice independent from blood pressure changes21. Beyond promoting 
hypertrophy, inflammatory cytokines also directly impact the progression of heart failure 
by inducing myocyte death, fetal gene expression, contractile dysfunction, and interstitial 
fibrosis leading to left ventricular dysfunction, pulmonary edema, and cardiomyopathy22. 
In patients, circulating levels of tumor necrosis factor (TNF-α), interleukin-1β (Il-1β) and Il-6 
are elevated earlier during heart failure progression than are classical neurohormones23 and 
TNF-α and Il-6 levels are predictors of mortality independent of age, left ventricular ejection 
fraction and New York Heart Association (NYHA) class24. In conclusion, a firm rationale 
supports the investigation of inflammation in hypertrophic remodeling and heart failure, 
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and of the miRNAs controlling inflammatory activity as potential therapeutic targets for 
these diseases8.   
MiRNAs are expressed by many cell types in the heart, as evidenced by a large number 
of miRNAs whose cardiac levels are not affected by myocyte-restricted Dicer deletion in 
the post-natal mouse heart25. We found that among these miRNAs, miR-155 is expressed 
by infiltrating inflammatory cells in the pressure-overloaded heart and contributes to pro-
hypertrophic paracrine signaling from macrophages to cardiomyocytes (Chapter 6 and 
Figure 1). MiR-155 promotes cardiac inflammation in response to angiotensin II infusion 
at multiple levels, as miR-155 deficiency results in decreased monocyte recruitment to 
circulating blood, reduces numbers of macrophages infiltrating the heart, and attenuates 
pro-inflammatory cytokine secretion from infiltrating cells. Attenuated inflammation 
dampened cardiac hypertrophy and consequent systolic dysfunction in mice without altering 
blood pressure responses to angiotensin II. These effects were primarily leukocyte-
autonomous and based on miR-155-dependent pro-hypertrophic effects of the macrophage 
secretome on myocytes (Chapter 6). These data add new weight to the importance of the 
cardio-inflammatory crosstalk and suggest that targeting miR-155 may be of benefit in the 
treatment of hypertrophic remodeling. 
Our work raises a number of general questions. For instance, what paracrine factors from 
macrophages promote myocyte hypertrophy? While cytokines such as TNF-α and the Il-1 
and Il-6 family may fully account for hypertrophic stimulation, other secreted factors may 
also be involved. We have found a large number of protein levels altered in the secretomes 
of miR-155 wild-type versus knockout macrophages. An interesting approach would be to 
systematically study the hypertrophic effects of secretome fractions defined by size or 
sensitivity to proteolytic versus ribonucleic digestion. Another question coined is whether 
the observed protection of contractile function is secondary to blunted hypertrophy or 
caused by a parallel mechanism such as an attenuated negative-inotropic cytokine milieu. 
Also, might inflammation be the trigger that differentiates between physiological and 
pathological hypertrophy? While the lack of inflammation associated with physiological 
hypertrophy in athletes supports such a hypothesis, NF-κB is necessary for adaptive 
physiological hypertrophy in mice26. In contrast, inhibition of miR-155 leads to decreased 
hypertrophy and preserves cardiac function (Chapter 6). Therefore, it may be the nature 
and severity, rather than the occurrence of inflammation that determines outcome. It is 
noteworthy that such dose-dependent phenotypic outcomes of signaling are recurrently 
observed in inflammatory and cardiovascular signaling. Inflammatory responses protect 
the organism against acute threats while chronic inflammatory activation is the cause of 
many human diseases. In parallel, initially compensatory hypertrophy is detrimental in the 
setting of chronic overload. Also, the hypertrophic and inflammatory signaling pathways 
are often myocyte pro-survival pathways in acute settings (such as transient or permanent 
myocardial ischemia) while chronic activation is deleterious27-29. Remedying chronic effects 
of such pathways will become more urgent due to the increasing chronic disease burden 
in our progressively aging Western population. 
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Plasma miRNAs as biomarkers of cardiovascular disease
The stability and detectability of miRNAs released into the circulation offers opportunities 
for their use as biomarkers for human disease. By comparing plasma miRNA levels in 
patients suffering from cardiovascular disease – including acute myocardial infarction (AMI), 
viral myocarditis (VM), heart failure and diastolic dysfunction – we identified miR-208b and 
miR-499 as sensitive indicators of cardiomyocyte injury (Chapter 7 and Figure 2). Both 
miRNAs are strongly enriched in muscular cells and their plasma levels in the general 
population are low to absent. Their plasma levels are not affected by typical clinical 
confounding parameters (age, gender, arterial blood pressure, body-mass index, renal 
function) but rise sharply during acute myocardial infarction and viral myocarditis. Elevations 
correlated strongly with circulating levels of troponin T and could accurately discriminate 
AMI patients from controls (Chapter 7). Plasma levels of two other myocyte-enriched 
miRNAs, miR-1 and miR-133b, were also elevated in AMI patients, albeit less profoundly. 
In patients with diastolic dysfunction, a condition not associated with myocyte death, we 
found no significant differences in any of the miRNAs studied. 
Figure 2. Cardiomyocyte damage leads to the release of myocyte-enriched miRNAs into the systemic 
circulation. MiR-208b and miR-499 are highly expressed in viable cardiomyocytes and are hardly detectable 
in plasma samples of healthy individuals. However, during acute cardiac damage caused by acute myocardial 
infarction or viral myocarditis, dying myocytes release miR-208b and miR-499 into the blood stream. The 
resulting elevation of miR-208b and miR-499 can be detected in plasma samples, allowing their use as early 
and sensitive biomarkers of cardiac damage.
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Finally, we hypothesized that assessment of inflammatory miRNAs in addition to miR-208b 
and miR-499 might aid the clinically challenging differential diagnosis between AMI and 
VM. However, levels of inflammation-associated miR-146a, miR-146b, miR-155 and miR-
223 were not significantly elevated or depressed during VM. Though miR-223 levels were 
mildly lower in AMI patients versus controls, we did not find evidence supporting a strong 
discriminatory potential of inflammation-associated miRNAs. Rather, plasma patterns of 
miRNAs enriched in circulating blood cells strongly resembled the miRNA patterns in these 
cells, suggesting that leakage of such miRNA from blood cells confounds their plasma 
levels and diagnostic potential (Chapter 7). These findings have been corroborated by other 
groups50, 51, indicating that miRNAs not enriched in blood cells, such as the myocyte-
enriched miRNAs may be most suited as biomarkers for cardiovascular disease.
Our findings with regard to myocyte-miRNA elevation in AMI patient plasma have been 
confirmed by a number of independent studies during the preparation and after publication 
of our manuscript52-56. To be clinically useful, biomarkers must provide information not 
available from clinical assessment or existing blood tests57. For AMI diagnosis, the most 
widely used tests measure plasma levels of cardiac troponins. The major limitation of these 
tests is their low sensitivity at the time of patient presentation due to a delayed increase 
in circulating levels of cardiac troponins. This necessitates serial blood testing up to 6 hours 
after onset of complaints and causes treatment delay and increased complications58. While 
the recently introduced high-sensitivity troponins (hs-TNT and hs-TNI) have markedly 
improved early diagnostic accuracy, there is considerable room left for improvement since 
the negative predictive value of hs-TNI testing within 3 hours after onset of complaints 
does not exceed 84%59, 60. We have therefore expanded upon the findings presented in 
Chapter 6 and studied the diagnostic performance of miR-208b and miR-499 in comparison 
to hs-TNT in a larger cohort of AMI patients (n=510) with a focus on early diagnosis. MiRNA 
and hs-TNT levels were both detectable in plasma from 1 hour after onset of complaints 
and 3 hours after onset the percentage miR-499 positivity was by trend higher than hs-TNT 
positivity (93% versus 88%)61. However, both miRNA and hs-TNT testing provided 
comparably high diagnostic value (areas under the curve of 0.97) and miR-499 levels did 
not significantly contribute to a clinical classification model including hs-TNT as well as 
several risk factors61. In agreement, a study investigating miRNA levels in plasma of n=444 
patients with acute coronary syndromes reported that miR-133a and miR-208b were 
associated with risk of death after adjusting for age and gender but lost their association 
after adjusting for hs-TNT56. While these findings suggest that miRNAs are powerful but 
not superior biomarkers for AMI in comparison to high-sensitivity troponins, a number of 
practical considerations must be taken into account before definite conclusions can be 
drawn. First, technical differences in isolation and miRNA measurements between labs 
considerably impact elementary outcomes, such as the measurability of low abundance 
miRNAs in controls and the reported fold-increases of miRNAs62, 63. Improved and 
standardized measurements will be instrumental in integrating study results for generalizable 
conclusions. In addition, both detectability and kinetics of miRNA increases after onset of 
complaints affect diagnostic usefulness: while miR-499 performed as good as hs-TNT in 
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our hands at 3 hours after onset of complaints, the miR-499 levels peak several hours later 
than those of miR-208, miR-1 and miR-13353, 54. Finally, the straightforward measurement 
of different miRNAs facilitates the integration of multiple miRNAs into a multiplex classifier 
that may outperform single biomarkers64. 
In conclusion, we and others have demonstrated the feasibility of using miRNAs as plasma 
biomarkers for cardiovascular disease. Improvements in isolation techniques are required 
to adequately address their potential for clinical translation. From a general perspective, 
these findings have raised vexing questions regarding the significance of cellular export or 
leakage of miRNAs and their potential biological functions. Though myocyte necrosis is 
likely an important source of myocyte miRNA elevation in plasma, miR-499 levels are 
downregulated in infarcted hearts54, possibly indicating active cellular miRNA export. 
Similarly, liver miRNAs elevated in plasma during drug-induced hepatotoxicity are 
simultaneously downregulated in hepatic tissue65. In addition, proteins and lipid carriers 
carry distinct miRNA populations in plasma and the cellular export of these populations is 
differently regulated66-69. Selective measurements of miRNAs in these compartments may 
therefore provide novel dimensions of diagnostic information. Finally, some lines of evidence 
suggest that plasma miRNAs may be involved in paracrine signaling after uptake in remote 
cells67, 70-73. Efforts are ongoing to better understand the basic biology underlying the 
phenomenon of plasma miRNA, and these insights may translate into clinical applications 
within the next decade.
Conclusions and future perspectives
This thesis presents important roles for miRNAs during inflammation in hypertrophic and 
inflammatory heart disease, as well as their use as biomarkers for cardiac disease. The 
beneficial effect of suppressing cardiac inflammation through miR-155 has two important 
implications. First, it emphasizes the importance of inflammation as a contributor and 
therapeutic target in heart failure. Secondly, it directly suggests that miR-155 inhibitors 
may benefit patients with viral myocarditis or myocardial hypertrophy. The clinical translation 
of these findings will nevertheless require rigorous additional studies. Though miRNA 
inhibitors have been successfully tested in non-human primates and are currently in phase 
II clinical trials41, 42, 74, an attractive feature of miRNA therapeutics also represents a 
disadvantage: the nuanced effects on gene expression through concerted repression of 
hundreds of mRNA targets complicate predictions of side-effects. From a mechanistic 
perspective, the multitude of miRNA targets also complicates pinpointing single targets 
as responsible for miRNA loss-of-function phenotypes. MiRNA biology challenges the 
traditional approach to biological interactions as more or less linear signaling pathways by 
adding a new dimension of complexity. This complexity involves dynamic regulation of 
extensive signaling networks with complex feedback and feed-forward systems. Systems 
biology approaches will be indispensable for studying these signaling environments, and 
a key challenge for molecular biologists will be to translate the generated complexity into 
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understandable knowledge and intuitive heuristics. In contrast, utilizing miRNAs as 
biomarkers for cardiovascular disease does not require in-depth understanding of their 
biological roles but will require standardized methods for reproducible measurements 
across different centers. In spite of these challenges, our knowledge about the role of 
miRNAs in cardiovascular disease accumulates rapidly and their translation into clinically 
applicable therapeutic and diagnostic tools is probably a matter of time. 
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Summary 
Heart failure is associated with both structural and molecular changes in the heart. Cardiac 
cells respond to stress through the dynamic production of signaling molecules that direct 
cell behavior. While some of these signaling molecules are adaptive and protect against 
the development of heart failure, others have frank deleterious effects. The research 
field of molecular cardiology aims to identify adaptive and maladaptive molecules as 
targets for clinical therapies and diagnostics. An important and relatively novel class of 
signaling molecules is formed by the microRNAs. The human genome encodes 
approximately one thousand microRNAs that govern virtually all cellular processes by 
binding to messenger RNA and repressing the expression of target proteins. Each 
microRNA has a unique set of targets that can include hundreds of proteins. MicroRNAs 
are important for normal bodily functions, but additionally play important roles during a 
variety of human diseases, including cardiovascular diseases and cancer. In this thesis, 
we have identified microRNA functions in cardiac inflammation and the development of 
heart failure, as well as the possibility of using microRNAs in circulating blood as 
biomarkers for heart disease.
To study dysregulated microRNAs in cardiac inflammation we first profiled cardiac microRNA 
changes during viral myocarditis. Viral myocarditis is an inflammatory disease of the heart 
that is often caused by infection with common viruses. Although these viruses directly 
damage cardiac cells, the immune response significantly contributes to cardiac injury and 
heart failure development. A large number of microRNAs is up or downregulated in the 
hearts of both patients and mice suffering from viral myocarditis. We identified patterns 
of microRNA changes associated with acute inflammation, as well as with disease 
susceptibility and selected strikingly dysregulated microRNAs for further investigation in 
a mouse model of viral myocarditis. MicroRNA-155 expression strongly increases in human 
and mouse myocarditis hearts. Inhibition of microRNA-155 during viral infection reduces 
immune infiltration and activation, attenuates necrosis in the acute phase and improves 
survival and cardiac function in mice. In contrast, inhibitors against microRNA-221 and 
microRNA-222, two highly related microRNA family members that are upregulated in mouse 
myocarditis, enhance viral replication and aggravate cardiac inflammation and injury. Our 
results indicate that microRNA changes in the heart during myocarditis include adaptive 
and maladaptive responses and that inhibiting microRNA-155, or conversely supporting 
microRNA-221-222, may benefit patients.
Next, we studied the importance of microRNA-155 for the development of heart failure 
during pressure overload, a model roughly equivalent to arterial hypertension in humans. 
Mice that lack the microRNA-155 gene exhibit a reduced influx of inflammatory cells in 
the heart and this is associated with protection from cardiac hypertrophy and contractile 
dysfunction. Mechanistically, activated inflammatory cells secrete cytokines that 
contribute to cardiac hypertrophy. Secretion of these factors is promoted by microRNA-155 
and is reduced in immune cells of microRNA-155 knockout mice. MicroRNA-155 is 
2012100 proefschrift Maarten Corsten.indd   202 07-08-2012   08:40:23
Summary 
203
therefore a maladaptive mediator of inflammation and heart failure during pressure 
overload and a potential therapeutic target in hypertensive heart disease.
MicroRNAs are abundant in living cells, but can also be detected as freely circulating in 
human plasma. To study whether such plasma measurements can be used for the diagnosis 
of cardiovascular disease, we measured microRNA levels in the plasma of patients with 
varying cardiovascular disorders. Plasma levels of microRNA-208b and microRNA-499, two 
microRNAs that are enriched in cardiomyocytes, sharply increase during acute myocardial 
infarction and acute viral myocarditis. Their levels correlate strongly with markers of 
cardiomyocyte necrosis and are not affected by clinical characteristics such as age, gender, 
body-mass index, blood pressure, and kidney function. Our data demonstrate the feasibility 
of using myocyte-enriched microRNAs as biomarkers for cardiac injury during cardiovascular 
disease in patients.
In summary, this thesis presents important roles for microRNAs during inflammation in 
hypertrophic and inflammatory heart disease, as well as their use as biomarkers. The 
studies presented provide insight into the contribution of inflammatory signaling to heart 
failure. In addition, the identification of individual microRNAs as potential diagnostic and 
therapeutic targets contributes to the translation of basic microRNA research into clinical 
applications for cardiovascular disease. 
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Bij hartfalen treden zowel structurele als moleculaire veranderingen in het hart op. Cellen 
in het hart reageren op uiteenlopende soorten stress door de dynamische productie van 
signaalmoleculen welke de werking van de cel beïnvloeden. Sommige van deze 
signaalmoleculen zijn adaptief en beschermen tegen het ontstaan van hartfalen, terwijl 
anderen juist overwegend schadelijke effecten hebben op het hart. In de moleculaire 
cardiologie proberen onderzoekers zulke adaptieve en maladaptieve moleculen te 
identificeren als aangrijpingspunten voor nieuwe behandelingsmethoden en diagnostiek 
bij patiënten. Een belangrijke en relatief nieuwe klasse signaalmoleculen zijn de 
microRNAs. Het totaal menselijke DNA, ofwel genoom, bevat bouwtekeningen voor 
ongeveer een duizendtal microRNAs. Deze microRNAs beïnvloeden vrijwel alle cellulaire 
processen door binding aan specifieke ‘target’ messenger RNAs, hetgeen leidt tot 
remming van target eiwit productie. Elk microRNA heeft een unieke set aan targets die 
wel honderden eiwitten kan omvatten. MicroRNAs zijn belangrijk voor normale 
lichaamsfuncties, maar spelen ook een belangrijke rol bij een veelvoud aan menselijke 
ziekten, zoals hart- en vaatziekten en kanker. In dit proefschrift hebben we enerzijds 
microRNAs geïdentificeerd welke betrokken zijn bij ontsteking in het hart en hartfalen, 
en anderzijds de mogelijkheid onderzocht om vrij circulerende microRNAs in het bloed 
te gebruiken als biomarkers voor hartziekten.
Om microRNAs met een rol in cardiale ontsteking te identificeren hebben we eerst een 
expressie ‘profiling’ uitgevoerd van alle microRNAs in het hart tijdens virale myocarditis. 
Virale myocarditis is een ontsteking van het hart die wordt veroorzaakt door infectie van 
het hart met veelvoorkomende virussen. Hoewel deze virussen directe hartschade 
kunnen veroorzaken, draagt de immuunrespons in belangrijke mate bij aan de 
onomkeerbare hartbeschadiging en daaruit volgend hartfalen. In de harten van patiënten 
en muizen welke lijden aan virale myocarditis is de concentratie van een groot aantal 
microRNAs, vergeleken met gezonde controles, verhoogd of juist verlaagd. Op deze 
wijze konden we microRNA patronen identificeren welke geassocieerd zijn met acute 
ontsteking of gevoeligheid voor de ziekte. Vervolgens hebben we microRNAs met een 
opvallend expressiepatroon tijdens virale myocarditis geselecteerd voor andere 
bestudering in een muizenmodel van deze ziekte. De expressie van microRNA-155 in 
het hart neemt sterkt toe tijdens virale myocarditis in zowel mensen als muizen. Remming 
van microRNA-155 activiteit tijdens virale infectie remt de immuunrespons in het hart, 
vermindert necrose van hartspiercellen tijdens de acute ziektefase en verbetert de 
overleving en hartfunctie in muizen. Remming van de twee sterk aan elkaar verwante 
microRNAs-221 en -222, welke ook verhoogd tot expressie komen tijdens virale 
myocarditis in de muis, leidt daarentegen tot toegenomen virusvermenigvuldiging, 
ontsteking en schade aan het hart. Deze bevindingen laten zien dat microRNA 
veranderingen in het hart tijdens virale myocarditis zowel adaptieve als maladaptieve 
veranderingen omvatten en dat remming van miR-155, of juist stimulering van 
microRNA-221 en -222, gunstig zou kunnen zijn voor patiënten met deze ziekte. 
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Vervolgens hebben we de effecten van microRNA-155 bestudeerd tijdens de ontwikkeling 
van hartfalen door drukoverbelasting in muizen, middels een diermodel dat vergelijkbaar 
is met arteriële hypertensie bij mensen. Muizen welke het microRNA-155 gen missen 
(microRNA-155 knockout muizen) vertonen bij drukoverbelasting een verminderde infiltratie 
van ontstekingscellen in het hart en zijn deels beschermd tegen hartspierverdikking en 
afname van knijpkracht in vergelijking met normale muizen. Geactiveerde ontstekingscellen 
scheiden stoffen (cytokinen) uit welke bijdragen aan hartspiercelverdikking. Uitscheiding 
van deze cytokinen wordt gestimuleerd foor microRNA-155 en is verminderd in 
ontstekingscellen van microRNA-155 knockout muizen. MicroRNA-155 is dus een 
maladaptieve regulator van ontsteking en hartfalen tijden drukoverbelasting, en vormt een 
potentieel doelwit voor de behandeling van hypertensieve hartziekten.
MicroRNAs bevinden zich voornamelijk in levende cellen, maar kunnen ook gedetecteerd 
worden als vrij circulerende deeltjes in het plasma van de menselijke bloedsomloop. Om 
te bestuderen of zulke plasma bepalingen bruikbaar zijn voor de diagnose van hart- en 
vaatziekten, hebben we microRNA niveaus gemeten in het plasma van patiënten met 
uiteenlopende cardiovasculaire aandoeningen. Plasma niveaus van microRNA-208b en 
microRNA-499, twee microRNAs die sterk geconcentreerd zijn in hartspiercellen, vertonen 
een sterke stijging tijdens het doormaken van een acute hartinfarct of acute virale 
myocarditis. Deze plasma niveaus correleren goed met gevestigde markers van 
hartspiercelverval en worden niet verstoord door patiënt-specifieke factoren zoals leeftijd, 
geslacht, gewicht, bloeddruk of nierfunctie. Onze data tonen daarmee aan dat het mogelijk 
is om hartspiercel-microRNAs te gebruiken als plasma biomarkers voor hartschade bij met 
cardiovasculaire aandoeningen. 
Samenvattend presenteert dit proefschrift belangrijke rollen voor microRNAs bij het 
ontstekingsproces in hypertrofische en inflammatoire hartziekten, en poneert het tevens 
de mogelijkheid tot het gebruik van microRNAs als biomarkers voor hart- en vaatziekten. 
De beschreven studies bieden inzicht in de bijdrage van ontsteking aan de ontwikkeling 
van hartfalen. Daarnaast draagt de identificatie van individuele microRNAs als potentiële 
doelwitten voor nieuwe diagnostiek en behandelingen bij aan de vertaalslag van basaal 
microRNA onderzoek naar klinische toepassingen voor de hart- en vaatziekten. 
Samenvatting 
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Klaar. Met de proeve van wetenschappelijke bekwaamheid die minstens zozeer 
doorzettingsvermogen test. Na jaren van veel struikelen en veel opstaan een onwerkelijk 
maar heerlijk gevoel. Sinds mijn eerste wankele wetenschappelijke stapjes als student in 
2004 heeft het onderzoek me veel verscheidenheid gebracht. Van imaging in Maastricht 
en Irvine naar de microRNAs en oncologie in Boston, om vervolgens via de wondere wereld 
van targeted delivery-research wederom in Maastricht bij mijn uiteindelijke promotieproject 
van microRNAs in de cardiologie uit te komen. Een mens heeft wel eens een rechtere lijn 
getrokken. Desalniettemin heeft de variëteit aan verschillende labs en onderwerpen een 
weelde aan ervaringen opgeleverd. Ik ben dankbaar voor de bijdrage die velen hieraan 
geleverd hebben en wil enkele personen in het bijzonder  bedanken.
Allereerst mijn promotor. Geachte professor Heymans, beste Stephane, hartelijk dank voor 
het vertrouwen dat ik de afgelopen drie jaar van je heb ontvangen. Je explosief enthousiasme 
en optimisme zijn ongeëvenaard en na de brainstorms over mijn projecten heb ik geregeld 
een extra bakje koffie nodig gehad om mijn gedachten weer in het gareel te krijgen. Juist 
door onze verschillen in stijl van onderzoek doen en schrijven heb ik veel van je kunnen 
leren, met name over de balans tussen nuance en leesbaarheid. Ik ben benieuwd welke 
opportuniteiten zich de komende jaren nog aan je zullen voordoen, maar je mix van 
Belgische vermomming en Hollandse assertiviteit zullen ongetwijfeld op velerlei plekken 
tot hun recht komen.
Mijn copromotor Blanche Schroen. Je technische kennis en analytisch vermogen hebben 
een grote invloed gehad op dit proefschrift. Je was zowel begeleider, klankbord als 
teamgenoot. Bij ons gezamenlijke puzzelen aan de microRNA projecten in dit boekje hebben 
we een hoop hoofdbrekens, teleurstellingen en overwinningen gedeeld. Ik wens je alle 
succes toe met de ontpopping tot zelfstandig PI en met combinatie tussen werk en jullie 
groeiende gezinnetje.
Mijn paranimfen Bob en Johan. Bob, sinds de brugklas lopen we eigenlijk op bijna alle 
fronten gelijk op. Des te mooier dat we grofweg gelijktijdig onze promoties af zullen ronden. 
Je nuchtere humor is het perfecte antigif tegen zowel teleurstellingen als zelfoverschatting 
(dit in tegenstelling tot je sportkwaliteiten: die werken bij mij enkel tegen zelfoverschatting). 
Ik ben trots dat je bij mijn verdediging achter me zult staan. 
Johan, collega-telg van de MMIT PhD academy. Enthousiaste jonge researchhond, 
hoogleraar in de gadgetkunde en trouwe karaokepartner ‘voor al uw feesten en partijen’. 
Ik heb genoten van onze tijd als kamergenoten op de 4e en alles wat daaruit voortgevloeid 
is. Hopelijk kunnen we je het komend jaar weer op komen zoeken bij je nieuwe 
researchavontuur in Boston. Mooi dat je er als paranimf bij bent. 
En dan natuurlijk het lab zelf. De grillen van een promovendus komen nergens zo prachtig 
tot uiting als bij de collega’s die de hele week naast je staan en zitten. Ons clubje heeft 
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inmiddels een aardige kritische massa bereikt maar daarbinnen heeft zo’n beetje iedereen 
wel bijgedragen aan mijn werkplezier van de afgelopen jaren. Laat ik beginnen met Wouter 
Verhesen, collega en kamergenoot in mijn laatste jaren. Moleculaire hoeksteen van het lab 
en uomo universale. Je vele kanten hebben ogenschijnlijk niets met elkaar van doen: 
wetenschapper, sterrenkijker, stemmings-inverteur, archeoloog, kunstenaar, darter en 
cartoonist. Je gevoel voor humor en hand van de meester zijn van grote waarde geweest 
voor zowel het proces als resultaat van deze promotie, waarvoor dank. Rick, nestor en 
labmanager: door jouw organisatie was werken in ons lab een logistiek feest en ik heb met 
veel plezier met je samengewerkt. Anna, de beste pretoogjes van het lab en een Brits accent 
om jaloers op te zijn. Wat je ook zegt, het klinkt altijd goed. Met levenservaring opgedaan 
in zo’n beetje alle landen van Europa – behalve Luxemburg – raak je je relaxte mojo niet 
een-twee-drie kwijt en jouw “it’ll be fine…” is inmiddels een begrip. Geert van Almen, 
Eindhovense boy uit het boekje, prins van de koffie en koning van de woordgrap. Jammer 
dat we maar een jaartje een kamer gedeeld hebben! Gelukkig was dit niet te kort om te 
genieten van jouw zelf gezette bakkies (the best in town), je muzikale inborst (“ik heb effe 
underground radio aangezet op JOUW computer, dat is wel ok toch?”), en prachtige verhalen 
(“ben jij misschien dokter want ik heb hier ECHT last van”). Mooie tijden. Marieke Rienks, 
of rupsie, of mimelecan: medisch partner in basic crime en trouwe congresgenoot. Hebben 
samen nog ontdekkingen gedaan, bijvoorbeeld dat er in de buurt van Les Diablerets twee 
hotel Eurotel Victoria’s zijn. We zaten vaak op één lijn qua lab-beleving en dat is in een 
promotie heel wat waard. Succes met je eigen afronding, ik heb er alle vertrouwen in dat 
je dat varkentje gaat wassen. Derks, ongepolijste bioloog met de beste T-cel receptor imitatie 
van ons lab. Je bent zo eigenwijs als nieuwsgierig en enthousiast en van die mix zal je in 
de wetenschap nog veel plezier beleven. Bedankt voor de gezelligheid. Tim, je hebt een 
waardevol snufje Deutsche Grundlichkeit aan het lab toegevoegd. Ik ben benieuwd wat er 
de komende jaren uit jouw koker rolt en wens je alle succes en plezier met het proces. 
Lucas, Ward en Sophie, kroonprinsen en -prinses van onze Belgische (pardon Vlaamse) 
dependance. Veel succes met ook jullie laatste loodjes binnenkort. In Leuven ook een 
bijzonder woord van dank aan Paolo. We hebben samen heel wat uurtjes dierenwerk 
versleten en je bijdrage aan dit proefschrift is groot geweest. Grazie amico! Georg, bless 
the Suiss for sending you over to us. I imagine you still have nightmares about my relentless 
bothering you about the arrays. Sudo sleep well, it is done now! Thanks for everything. 
Laura, je nuchtere vrolijkheid wordt gemist op het lab. Ik heb met plezier met je gewerkt 
en ga de uitspraak van nexetrien niet meer vergeten. Verder dank voor een leuke 
samenwerking aan Mark Schellings, Mark van Bilzen, Sylvia en tot slot onze onmisbare 
klinische tak: achtereenvolgens Robert, Casper en Hazebroek. De raakvlakken waren met 
eenieder van jullie verschillend (boksen, muziek en studententijd) maar daarom niet minder 
goed. Wat Casper en Mark betreft: een man weet pas wattie mist als zijn WESP-student 
er niet is. Bedankt voor het enthousiasme en het snijden van heel veel coupes. Barbara, 
rots in de administratieve branding: ik ga je gevoel voor humor missen. 
Mijn bazen van het eerste uur, professor Hofstra, Reutelingsperger en Narula! Leo, spin 
doctor van het MMIT laboratory. Waar jij je hoofd laat zien is het nooit saai. Wat heb je me 
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veel uitgedaagd om mijn grenzen te verleggen. Van reviews schrijven (“het is nog niet sexy 
genoeg..”) tot spreken op te grote congressen (“of vind je dat je daar nog te licht voor 
bent?”) en geweldige onderzoeksstages in California en Boston. Het heeft mijn 
wetenschappelijke honger sterk geprikkeld. Een aantal van je bijzondere kwaliteiten zie ik 
als voorbeeld, zoals je hypnotiserende sprekerskwaliteiten en denkkracht in de grote lijnen. 
Selectief niet beantwoorden van mails valt daar overigens niet onder, je capaciteit om 
daarmee weg te komen dan weer wel. Chris, je was de eerste basaal onderzoeker die ik 
in het wild tegenkwam. Ik heb genoten van jouw zorgvuldig zoeken naar de juiste 
onderzoeksvragen en non-template experimenten die deze vragen zouden kunnen 
beantwoorden. Finally, Jagat, thank you for many stimulating discussions both in Irvine 
and afterwards. Mijn overige collega’s van de MMIT clan. Nicole, jouw vast chirurgische 
hand is de meest constante factor geweest in de afgelopen jaren. Bedankt voor al je inzet 
en warme interesse. Maarten Anderegg aka Maar-eleven: een maand lang met twee 
volwassen kerels in harmonie op dezelfde kamers wonen en werken is niet vanzelfsprekend. 
Vraag maar aan Makiki. Toch was ons avontuur in Boston een fantastische ervaring waar 
ik onverwacht een goede vriend aan over gehouden heb. Suus en Reinier, California was 
niet hetzelfde geweest zonder jullie. Het waren memorabele maanden die ik door de ‘casual 
fridays’, goede tripjes en natuurlijk de Cadillac niet snel zal vergeten. Ward, bedankt voor 
je gezelligheid en mooie lange verhalen. Ik hoop dat promotiegate nog een goed vervolg 
gaat vinden. Dank ook aan Abdel, Ewald en Bas en aan de biochemische kant Niko, Petra, 
Lisette, Heidi, Cecile en Kristoff.
Khalid Shah, my mentor in Boston. Dear Khalid, your receiving the Harvard Medical School 
Young Mentor Award earlier this year comes as no surprise to me. The amount of hands-
on supervision that you invest in your students is amazing. You have taught me the basics 
of molecular biology, stell cells, gene therapy and of course the psychology of science. 
Your faith in my capabilities has been a huge stimulus. I look forward to keeping in touch 
with you. In your lab I would especially like to thank Shawn “living the dream” Hingtgen 
for a lot of help and a good time.
De open samenwerking tussen labs in het Groot Cardiolab biedt een geweldige omgeving 
om ieders onderzoek optimaal tot zijn recht te laten komen. Enkelen die hieraan hebben 
bijgedragen wil ik met name noemen: Leon, Paula, Kanita, Steve, Leonne, Gustavo, Natasja, 
Monica, Ella, Ellen, en Rio. De kerst- en afscheidsborrels met labdance waren op hun 
manier uniek. Tenslotte mijn dank aan alle indirecte collega’s die verder hebben bijgedragen 
aan mijn werk de afgelopen jaren. Fazzi, Ben, Agnieszka, Jacques, Helma en Peter van de 
farmacologie, Nico van de kindergeneeskunde. Bij de moleculaire genetica Lauran, Marion 
en Menno en zeker ook Guillaume, bij wie ik altijd terecht kon voor een vraag of ontspannend 
praatje. De medewerkers van het CPV, in het bijzonder Rick en Clarice.
Graag wil ik ook Prof. L. de Windt, Prof. H.J.G.M. Crijns, Prof. M.J. Post, Prof. Y.M. Pinto 
en Prof. T. Thum bedanken voor het beoordelen van mijn proefschrift.
2012100 proefschrift Maarten Corsten.indd   210 07-08-2012   08:40:24
211
Nawoord 
Tot slot wil ik graag nog wat veren uitdelen aan degenen die op de achtergrond zo belangrijk 
zijn geweest. Allereerst mijn vader en moeder, respectievelijk de bèta en alfa in mij, en 
mijn zusje Ilke. Een vaste basis is onmisbaar voor al dat wil groeien. Als die basis ook nog 
een warm, veilig en humorvol nest vormt mag de spruit zich gelukkig prijzen. Bij dezen. 
Lieve Veer, de laatste loodjes hebben ook van jou offers gevergd. Bedankt voor je 
onaflatende lieve aandacht, afleiding en ondersteuning. Ik kan met je lachen en op je 
bouwen. Je bent een levenskunstenares waar ik nog lang van en mee hoop te genieten. 
Maarten Corsten,
Maastricht, juni 2012
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Curriculum Vitae
Maarten Corsten was born on June 27th 1983 in Breda, The Netherlands. After obtaining 
his gymnasium degree summa cum laude at the Mencia de Mendoza Lyceum in Breda in 
2001, he enrolled in his medical studies at Maastricht University that same year. He initiated 
training in cardiovascular research as a student with Prof. dr. L. Hofstra in 2004, focusing 
on molecular imaging of cell death. Supported by grants from the Netherlands Heart 
Foundation and the KWF Cancer Foundation he spent several months in the labs of Prof. 
dr. J. Narula at the University of Irvine, California in 2005 and of Dr. K. Shah at the Center 
of Molecular Imaging Research at Massachusetts General Hospital in Boston in 2006, 2008 
and 2009. Meanwhile, he completed the first year of Economics at Maastricht University 
in 2005 and received the Kootstra Talent Fellowship from the Maastricht University Faculty 
of Medicine in 2007. After receiving his medical degree in 2009, Maarten Corsten 
commenced his PhD program in the lab of Prof. dr. S. Heymans at the Maastricht University 
Department of Cardiology, studying the biological importance of microRNAs in inflammatory 
heart disease. In 2011, he was awarded the Dutch-German Basic Research young 
investigator award and the runner-up young investigator award at the Heart Failure 
Association of the European Society of Cardiology. He finished his research in June 2012 
and currently works as a resident specializing in Internal Medicine at the Meander Medisch 
Centrum in Amersfoort.
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